Terms and Conditions of Use of Digitised Theses from Trinity College Library Dublin

Copyright statement

All material supplied by Trinity College Library is protected by copyright (under the Copyright and Related Rights Act, 2000 as amended) and other relevant Intellectual Property Rights. By accessing and using a Digitised Thesis from Trinity College Library you acknowledge that all Intellectual Property Rights in any Works supplied are the sole and exclusive property of the copyright and/or other IPR holder. Specific copyright holders may not be explicitly identified. Use of materials from other sources within a thesis should not be construed as a claim over them.

A non-exclusive, non-transferable licence is hereby granted to those using or reproducing, in whole or in part, the material for valid purposes, providing the copyright owners are acknowledged using the normal conventions. Where specific permission to use material is required, this is identified and such permission must be sought from the copyright holder or agency cited.

Liability statement

By using a Digitised Thesis, I accept that Trinity College Dublin bears no legal responsibility for the accuracy, legality or comprehensiveness of materials contained within the thesis, and that Trinity College Dublin accepts no liability for indirect, consequential, or incidental, damages or losses arising from use of the thesis for whatever reason. Information located in a thesis may be subject to specific use constraints, details of which may not be explicitly described. It is the responsibility of potential and actual users to be aware of such constraints and to abide by them. By making use of material from a digitised thesis, you accept these copyright and disclaimer provisions. Where it is brought to the attention of Trinity College Library that there may be a breach of copyright or other restraint, it is the policy to withdraw or take down access to a thesis while the issue is being resolved.

Access Agreement

By using a Digitised Thesis from Trinity College Library you are bound by the following Terms & Conditions. Please read them carefully.

I have read and I understand the following statement: All material supplied via a Digitised Thesis from Trinity College Library is protected by copyright and other intellectual property rights, and duplication or sale of all or part of any of a thesis is not permitted, except that material may be duplicated by you for your research use or for educational purposes in electronic or print form providing the copyright owners are acknowledged using the normal conventions. You must obtain permission for any other use. Electronic or print copies may not be offered, whether for sale or otherwise to anyone. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement.
Noradrenaline acting on astrocytic β-adrenoceptors enhances neuronal complexity in primary cortical neurons

Jennifer Day

Thesis submitted for the degree of Doctorate of Philosophy at the University of Dublin, Trinity College

Thesis submitted June 2012

Department of Physiology,
Trinity College Institute of Neuroscience
Trinity College,
Dublin 2.
In loving memory of:

Joan Flower  
(1927-2012)  

And  

Keith Flower  
(1984-2012)
I Declaration

I declare that this thesis has not been submitted as an exercise for a degree at this or any other university and it is entirely my own work.

I agree to deposit this thesis in the University’s open access institutional repository or allow the library to do so on my behalf, subject to Irish Copyright Legislation and Trinity College Library conditions of use and acknowledgement.

Jennifer S. Day
II Summary

The complex structure of a neuron, comprising of an axon and dendrites (collectively termed neurites), is integral to the formation of functional networks in the central nervous system during development and after injury. Understanding the mechanisms involved in neuritic growth is imperative for regenerative neuroscience, and may lead to symptomatic cures for neurodegenerative diseases.

Noradrenaline (NA) is a catecholaminergic monoamine neurotransmitter which has been shown to have many neuroprotective properties via an action on the glial β2-adrenoceptor. The first aim of this thesis was to assess the ability of NA to induce neuritic growth of primary cortical neurons in vitro via (a) a direct action on neuronal adrenoceptors, and (b) an indirect action via glial adrenoceptors on primary mixed glial cells. Neurons were treated either directly with NA (1, 5, 10 µM) or with the conditioned media (CM) from NA treated glial cells (NA CM). Any changes in neuronal morphology were determined using Sholl analysis, a method used to examine structure of primary neurites, neuritic branching and neuritic length of neurons. The results demonstrated that CM from NA treated glial cells, but not NA itself, increased the number of primary neurites, neuritic branching and the neuritic length of the primary cortical neurons when compared to control treated neurons.

The second aim of this study was to determine the receptor subtype and glial cell type by which NA-CM may be inducing its effect. It was determined that the effect of NA was mediated via the β2-adrenoceptor present on astrocytes as use of the β-adrenoceptor antagonist, propranolol, and not the α-adrenoceptor antagonist, phentolamine, attenuated NA CM-induced increases in neuritic growth. In addition, the selective β2-adrenoceptor agonists clenbuterol and salmeterol, but not the β1-adrenoceptor agonist, xamoterol, mimicked the NA CM-induced neuritic growth suggesting that it is in fact the β2-adrenoceptor and not the β1-adrenoceptor that is involved in this process. This was further supported by the finding that similar neuronal changes were found with the utilisation of the cell permeable cAMP analogue, dbcAMP, which is downstream of β2-adrenoceptor activation. Furthermore activation of the β-adrenoceptors on astrocytes but not on microglia led to increases in neuritic growth compared to control neurons, demonstrating that it is the astrocytes which are involved in this NA-mediated neuritic growth.

The ability of NA CM to induce neuritic growth was attributed to increased release of IL-6 and to a lesser extent GDNF and FGF-2 from the astrocytes, in combination with the presence of the neurotrophin, NGF-β. This was deduced as inhibition of each of these factors attenuated NA CM-induced neuritic growth to some degree. In addition to this, the phosphatidylinositol 3-kinase (PI3K), mitogen activated protein kinase (MAPK) and JAK-STAT signalling pathways have been implicated in NA CM-induced neuritic growth as phosphorylation of downstream mediators of each of these pathways was observed in NA CM-treated primary cortical neurons. Moreover, inhibition of these pathways via wortmannin and LY294002, PD98059 or S31-201 respectively attenuated the NA CM-induced neuritic growth previously observed.

Taken together, these results demonstrate a novel role for the astrocytic β2-adrenoceptor in inducing neuritic growth of cortical neurons. These findings may provide a therapeutic strategy for encouraging neuritic growth following neurodegeneration.
III Acknowledgements

I would first of all like to thank my supervisor, Professor Thomas Connor, for giving me the opportunity to complete my Ph.D. in his laboratory, and for all his guidance, support and well wishes over the years. Without him, this thesis would not have been possible, and so I am eternally grateful for his assistance.

I also wish to thank Professor Marina Lynch, TCIN, the department of Physiology and the HRB programme for taking me for this Ph.D. I have thoroughly enjoyed my time at TCIN and so would like to thank you for giving me this opportunity. I am also so grateful to all the staff in TCIN and physiology for all the assistance over the years.

In addition, a massive thank you to all the members of the TC/AH lab both past and present: Noreen, Karen, Dana, Lorna, Natacha, Alessia, Katie, Jen R, Aine, Valentina, Sinead, Óladaoin, Raasay, Eimear, Martina, Barry, Shane. Every single one of you has helped me bring this thesis to light, and for that I thank you. I would also like to thank my students over the years; Katie S., Katie M., Nick, Caroline and Eimear, thank you for your enthusiasm and hard-work, I wish you luck in all your future endeavours.

I would also like to take this opportunity to thank the other labs in TCIN. In particular Professor Mani Ramaswami and Dr. Joern Huelsmeier for their kindness in allowing use of their fluorescent microscope and all the assistance they gave me. Also to all the members of MAL, VAC, CC, Kelly, KKD and SOM labs for all the support over the years, both academic and social! In particular my HRB class: Ranya, Liz, Amy, Donal and Rodrigo, thank you guys, I couldn’t have done this without you.

And last but by no means least, my family and friends. My parents; Janet and Colin, and my brothers; Andrew and Steven, thank you for your love, support and words of encouragement. Thank you also to Owen, for putting up with me, and for always being so supporting. To the rest of my family; my grandparents, aunts, uncles, cousins, nephew and sisters-in-law thank you for believing in me.
IV Table of Contents

I Declaration........................................................................................................................i
II Summary........................................................................................................................iii
III Acknowledgements....................................................................................................v
IV Table of Contents.....................................................................................................vii
V List of Figures............................................................................................................xii
VI List of Tables...........................................................................................................xiv
VII Abbreviations...........................................................................................................xv
Chapter 1 .............................................................................................................................1
  1 Introduction.....................................................................................................................1
    1.1 Cells of the central nervous system .............................................................................1
      1.1.1 Astrocytes .............................................................................................................1
      1.1.2 Microglia ..............................................................................................................3
      1.1.3 Neurons and Neuronal Growth .............................................................................4
      1.1.4 The importance of neuronal protection and neuronal growth .........................7
    1.2 Noradrenaline ..........................................................................................................9
      1.2.1 Noradrenaline synthesis and metabolism .........................................................9
      1.2.2 The adrenoceptors ............................................................................................10
      1.2.3 Functions of NA .............................................................................................13
    1.3 Serotonin ..............................................................................................................14
      1.3.1 Serotonin synthesis and metabolism ...............................................................14
      1.3.2 Serotonin receptors .........................................................................................15
      1.3.3 Functions of 5-HT .........................................................................................15
    1.4 Pathways Associated with Neuronal Growth ..........................................................16
      1.4.1 The Mitogen Activated Protein Kinase Pathway .............................................16
      1.4.2 Phosphoinositide Signalling ...........................................................................20
      1.4.3 Signalling via the receptor tyrosine kinases ....................................................22
    1.5 Neuroprotective and neuronal growth inducing factors .........................................23
      1.5.1 Neurotrophins ..................................................................................................23
      1.5.2 Glial-derived neurotrophic factor .....................................................................28
      1.5.3 FGF-2 ...............................................................................................................31
      1.5.4 VEGF ..............................................................................................................34
      1.5.5 Interleukin-6 ....................................................................................................35

vii
1.6 Objectives of thesis .................................................................................................................. 39

Chapter 2 ......................................................................................................................................... 41

Materials and Methods .................................................................................................................. 41

2.1 Materials ..................................................................................................................................... 39

2.1.1 Animals ................................................................................................................................... 39

2.1.2 Experimental Treatments ......................................................................................................... 39

2.1.3 Cell Culture Materials ............................................................................................................ 41

2.1.4 Assay Kits ................................................................................................................................ 42

2.1.5 Molecular Reagents ................................................................................................................ 42

2.1.6 General Laboratory Plastics .................................................................................................... 43

2.1.7 General Laboratory Chemicals ................................................................................................. 43

2.1.8 Western Blotting and Staining reagents and antibodies .......................................................... 45

2.2 Methods ..................................................................................................................................... 46

2.2.1 Aseptic Technique .................................................................................................................. 46

2.2.2 Preparation of Culture Media and Test Compounds ............................................................... 47

2.2.3 Preparation of coverslips ......................................................................................................... 49

2.2.4 Preparation of Primary Cultures .............................................................................................. 49

2.2.5 Preparation of C6 glioma cells .................................................................................................. 52

2.2.6 Cell culture treatments ............................................................................................................ 53

2.2.7 Harvesting glial cultures for mRNA analysis ............................................................................ 54

2.2.8 Preparation of neuronal cultures for Western Immunoblotting ............................................. 54

2.2.9 RNA Analysis ........................................................................................................................ 54

2.2.10 Fluorescent Immunocytochemistry and Sholl Analysis ......................................................... 57

2.2.11 Cell Viability assay: Alamar Blue ............................................................................................. 61

2.2.12 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Immunoblotting .............................................................................................. 61

2.2.13 Enzyme-linked Immunosorbent assays (ELISA) .................................................................. 64

Table 2.4 ELISA antibodies and procedures ................................................................................. 65

2.2.14 Statistical Analysis ................................................................................................................ 66

Chapter 3 ......................................................................................................................................... 67

3.1 Examination of the impact of neurotransmitters on neuronal complexity .................................. 69

3.1.1 Effect of noradrenaline on neuronal complexity: A role for glial cells ................................. 70

3.1.2 NA has no effect on neuronal complexity of primary cortical neurons ............................... 75

3.1.3 5-HT CM has no effect on the morphology of primary cortical neurons ............................. 79
3.1.4 5-HT has no effect on neuronal complexity of primary cortical neurons ........................................ 82
3.1.5 Amitriptyline CM increases some measures of neuronal morphology ............................................... 85
3.1.6 Direct Amitriptyline treatment increases neuronal complexity .......................................................... 88

3.2 Examination of the glial adrenoceptor subtype involved in noradrenaline mediated neuronal morphology changes ......................................................................................................................... 91
3.2.1 NA CM-induced increases in neuronal morphology are primarily attributed to the β-adrenoceptor .................................................................................................................................................. 92
3.2.2 Salbutamol CM increases measures of neuronal morphology ................................................................. 96
3.2.3 The β2-adrenoceptor agonists, salmeterol and clenbuterol, but not the β1-adrenoceptor agonist, xamoterol, increases measures of neuronal morphology .......................................................... 99
3.2.4 The cAMP analogue, dbcAMP, CM increases neuronal complexity ...................................................... 102

3.3 NA stimulation of astrocytic β-adrenoceptors are responsible for the NA CM-induced increases in neuronal complexity .......................................................................................................................................... 106
3.3.1 NA CM from enriched astrocytes increases neuronal complexity ......................................................... 107
3.3.4 NA CM from enriched microglia does not increase neuronal morphology ........................................ 111
3.3.2 Salbutamol CM from enriched astrocytes increases neuronal complexity ........................................... 114
3.3.3 DbcAMP CM from enriched astrocytes increases neuronal complexity ............................................... 117

3.4 C6 glioma cells as a model of primary astrocytes .................................................................................... 120
3.4.1 C6 glioma cells express the astrocytic markers S100β and GFAP ...................................................... 121
3.4.2 The C6 glioma cells express the β2-adrenoceptor ................................................................................. 122
3.4.3 NA CM from C6 glioma cells shows no effect on neuronal morphology ............................................ 123

3.5 A role for glial-derived growth factors in mediating the effects of NA CM on neuronal morphology .................................................................................................................................................. 125
3.5.1 NA and Salb treatment of glial cells induce the expression of growth factors ................................... 126
3.5.2 NA increases the release of growth factors from glial cells ................................................................. 130
3.5.3 GDNF increases neuronal complexity of primary cortical neurons ................................................. 131
3.5.4 NGF-β increases neuronal complexity of primary cortical neurons .................................................... 134
3.5.5 BDNF increases neuronal complexity of primary cortical neurons .................................................... 137
3.5.6 FGF-2 increases neuronal complexity of primary cortical neurons ..................................................... 140
3.5.7 VEGF does not increase neuronal complexity of primary cortical neurons ........................................ 143
3.5.8 IL-6 increases neuronal complexity of primary cortical neurons ....................................................... 146
3.5.9 Neutralization of GDNF attenuates some NA CM-induced increases in measures of neuronal complexity ........................................................................................................................................ 149
3.5.10 Inhibition of NGF-β and BDNF signalling blocks NA CM-induced increases in neuronal complexity ........................................................................................................................................ 152
3.5.11 Neutralization of FGF-2 attenuates NA CM-induced increases in neuronal complexity ....................... 155
3.5.12 Inhibition of IL-6 Signalling blocks NA CM-induced increases in neuronal complexity
..................................................................................................................................................................158

3.6 Signalling pathways mediating the ability of NA CM to increase the complexity of primary
cortical neurons ............................................................................................................................................161

3.6.7 NA CM activates signaling pathways associated with neuronal growth in neurons.... 162

3.6.1 Inhibitors of the PI3K pathway blocks NA CM-induced increases in neuronal
morphology ............................................................................................................................................164

3.6.2 An inhibitor of the MAPK pathway attenuates NA CM-induced increases in neuronal
morphology ............................................................................................................................................167

3.6.3 An inhibitor of the STAT3 pathway blocks NA CM-induced increases in neuronal
morphology ............................................................................................................................................170

4 Discussion ........................................................................................................................................175

4.1 CM from NA treated glial cells but not a direct stimulation with NA, induces neuritic
growth of primary cortical neurons .......................................................................................................176

4.2 5-HT does not induce neuritic growth ...........................................................................................177

4.3 The NA/5-HT reuptake inhibitor, AMI, induces neuritic growth via both an action on glial
cells and a direct action on neurons .................................................................................................179

4.4 The β2-adrenoceptor is involved in NA CM-induced neuritic outgrowth ...............................181

4.5 Astrocytes and not microglia are involved in the NA CM-induced neuritic growth.............183

4.6 The C6 glioma cell line cannot be used as a model for the ability of primary astrocytes
in vitro to induce neuritic growth ........................................................................................................185

4.7 Factors involved in inducing neuronal growth by NA CM .......................................................186

4.7.1 GDNF contributes to the NA CM increases in neuronal complexity .....................................187

4.7.2 The presence of the neurotrophins; NGF-β and BDNF, are required for NA CM-
induced increases in neuronal complexity ..........................................................................................188

4.7.3 FGF-2 contributes to NA CM-induced increases in neuronal complexity .........................191

4.7.4 VEGF does not contribute to the NA CM-induced increases in neuronal complexity .......192

4.7.5 IL-6 is required for the NA CM-induced increases in neuronal complexity .................193

4.7.6 Cross-talk between the neuritic growth-inducing factors .................................................194

4.8 Signalling Pathways involved in NA CM-induced increases in neuronal morphology .........196

4.8.1 The PI3K pathway is involved in NA CM-induced increases in neuronal morphology ....196

4.8.2 The MAPK pathway is involved in NA CM-induced increases in neuronal morphology ....198

4.8.3 The STAT3 pathway is involved in NA CM-induced increases in neuronal morphology ....200

4.8.4 Cross-talk between the PI3K, MAPK and STAT3 Pathways ...........................................201

4.9 The induction of neuritic growth; the answer to neuronal degeneration? .........................202

4.10 Research Limitations and Future Directions ..........................................................................204
Chapter 5: References
### V List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Functions of astrocytes</td>
<td>2</td>
</tr>
<tr>
<td>1.2</td>
<td>A typical neuron</td>
<td>5</td>
</tr>
<tr>
<td>1.3</td>
<td>The noradrenergic neuron</td>
<td>11</td>
</tr>
<tr>
<td>1.4</td>
<td>Signalling at the $\beta_2$-adrenoceptor</td>
<td>13</td>
</tr>
<tr>
<td>1.5</td>
<td>Four main branches of MAPK Signalling</td>
<td>17</td>
</tr>
<tr>
<td>1.6</td>
<td>ERK1/2 Branch of MAPK Signalling</td>
<td>19</td>
</tr>
<tr>
<td>1.7</td>
<td>PI3K signalling leads to neuritic growth</td>
<td>21</td>
</tr>
<tr>
<td>1.8</td>
<td>Signalling via the Trk Receptors</td>
<td>24</td>
</tr>
<tr>
<td>1.9</td>
<td>Signalling via the p75 receptor</td>
<td>25</td>
</tr>
<tr>
<td>1.10</td>
<td>Signalling of GDNF</td>
<td>30</td>
</tr>
<tr>
<td>1.11</td>
<td>FGF-2 Signalling via the FGFR</td>
<td>33</td>
</tr>
<tr>
<td>1.12</td>
<td>IL-6 Signalling</td>
<td>37</td>
</tr>
<tr>
<td>2.1</td>
<td>C6 Glioma Cells growth and morphology</td>
<td>53</td>
</tr>
</tbody>
</table>
Figure 2.2  Neuron stained with βIII tubulin and Hoescht (A) with overlaying Sholl analysis concentric circles (B)

Figure 2.3  Sholl profile of untreated rat primary cortical neurons

Figure 4.1  AMI leads to dimerisation of Trk receptors which may lead to neuritic growth via the PI3K and MAPK pathway

Figure 4.2  A unified theory for NA CM-induced neuritic growth
## VI List of Tables

<table>
<thead>
<tr>
<th>Table 2.1</th>
<th>Drug Interventions</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 2.2</td>
<td>List of primers for PCR</td>
<td>57</td>
</tr>
<tr>
<td>Table 2.3</td>
<td>Antibody dilutions for western Immunoblotting</td>
<td>63</td>
</tr>
<tr>
<td>Table 2.4</td>
<td>ELISA antibodies and procedures</td>
<td>65</td>
</tr>
</tbody>
</table>
VII Abbreviations

5-HT \hspace{1cm} \text{Serotonin}
5-HTP \hspace{1cm} \text{5-Hydroxytryptophan}
AAAD \hspace{1cm} \text{L-Aromatic amino acid decarboxylase}
AD \hspace{1cm} \text{Alzheimer's Disease}
ALS \hspace{1cm} \text{Amyotrophic lateral sclerosis}
AMI \hspace{1cm} \text{Amitriptyline}
ANOVA \hspace{1cm} \text{Analysis of Variance}
Ask-1 \hspace{1cm} \text{Apoptosis signal-regulating kinase I}
ATF2 \hspace{1cm} \text{Activating transcription factor 2}
ATP \hspace{1cm} \text{Adenosine triphosphate}
BAD \hspace{1cm} \text{Bcl-2-associated death promoter}
BBB \hspace{1cm} \text{Blood-brain-barrier}
BDNF \hspace{1cm} \text{Brain-derived neurotrophic factor}
BSA \hspace{1cm} \text{Bovine serum albumen}
cAMP \hspace{1cm} \text{Cyclic adenosine monophosphate}
CBP \hspace{1cm} \text{CREB-binding protein}
CDMEM \hspace{1cm} \text{Complete DMEM}
Clen \hspace{1cm} \text{Clenbuterol}
CM \hspace{1cm} \text{Conditioned medium}
CNBM \hspace{1cm} \text{Complete NBM}
CNS \hspace{1cm} \text{Central nervous system}
CNTF \hspace{1cm} \text{Ciliary neurotrophic factor}
CREB \hspace{1cm} \text{cAMP response element binding}
DAPI \hspace{1cm} \text{4',6-diamidino-2-phenylindole}
dbcAMP \hspace{1cm} \text{Dibutyryl adenosine 3',5'-cyclic monophosphate}
DIV \hspace{1cm} \text{Days in vitro}
DMEM \hspace{1cm} \text{Dulbecco's modified eagles medium}
DOPA \hspace{1cm} \text{3,4-dihydroxyphenylalanine}
DPBS \hspace{1cm} \text{Dulbecco's phosphate buffered saline}
DRG \hspace{1cm} \text{Dorsal root ganglion}
EGF \hspace{1cm} \text{Epidermal growth factor}
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elk1</td>
<td>ETS-like transcription factor 1</td>
</tr>
<tr>
<td>EMT</td>
<td>Extraneuronal monoamine transporter</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signal-regulated kinases</td>
</tr>
<tr>
<td>EtOH</td>
<td>Ethanol</td>
</tr>
<tr>
<td>F-actin</td>
<td>Filamentous actin</td>
</tr>
<tr>
<td>FBS</td>
<td>Foetal bovine serum</td>
</tr>
<tr>
<td>FGF</td>
<td>Fibroblast growth factor</td>
</tr>
<tr>
<td>FGFR</td>
<td>FGF receptor</td>
</tr>
<tr>
<td>Frk</td>
<td>Forkhead-related transcription factor</td>
</tr>
<tr>
<td>FRS</td>
<td>Fibroblast growth factor receptor substrate</td>
</tr>
<tr>
<td>GAB</td>
<td>Grb-2 associated binder</td>
</tr>
<tr>
<td>GABA</td>
<td>γ-aminobutyric acid</td>
</tr>
<tr>
<td>GDNF</td>
<td>Glial-derived neurotrophic factor</td>
</tr>
<tr>
<td>GDP</td>
<td>Guanosine diphosphate</td>
</tr>
<tr>
<td>GFAP</td>
<td>Glial fibrillary acidic protein</td>
</tr>
<tr>
<td>GFL</td>
<td>GDNF family ligand</td>
</tr>
<tr>
<td>GFR-α</td>
<td>GDNF family receptor α-component</td>
</tr>
<tr>
<td>GPCR</td>
<td>G-protein coupled receptor</td>
</tr>
<tr>
<td>Grb-2</td>
<td>Growth factor receptor-bound protein 2</td>
</tr>
<tr>
<td>GSK3β</td>
<td>Glycogen synthase kinase 3β</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanosine triphosphate</td>
</tr>
<tr>
<td>HCL</td>
<td>Hydrochloric acid</td>
</tr>
<tr>
<td>HPA</td>
<td>Hypothalamic-pituitary-adrenal</td>
</tr>
<tr>
<td>IFN</td>
<td>Interferon</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Interleukin 1β</td>
</tr>
<tr>
<td>IL-6</td>
<td>Interleukin-6</td>
</tr>
<tr>
<td>IL-6R</td>
<td>Interleukin-6 receptor</td>
</tr>
<tr>
<td>IL-6Rα</td>
<td>IL-6 receptor α</td>
</tr>
<tr>
<td>IRS</td>
<td>Insulin receptor substrate</td>
</tr>
<tr>
<td>JAK</td>
<td>Janus kinases</td>
</tr>
<tr>
<td>JNK</td>
<td>c-Jun NH2-terminal kinases</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>MAP</td>
<td>Microtubule associated proteins</td>
</tr>
</tbody>
</table>
MAPK  Mitogen activated protein kinase
MAPKK  MAPK kinase
MAPKKK  MAPK kinase kinase
MEK  MAPK kinase
MHC  Major histocompatibility complex
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mTOR  Mammalian target of rapamycin
NA  Noradrenaline
NBM  Neurobasal Medium
NCAM  Neural cell adhesion molecule
NET  Noradrenaline transporter
NFAT  Nuclear factor of activated T cells
NFκB  Nuclear factor kappa B
NGF  Nerve growth factor
NGS  Normal goat serum
NIK  NFκB inducing kinase
NT3  Neurotrophin 3
NT4/5  Neurotrophin 4/5
P90  S6 Kinase p90
Pak  p21-activated kinase
PBS  Phosphate buffered saline
PCR  Polymerase Chain Reaction
PD  Parkinson's Disease
PDK1  Phosphoinositide dependent kinase I
PI3K  Phosphatidylinositol 3-kinase
PIP2  Phosphatidylinositol 4,5-bisphosphate
PIP3  Phosphatidylinositol 3,4,5-trisphosphate
PKA  protein kinase A
PKC  Protein kinase C
PTEN  Phosphatase and tensin homolog
Rac  Ras-related C3 botulinum toxin substrate
Rap-1  Ras-related protein 1
RET  Rearranged during transfection
RT  Room temperature
RTK  Receptor tyrosine kinase
RT-PCR  Real-time PCR
Salb  Salbutamol
Salm  Salmeterol
SERT  Serotonin transporter
SH  Src homology
sIL-6R  Soluble IL-6 receptor
SMA  Spinal muscular atrophy
SOCS  Suppressors of cytokine signalling
SOS  Son of sevenless
TGF-β  Transforming growth factor β
TNF  Tumour necrosis factor
Traf6  TNF receptor associated factor 6
Trk  Tropomyosin receptor kinase
VEGF  Vascular endothelial growth factor
VMAT  Vesicular monoamine transporter
Xam  Xamoterol
Chapter 1

Introduction
1 Introduction

"Intellectual power, and its most noble expressions, talent and genius, do not depend on the size or number of cerebral neurons, but on the richness of their connective processes”

Santiago Ramon y Cajal: Recollections of My Life, 1884

As Cajal realised in the 1800s, the complex structure of a neuron is essential to all aspects of neuronal function (Cajal, 1937). Understanding the mechanisms of neuritic growth, that is, the growth of axons and dendrites, is important to many areas including developmental neuroscience and regenerative medicine. This thesis largely focuses on the ability of noradrenaline (NA), a neurotransmitter, to impact upon the growth and complexity of primary cultures of cortical neurons (herein called “primary cortical neurons”).

1.1 Cells of the central nervous system

The cells of the central nervous system (CNS) primarily consist of neurons and glia. A neuron, or nerve cell, is the fundamental building block of the CNS. Neurons carry signals both electrically via propagation of an action potential, and chemically via neurotransmitter release at a nerve terminal (Rang & Dale, 2003). Glial cells outnumber neurons, constituting 90% of the cells in the brain and comprising of more than half the volume. There are four subtypes of glial cells in the CNS; astrocytes, microglia, oligodendrocytes and ependymal cells. Traditionally, glia were seen as support cells for neurons and nothing more, however, it is now known that glia have many important functions including synapse formation (for review, see Barker & Ullian, 2008) and immunity (for review, see Graeber et al., 2011).

1.1.1 Astrocytes

It was originally thought that astrocytes merely functioned as nutrient providers and buffers of ionic fluxes and neurotransmitter release. However, astrocytes are now known to be involved in neuronal development, synapse formation and upkeep, blood-brain-barrier (BBB) formation and upkeep, modulation of neuronal ionic signalling, support of neuronal metabolic pathways, neurotransmitter homeostasis, clearance of free radicals, immune function and also the provision of trophic support (see Figure 1.1; for reviews see Laming et al., 2000; Abbott et al., 2006; Markiewicz & Lukomska, 2006). Furthermore, astrocytes express receptors for most, if not all, neurotransmitters, and also demonstrate...
functional downstream signalling following neurotransmitter binding. As such, astrocytes express functional receptors for NA (both α and β adrenoceptors), acetylcholine, serotonin (5-HT), dopamine, γ-Aminobutyric acid (GABA), glutamate, neuropeptides, histamine and the opioids (for review see Kimelberg, 1995).

Figure 1.1: Functions of astrocytes
Astrocytes are involved in neuronal metabolism, the formation of the blood brain barrier, neurotransmitter removal, synapse formation, buffering ionic fluxes, trophic support, immune function and the clearance of free radicals.

1.1.1.1 Astrocytes and neuronal regeneration

Astrocytes are associated with the inability of neurons to regenerate following trauma. The astrocytes form a "glial scar" which is not only a physical barrier, but also an inhibitory environment as they secrete a number of inhibitory molecules that prevent axonal regrowth. These include tenascin, semaphorins and chondroitin sulphate proteoglycans (for review see Fitch & Silver, 2008). CNS neurons do however have the capacity for regeneration (Fitch & Silver, 2008), and so overcoming these inhibitory signals, or encouraging astrocytes to create a more permissive environment for neuronal regrowth is a promising strategy for neuronal regeneration research. Leading on from this, astrocytes are also vital for neuronal survival and growth. For example, astrocytes encourage a neuritic phenotype from neuronal cells in culture (Desagher et al., 1996; Trentin et al., 2003; Tom et al., 2004; Oh et al., 2009). Furthermore, astrocytes are capable of protecting neurons from toxic insults including amyloid-β toxicity (Yamamuro et al., 2003) and oxidative stress (Desagher et al., 1996; Tanaka et al., 1999; Takano et al., 2009), as well
as having the ability to produce and secrete a range of neurotrophic factors which provide protection to neurons. These include, for example; glial cell line-derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), nerve growth factor β (NGF-β), neurotrophin-3 (NT-3) and fibroblast growth factor 2 (FGF-2) (Appel et al., 1997; Basu & Yang, 2005; Toyomoto et al., 2005; Delgado-Rivera et al., 2009; Tanabe et al., 2009; Mele et al., 2010).

1.1.2 Microglia

Microglial cells, considered the brain’s immune cells, belong to the monocytic lineage but their immune receptors are less prevalent compared to those of macrophages. Much of the focus on microglial cells is on their capacity to be highly activated upon toxic stimuli, such as inflammation or neurodegeneration. Upon activation, the microglia retract their processes, and become more amoeboid in morphology. They upregulate the expression of major histocompatibility complex (MHC) class II receptors, adhesion molecules and endocytotic receptors, release pro-inflammatory cytokines and reactive oxygen species, and increase their phagocytic capacity (for reviews, see Aloisi et al., 2000; Galea et al., 2007). In addition to this, activated microglial cells are capable of producing a range of pro-inflammatory mediators which are detrimental to neurons, for example; tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interferon-γ (IFN-γ) (for review, see Liu & Hong, 2003). Further, microglial cells have been associated with many of the neurodegenerative diseases in the brain which can be considered as chronic inflammatory states. For example, activated microglial cells associate with amyloid plaques in Alzheimer’s Disease (AD) and are found activated in the substantia nigra of Parkinson’s Disease (PD), the main area of neuronal loss in this disease (for review, see Liu & Hong, 2003).

Unactivated microglial cells are considered as “resting”, but are far from that. These “resting” microglial cells continuously extend and retract their processes, possibly sampling their environment for pathogens (Davalos et al., 2005; Nimmerjahn et al., 2005). In addition to a role in immunity, microglial cells are also vital for synaptic pruning during development, and may also be important for ongoing experience-driven synaptic remodelling (for review, see Tremblay et al., 2011). Indeed, pruning of synaptic contacts by microglia requires the use of complement receptors, which are more commonly associated with the innate immune system (for review see Schafer & Stevens, 2010).
Interestingly, there is evidence to suggest that this process may become overactivated during neurodegenerative episodes, leading to excessive synaptic pruning (Stevens et al., 2007). Furthermore, microglial cells express a large range of neurotransmitter receptors. These include receptors for glutamate, GABA, ATP, acetylcholine, cannabinoids, NA, dopamine and for the neuropeptides (for review, see Pocock & Kettenmann, 2007). These neurotransmitter receptors have many functions, for example activation of the adrenergic receptors reduces microglial activation and attenuates cytokine release upon LPS stimulation (Pocock & Kettenmann, 2007). In addition to this, microglial cells can also release trophic factors such as BDNF, GDNF, ciliary neurotrophic factor (CNTF), NGF and FGF-2 (Heese et al., 1998; Batchelor et al., 2002; Harada et al., 2002).

1.1.3 Neurons and Neuronal Growth

Neurons are comprised of a cell body, an axon and dendrites (see Figure 1.2). Understanding the mechanisms of neuronal growth is vital firstly for unravelling the development of the nervous system and secondly, to develop strategies for encouraging neuronal growth following brain trauma, infection or neurodegenerative disorders. Neuronal growth can be divided into two main types; the elongation of a neurite, and the generation of new neuritic branches. Although much of the work on neuronal growth focuses on the growth of an axon, research shows that the same fundamental mechanisms (described below) also occur in dendrites (for review, see Scott & Luo, 2001).
Neurons contain a cell body off which stems dendrites and an axon (collectively termed neurites). Growth cones contain protruding F-actin filopodia and are invaded by microtubules to lengthen the neurite.

1.1.3.1 Mechanisms involved in increasing neuritic length

The lengthening of a neurite is fundamentally controlled by the growth cone. The growth cone located at the tip of the neurite is comprised of a central domain and a peripheral domain. The central domain contains a large concentration of the cytoskeletal protein microtubule similarly to as found in the main axon shaft, while the peripheral domain has a higher concentration of actin filaments (for review, see Goldberg, 2003). Growth cone advancement can be divided into three main stages; ‘protrusion’ of filamentous actin (F-actin)-containing filopodia into the environment; ‘engorgement’, where microtubules invade the F-actin peripheral domain often bringing essential membrane components and other machinery; and ‘consolidation’ where the growth cone has advanced and its remnants begin to reassemble the axon shaft. The F-actin polymers are composed of monomers of β-actin and γ-actin (for review, see Dent & Gertler, 2003). The peripheral domain actin filaments are continuously polymerising thus driving the growth cone forward. However, at the same time myosin motors at the central domain pull back the entire actin filament where it depolymerises. This backward flow of actin filaments prevents the central domain from moving forward and hence prevents advancement of the growth cone. It is the balance of the backward and forward actin polymerisation that drives growth cone advancement, with growth-promoting external cues pushing the
balance in favour of forward motion. The forward motion is accompanied by microtubule invasion into the peripheral zone, which moves the central domain forward and hence elongates the axon (for review, see Goldberg, 2003). Microtubules are composed of tubulin heterodimers of one α-tubulin and one β-tubulin unit (for review, see Dent & Gertler, 2003). Microtubules are formed into linear protofilaments of which 10-15 come together to form a protofilament. These heterodimers line up in a specific manner with the β-tubulin facing towards the growing end of the protofilament (plus end) and the α-tubulin facing the opposite end (minus end). Guanosine triphosphate (GTP) is bound to the tubulin heterodimer, and is hydrolysed to guanosine diphosphate (GDP) upon the dimer joining another dimer in a protofilament. Thus the protofilament has mainly GDP attached, with a GTP cap at the growing end ready to be hydrolysed by the addition of the next dimer. This GTP cap stabilises the structure, and if this is lost, the protofilament quickly depolymerises. Upon entering the growth cone, microtubules depolymerise and reorganise, a step which is essential for growth cone advancement and axonal elongation. The assembly of microtubules is regulated by microtubule assembly promoting factors, microtubule stabilising factors, microtubule associated proteins (MAPs), as well as microtubule associated motors (for review, see Conde & Caceres, 2009). Furthermore, the growth of an axon requires the insertion of new membrane which is primarily formed in the cell bodies and transported to the growing axon, or in endoplasmic reticulum at the axon itself. Also, the axon is capable of synthesising proteins which are required for neuronal growth (for review, see Goldberg, 2003).

1.1.3.2 Mechanisms involved in increasing axonal branching

The branching of an axon can occur via two main methods. Firstly, the axon can split into two at the growing growth cone at the axons tip. This method can occur for example if the growth cone approaches an inhibitory signal head-on. The signal halts straight-forward axonal growth but the growth cone at each side continues to advance, leading to uneven growth between the sides and the middle. Eventually the two sides will split to result in two independent branches.

The second mechanism is the formation of an axon collateral, that forms independently of the growth cone (for review, see Gallo, 2011). Axon collaterals are the branches of an axon occurring along its shaft rather than from the growth cone. It begins by the collection of F-actin, known as F-actin patches which will either eventually dissipate or form a
Chapter 1: Introduction

filopodium and thus a neuritic branch. It is not known how these patches turn into a filopodium but the actin-associated protein fascin might be involved (Ketschek et al., 2011). For a filopodium to evolve into a mature neurite it must be stabilised to prevent its integration back into the main axon shaft, this is helped by the invasion of axonal microtubules into the filopodium. In addition to this, at points where the growth cone pauses, axon collaterals often emerge (for review, see Gallo, 2011). Most of the knowledge about collateral branching has focused on axonal branching; however collaterals also form on dendrites and the same mechanisms are thought to produce dendritic branches (Scott 2001). Furthermore, neurons also undergo the process of producing primary neurites, that is, neurites that extend directly from the cell soma. It is these neurites that will also eventually become the axon and the dendrites. However, surprisingly little is known about how a neuron initiates the formation of a primary neurite (for review, see Luo, 2002).

1.1.4 The importance of neuronal protection and neuronal growth

Although there is limited potential of the brain to produce new neurons during a lifetime (for review, see Gage, 2002), the neurodegeneration that occurs during brain injury, stroke, AD, PD, ageing and infection is permanent, and leads to debilitating symptoms. Therefore, developing methods of protecting neurons from cell death during these conditions, as well as methods to encourage the regrowth of damaged neurons are vital for a cure for these CNS conditions. Neurotrophic factors, for example, are often associated with an ability to protect neurons from toxicity (e.g. Nagahara et al., 2009), and clinical trials for the use of, for example, the neurotrophin BDNF in neurodegenerative diseases are ongoing (for review, see Nagahara & Tuszynski, 2011). Unfortunately, neurotrophic factors cannot pass the BBB and so invasive procedures are required to directly utilise them in CNS disorders. Methods of indirectly increasing expression of neurotrophic factors via e.g. by encouraging neurotrophic factor release by glial cells following receptor activation could therefore prove beneficial for neuroprotective based therapies. As well as an ability to protect neurons from cell death, neurotrophic factors can also encourage neuritic growth of neurons both under basal conditions e.g. (Chao et al., 2003; Lee et al., 2009c; Cohen-Cory et al., 2010), and following neurodegeneration (Cao et al., 2008). Neuritic growth of neurons is vital for their integration into functional networks, and thus the use of neurotrophic factors would be of therapeutic value. For example, neuritic
growth is fundamental for memory formation, and thus encouraging neuritic growth could be beneficial to AD (for review, see Holtmaat & Svoboda, 2009). In line with this, the amyloid-β peptide induces neuritic loss from primary hippocampal neurons, which was attributed to activation of the p75 neurotrophin receptor (Knowles et al., 2009). Furthermore, a long-term imaging study of neuronal morphology in a mouse model of AD demonstrated that neurites passing near amyloid-β plaques were thinner and terminated abruptly (Tsai et al., 2004). Thus, an interesting strategy for neuronal regeneration could investigate means of enhancing neurotrophic factor production in the CNS without the need for an invasive procedure, and thus encourage neuritic growth.
1.2 Noradrenaline

Noradrenaline (NA) is a catecholaminergic monoamine neurotransmitter which is most abundantly expressed in the locus coeruleus complex, a cell group located in the brain stem. From this relatively small neuronal group, comprising only approximately 1,600 cells in the rat brain, the noradrenergic neurons project to almost all areas of the cerebral cortex, including; hippocampus, neocortex, amygdala, thalamus and hypothalamus, as well as to cerebellum and spinal cord (for review, see Feldman et al., 1997). NA activates a wide range of so-called adrenergic receptors, which are broadly divided into the alpha-adrenoceptors and the beta-adrenoceptors based on agonist potency (Rang & Dale, 2003). All of the adrenoceptors are G-protein coupled receptors (GPCR) and can mediate the actions of both NA and adrenaline.

1.2.1 Noradrenaline synthesis and metabolism

NA is synthesised from the amino acid tyrosine via three enzymatic steps (see Figure 1.3). Tyrosine, a non-essential amino acid found in many foodstuffs such as dairy products, chicken, fish and nuts, is taken up into catecholaminergic neurons. The enzyme tyrosine hydroxylase converts the tyrosine into 3,4-dihydroxyphenylalanine (DOPA). This enzyme is confined to noradrenergic and dopaminergic neurons in the CNS, and sympathetic and adrenal cells in the periphery, and is the rate limiting step for catecholamine synthesis. The enzyme is also inhibited by NA leading to strict regulation of the pathway. DOPA is then converted to dopamine by L-aromatic amino acid decarboxylase (AAAD), a relatively nonspecific enzyme as it also decarboxylates other aromatic amino acids such as L-histidine and L-tryptophan. In noradrenergic neurons, the dopamine is transported into vesicles by the vesicular monoamine transporter (VMAT) and converted to NA by dopamine β-hydroxylase located inside the vesicles in membrane-bound form. Because of this, only a small amount of the enzyme is released with NA release (for reviews, see Eisenhofer et al., 2001; Rang & Dale, 2003). VMATs, of which there is VMAT1 and VMAT2, package the monoamines into the vesicles in very high concentrations by use of a proton gradient across the membrane. Both transporters recognise all monoamines, with VMAT2 preferentially located in the nervous system (for review, see Iversen, 2006).

The catecholamines are metabolised via three enzymes; monoamine oxidase, catechol-O-methyltransferase and sulphotransferase (for review, see Eisenhofer et al., 2001). These enzymes are mainly intracellular, therefore the main method of inactivation of synaptic
NA is via active transport into both nerve terminals and astrocytes by the neuronal NA transporter (NET) (Inazu et al., 2003; Sager & Torres, 2011) or the extraneuronal monoamine transporter (EMT, also known as OCT3 in rat and mouse) which is expressed by astrocytes (Inazu et al., 2003) and neurons (Shang et al., 2003). The monoamine transporters function by using the electrochemical gradient of sodium and chloride ions. They transport the monoamine into the cell accompanied by both a sodium and chloride ion leading to a net increase in positive ion charges inside the cell (for review, see Iversen, 2006). These transporters are the targets of many antidepressant drugs which block the transporter and thus inhibit the reuptake of 5-HT (e.g. citalopram, fluoxetine), NA (e.g. reboxetine) or both (e.g. venlafaxine, amitriptyline) (for review, see Iversen, 2006).

1.2.2 The adrenoceptors

The adrenoceptors were first classified into α or β subtypes based on the potency of various synthetic amines on several physiological functions. For example, the α-adrenoceptors were shown to be mainly excitatory and to induce vasoconstriction, while the β-adrenoceptors were shown to be mainly inhibitory and to control vasodilation. The β-adrenoceptors were then further classified into β₁ and β₂ subtypes while further studies have since identified the β₃ subtype (for review, see Civantos Calzada & Aleixandre de Artinano, 2001).
Chapter 1: Introduction

Figure 1.3: The noradrenergic neuron

NA is produced from tyrosine in noradrenergic neurons via a series of enzymatic steps. Upon stimulation, the neuron releases a vesicle of NA which can bind to adrenergic receptors on both postsynaptic neurons and on surrounding astrocytes. NA is removed from the synaptic cleft by active reuptake into the nerve terminal by NET and EMT present on neurons and astrocytes. AAAD L-aromatic amino acid decarboxylase; β-AR, β-adrenoceptor; cAMP, cyclic adenosine monophosphate; DOPA, 3,4-dihydroxyphenylalanine; EMT, extraneuronal monoamine transporter; NA, noradrenaline; PKA, protein kinase A; VMAT, vesicular monoamine transporter.

1.2.2.1 The Alpha-adrenoceptors

The α-adrenoceptors are further classified into the α₁ and the α₂ subclass of receptors based on agonist sensitivity. The α₁-receptors all activate phospholipase C to produce inositol trisphosphate and diacylglycerol as secondary messengers (Rang & Dale, 2003). Each function via the G_{q/11} GPCR. These α₁ receptors are the most abundant of the adrenoceptors in the CNS; however their function is not entirely clear. The lack of specific α₁ agonists and antagonists has led to inadequate functional profiles of the α₁ subtypes in the CNS (Tanoue et al., 2003).
The $\alpha_2$-adrenoceptor agonists are widely used for the treatment of hypertension, glaucoma and attention deficit disorder (for review, see Gyires et al., 2009). In general, the $\alpha_2$ receptors lead to a reduction in cyclic adenosine monophosphate (cAMP) via coupling to $G_i$ and $G_o$, however, they can also lead to an increase in cAMP via coupling to $G_s$. Most of the physiological effects of $\alpha_2$ agonists can be attributed to function via the $\alpha_{2A}$ receptor. These receptors are involved in pre-synaptic inhibition of NA release, antinociception and hypothermia (for review, see Gyires et al., 2009).

1.2.2.2 Beta adrenoceptors

Each of the $\beta$-adrenoceptors are classed as GPCRs. Activation of the $\beta_1$-adrenoceptor stimulates salivation, increases heart rate and stimulates the breakdown of lipids (Rang & Dale, 2003). The $\beta_2$-adrenoceptor shows strong expression in the heart but is also expressed in the brain. Activation of the $\beta_2$-adrenoceptor has been associated with vasodilation of blood vessels and heart circadian rhythm regulation (for review, see Gauthier et al., 2011). However, of the three subtypes of $\beta$-adrenoceptors, it is the $\beta_2$-adrenoceptor which is primarily involved in the extra-synaptic functions of NA in the CNS. The $\beta_2$-adrenoceptor is positively coupled to the membrane-bound enzyme adenylate cyclase through a trimeric $G_s$ protein which has an $\alpha$ and $\beta\gamma$ subunit. Upon ligand binding, the receptor becomes stabilised which allows the $\alpha$-subunit to preferentially bind GTP rather than GDP. The energy from GTP catalyzes the conversion of adenosine triphosphate (ATP) to cAMP via adenylate cyclase. This cAMP then activates protein kinase A (PKA) (See Figure 1.4, for review, see Johnson, 2001). The $\beta_2$-adrenoceptor can also bind to $G_i$ and $G_q$ proteins (Daaka et al., 1997; Wenzel-Seifert & Seifert, 2000). $G_i$ protein coupling results in the stimulation of the mitogen-activated protein kinase (MAPK) pathway. It is thought that this occurs via the $\beta\gamma$ subunit of the $\beta$-adrenoceptor which acts as a scaffold protein for the tyrosine kinase proteins Src, Raf and Ras (for review, see Johnson, 2006). This pathway requires PKA phosphorylation of the $\beta_2$ receptor, as this impairs adenylate cyclase coupling. As adenylate cyclase activates PKA via $G_s$, this results in a negative feedback system, in which agonism at the $\beta_2$-adrenoceptor can lead to PKA activation, which then shuts down the $G_s$ pathway and activates the $G_i$ pathway leading to MAPK activation (Daaka et al., 1997). PKA results in the activation of the transcription factor cAMP response element-binding (CREB), which associates with the CREB-binding protein (CBP) and leads to the transcription of various genes (Herdegen & Leah, 1998).
As noradrenergic neurons project to such a wide range of CNS regions, e.g. prefrontal cortex, hypothalamus, thalamus, hippocampus and spinal cord (for review, see Feldman et al., 1997), it makes sense that NA is also involved in a wide range of CNS functions, for example; alertness, motivation, attention, sleep, the stress response and memory formation (for reviews, see Kobayashi & Yasoshima, 2001; Rang & Dale, 2003; Dunn & Swiergiel, 2008). For example, the hypothalamic-pituitary-adrenal axis (HPA), the main controller of stress, receives major input from noradrenergic neurons (for review, see Dunn & Swiergiel, 2008). NA also has an emerging role in memory consolidation. Activation of the cAMP/PKA pathway via β-adrenoceptor activation can modulate long-term potentiation, while depletion of the NA system can inhibit the formation of new memories (for review see Kobayashi & Yasoshima, 2001). Furthermore, there is a wealth of information linking NA to sleep, for example; blockade of adrenoceptors results in sedation, while knock-out mice for dopamine β-hydroxylase and thus for NA, show
altered sleep patterns (for reviews, see Gottesmann, 2008; Mitchell & Weinshenker, 2010). NA and in particular activation of the β-adrenoceptor is also associated with the dampening of the immune response in the CNS (for review, see Sanders & Straub, 2002). For example, NA induces the expression of the IL-1 receptor antagonist in primary cultures of mixed glial cells, which prevents IL-1 from binding to its receptor and thus limits pro-inflammatory downstream effects of IL-1 (McNamee et al., 2010b). Reports also show that depression and anxiety are associated with downregulation of the noradrenergic system in the CNS (for review, see Goddard et al., 2010)

Although there is only limited evidence that shows that NA might have a role in neuritic growth (Clarke et al., 2010), there is a wealth of information on the neuroprotective potential of NA. Firstly, NA, via an action on the β2-adrenoceptors, induces the production of a range of neurotrophic factors (Schwartz & Costa, 1977; Follesa & Mocchetti, 1993; Yamashita et al., 1995; Culmsee et al., 1999; Counts & Mufson, 2010; Manni et al., 2011). Secondly, there is much evidence both in vitro (Semkova et al., 1996; Junker et al., 2002) and in vivo (Zhu et al., 1998; Zeman et al., 1999; Zhu et al., 1999) demonstrating the ability of NA to protect neuronal cells from toxic insults. Therefore, the potential of utilising brain-permeable NA agonists, in particular β-adrenoceptor agonists, should be investigated as a possible means for encouraging neuronal regeneration.

1.3 Serotonin

Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter which is formed in serotonergic neurons originating in the raphe nuclei in the brainstem. These serotonergic nuclei can be divided into a rostral group, which mainly project to the cortex, hypothalamus, amygdala and hippocampus; and a caudal group which project to the brainstem and spinal cord (for review, see Hornung, 2003). 5-HT activates a wide range of receptors which are tentatively divided into seven families (5-HT1-7) and includes GPCRs and ligand-gated ion channels (for review, see Hannon & Hoyer, 2008).

1.3.1 Serotonin synthesis and metabolism

5-HT is synthesised from the essential amino acid tryptophan via two enzymatic steps. First, tryptophan is converted to 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan-5-hydroxylase. 5-HTP is then converted to 5-HT via the enzyme AAAD. Tryptophan is found in many foodstuffs including eggs, dairy, fish and seeds (Rang & Dale, 2003).
Synaptic 5-HT is taken back into the nerve terminal by the serotonin transporter (SERT), which is driven by sodium and chloride ions similarly to NET. 5-HT is also transported into synaptic vesicles by VMAT (for review, see Iversen, 2006).

1.3.2 Serotonin receptors

As previously mentioned, there are seven 5-HT receptor families (5-HT_{1-7}). The 5-HT_{1} family has five members (5-HT_{1A, B, D, E, F}) all of which are GPCRs and preferentially bind to G_{i/o} and thus negatively regulate adenylate cyclase (for review, see Hannon & Hoyer, 2008). The 5-HT_{1A} receptor for example has high expression on neurons of the cortex and hippocampus, and there is some evidence that it is also expressed on glial cells (for review, see Barnes & Sharp, 1999). Interestingly, this receptor is associated with inducing the release of NA from the cerebral cortex and hippocampus, and also may have an antidepressant action (Barnes & Sharp, 1999). The 5-HT_{2} family has three members 5-HT_{2A, B, and C} which are also all GPCRs and bind to G_{q/11} and therefore increase inositol phosphates and intracellular Ca^{2+} (for review, see Hannon & Hoyer, 2008). For example, the 5-HT_{2A} receptor has high expression on both neurons and glial cells in the cortex, hippocampus and the caudate nucleus (for review, see Barnes & Sharp, 1999). In addition, activation of this receptor increases BDNF expression (Vaidya et al., 1997). The 5-HT_{3} family are all ligand-gated ion channels which upon activation trigger depolarization of a neuron. There are two members of the 5-HT_{3} family, 5-HT_{3A, B}. Three of the other families, 5-HT_{4, 6 and 7}, preferentially bind to G_{s} and so positively regulate adenylate cyclase leading to the formation of cAMP (for review, see Hannon & Hoyer, 2008), while the 5-HT_{3} family has not been well characterised but is believed to also be a GPCR and is predominately expressed on astrocytes (Carson et al., 1996).

1.3.3 Functions of 5-HT

5-HT is involved in a wide range of physiological functions including digestion and cardiovascular regulation, as well as many behavioural functions such as the sleep-wake cycle, appetite, pain modulation, mood, and learning and memory (for review, see Lucki, 1998). Of importance is the association of 5-HT with major depressive disorder. Selective serotonin reuptake inhibitors such as fluoxetine and sertraline remain the most commonly prescribed drugs for depression (Rang & Dale, 2003). 5-HT is also an emerging target for
managing chronic pain, with 5-HT1A receptor agonists in particular being investigated as potential therapeutic agents (for review, see Bardin, 2011).

Many studies have also shown the ability of 5-HT to induce neuroprotection, in particular via the 5-HT1A receptor. For example, 5-HT1A receptor agonists have shown therapeutic efficacy against models of excitotoxicity (Oosterink et al., 1998), ischemia (Semkova et al., 1998) and staurosporine-induced apoptosis (Suchanek et al., 1998). Furthermore, the neuroprotection mediated by activation of the 5-HT1A receptor may occur via activation of both the phosphoinositide 3-kinase (PI3K) and the MAPK pathway (Druse et al., 2005).

1.4 Pathways Associated with Neuronal Growth

Many molecules and signalling pathways have been associated with neuronal growth, of these, the MAPK pathway and PI3K pathways predominate (for reviews, see Redmond et al., 2002; Read & Gorman, 2009).

1.4.1 The Mitogen Activated Protein Kinase Pathway

The MAPK pathway has many different branches; however each can be represented in a basic form, whereby the pathway is initiated by an activator or stimulus. This stimulus activates a MAPK kinase kinase (MKKK), which induces the activation via phosphorylation of a MAPK kinase (MKK) which activates a MAPK, which then activates a specific substrate, most commonly a component of a gene transcription factor (see Figure 1.5, for review, see Widmann et al., 1999). The MAPK pathway has four main branches: the extracellular signal-regulated kinases (ERK) ERK 1 and ERK 2 (ERK1/2); the c-Jun NH2-terminal kinases JNK1, JNK2 and JNK3; the p38 enzymes p38α, p38β p38γ, p38δ; and ERK5 (for review, see Johnson & Lapadat, 2002). However, although each pathway has specific MKKKs, MKKs and MAPKs associated with it, there is much cross-over and complexity in MAPK signalling pathways (Widmann et al., 1999). In addition to these four main branches, there are also atypical MAPK pathways leading to the activation of the MAPKs; ERK3, ERK4, nemo-like kinase, and ERK7 (Obara & Nakahata, 2010). The MAPK pathway, in particular the ERK1/2 branch, has been highly associated with neuronal growth. For example, MAPK activation is associated with the induction of a neuronal phenotype in rat PC12 cells (Traverse et al., 1992; Cowley et al., 1994; Ihara et al., 1997; Sole et al., 2004), the growth of neurites in sympathetic neurons
(Atwal et al., 2000; O’Keeffe et al., 2008), and the growth of neurites from primary cortical neurons (Abe et al., 2001; Redmond et al., 2002; Lee et al., 2009c).

Figure 1.5: Four main branches of MAPK Signalling

MAPK signalling primarily occurs via the ERK1/2 branch, JNK branch, p38 branch and the ERK5 branch.

1.4.1.1 MAPK Signalling: ERK1/2 Branch

The ERK1/2 branch (see Figure 1.6) of the MAPK pathway is the most extensively studied branch and has roles in cell division, differentiation and cell survival. Activation of Ras by, for example, an activated receptor tyrosine kinase (see section 1.4.3) leads to the recruitment of Raf-1 (the MAPKKK) to the plasma membrane, where a tyrosine kinase such as c-Src phosphorylates and activates it. A second MAPKKK, B-raf, exists in neurons for the ERK1/2 branch of MAPK signalling. B-raf is activated not only by Ras but also via Ras-related protein-1 (Rap-1) (for review, see Widmann et al., 1999). Activation of Raf-1 or B-raf then activates MAPKK1 (also known as MEK1/2 or ERK activator kinase 1), which leads to the phosphorylation and activation of ERK1/2. ERK1/2 goes on to phosphorylate S6 kinase p90 (p90), phospholipase A2 and microtubule associated proteins (MAPs) such as MAP-1, MAP-2 and MAP-4. P90 goes onto phosphorylate c-Fos and inhibits glycogen synthase kinase 3β (GSK3β). As GSK3β
normally inhibits c-Jun, p90 inhibition of GSK3β activates c-Jun, and thus the transcription factor AP-1 activation, which is produced by the dimerisation of c-Jun and c-Fos. Phospholipase A2 phosphorylation catalyses the release of arachidonic acid and the subsequent production of eicosanoids such as prostaglandins. Negative feedback of the ERK1/2 pathway occurs as ERK1/2 can phosphorylate son of sevenless (SOS; the Ras exchange factor), Raf-1 and M KK1, thereby reducing their activity, and thus negatively controlling the MAPK pathway. ERK1/2 can also translocate to the nucleus and directly activate transcription factors such as ETS-like transcription factor1 (Elk1), Ets1, Sap1a, c-Myc, Tal and signal transducers and activators of transcription (STAT) proteins (for review, see Widmann et al., 1999). Apart from direct interaction with the MAPs, the inhibition of GSK3β activity, as occurs via the MAPK pathway, has been highly associated with the induction of neurite growth (for review, see Hur & Zhou, 2010). Furthermore the downstream transcription factors to ERK1/2; Elk1 and c-Myc, have also been associated with neuritic growth (Kim et al., 1997; Vanhouette et al., 2001). Thus there appears to be many ways in which activation of the MAPK pathway can lead to changes in neuritic growth.
Chapter I: Introduction

Figure 1.6: ERK1/2 Branch of MAPK Signalling

Activation of the ERK1/2 branch of MAPK signalling leads to the activation of microtubule associated proteins (MAPs), the inhibition of GSK, activation of c-Fos, increased transcription of Elk1, c-Myc and STATs, as well as the production of eicosanoids via phospholipase A2.

1.4.1.2 MAPK Signalling: JNK Branch

The JNK MAPKs are activated through a variety of cell surface receptors including GPCRs, cytokine receptors and the receptor tyrosine kinases (RTKs). JNK activity is regulated via two main activators; ras-related C3 botulinum toxin substrate (Rac) and Cdc42. These then go on to activate MEKK1 (a MAPKK) which in turn activates JNK. MEKK1 however has also been shown to activate nuclear factor kappa B (NFκB) and ERK (for review, see Widmann et al., 1999). Interestingly, the NFκB pathway can also modulate neuritic growth (Sole et al., 2004; Gutierrez et al., 2008). Although normally associated with apoptosis, the JNK pathway can also mediate cell survival (for review, see Widmann et al., 1999).
1.4.1.3 MAPK Signalling: p38 Branch

The p38 MAPKs are generally activated upon stressors to the cell such as heat shock, inflammation or ultraviolet radiation. The Rac1 and Cdc42 Rho kinases can also activate the p38 MAPK possibly via the p21-activated kinase (Pak). P38 then goes onto activate the MAPK activated protein kinase which induces the expression of heat shock proteins. P38 can also activate activating transcription factor 2 (ATF2), Elk1 and Max transcription factors. Furthermore, Max associates with c-Myc (induced by ERK 1/2) (for review, see Widmann et al., 1999).

1.4.1.4 MAPK Signalling: ERK 5 branch

The ERK5 branch is the least researched branch but is thought to be activated by MKK5 and ultimately leads to the activation of c-Jun (Widmann et al., 1999). The ability of Ras to induce ERK5 activation however remains controversial. Rap-1 has been shown however to induce ERK5 activity (Obara & Nakahata, 2010).

1.4.2 Phosphoinositide Signalling

Phosphoinositide signalling involves the enzyme PI3K (see Figure 1.7). There are three classes of PI3K, of which the class I PI3Ks are the best characterised and are generally activated in response to extracellular signals. This class can be further divided into class IA, regulated by RTKs, GPCRs and Ras, and the class IB which are regulated only by GPCRs. The class IA PI3K is comprised of a p85 regulatory subunit and a p110 catalytic subunit (Zhang et al., 2011). PI3K is recruited to the plasma membrane by phosphorylated residues via its regulatory subunit. Upon binding to the phosphorylated residue, the regulatory subunit activates the catalytic subunit which is further activated by Ras. Activated PI3K then phosphorylates the membrane-bound lipid phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 is capable of activating many other kinases and is converted back to PIP2 by many phosphatases including phosphatase and tensin homolog (PTEN) (for review, see Gallo, 2011). PIP3 has docking sites for both AKT and phosphoinositide dependent kinase 1 (PDK1). PDK1 phosphorylates AKT at a tyrosine residue while mammalian target of rapamycin (mTOR) phosphorylates AKT in a serine residue leading to its full activation. AKT then translocates to the nucleus (Zhang et al., 2011). For example, AKT phosphorylates Forkhead-related transcription factor 1 (Frk) and inhibits its activation, it also
phosphorylates Bcl-2-associated death promoter (Bad), which prevents cellular apoptosis. AKT inactivates the constitutively active GSK3β and thus activating pathways which are normally inhibited by it. Separate to AKT signalling, the protein kinase C enzyme can be activated via PI3K by PDK1 and PIP3 also activates the GTPase, Rac, which is important for actin remodelling (for review, see Cantley, 2002). Similarly to MAPK ERK1/2 signalling, the PI3K pathway has many methods of influencing neuritic growth. PI3K, for example, also inactivates GSK3β, which is highly associated with neuritic growth (for review, see Hur & Zhou, 2010). In addition to this, the PI3K pathway activates members of the Rho kinases family, of which Rac, Cdc42 and RhoA are particularly associated with neuritic growth via interactions with actin and microtubules, as well as interacting with various scaffolding proteins (for review, see Govek et al., 2005). Furthermore, the phosphorylated AKT has many other downstream targets which are associated with neuritic growth, such as Ezrin and Tau (for review, see Read & Gorman, 2009).

**Figure 1.7: PI3K signalling leads to neuritic growth**
Activation of the PI3K enzyme leads to the production of PIP3 and phosphorylation of AKT. This leads to the activation of NFκB and downstream gene transcription, the activation of many proteins associated with neuritic growth, the inhibition of pro-apoptotic proteins and the activation of PKC.
1.4.3 Signalling via the receptor tyrosine kinases

Many growth factor receptors are RTKs. Upon ligand binding, two RTKs dimerise and auto-phosphorylate each other. This phosphorylation can recruit and activate enzymes and transcription factors, or can provide docking sites for adaptor proteins. Adaptor proteins generally lack their own catalytic activity but will associate with enzymes that do. They also associate with scaffolding adaptor proteins which can dock many signalling proteins (for review, see Gu & Neel, 2003). Scaffolding adaptor proteins can either contain several tyrosine phosphorylation sites to dock many signalling proteins or can contain Src homology (SH) 3 or SH2 domains to bind signalling proteins. Members of the first group include fibroblast growth factor receptor substrate 2 (FRS2), SH2 containing sequence Shc, Grb-2 associated binder (Gab), insulin receptor substrate (IRS) and downstream of kinase (Dok)-family proteins. The second group include growth factor receptor-bound protein 2 (Grb2) and Crk (for review, see Gotoh, 2008).

FRS2 for example is a scaffolding protein which upon activation is tyrosine phosphorylated. Activated FRS2 leads to recruitment of the adaptor protein Grb-2 and also Shp2; an Sh2 containing tyrosine phosphatase. Grb-2 is often associated with SOS, Cbl and Gab-1. SOS is a guanine nucleotide exchange (GEF) factor for Ras, thus activating the ERK MAPK pathway (see section 1.4.1.1). Cbl is a ubiquitin ligase which results in the degradation of the tyrosine kinase receptor via ubiquitination. While Gab-1 recruits PI3K and thus activates this pathway. Activation of the ERK pathway may also occur via Shp2 activation, although how Shp2 can activate Ras is controversial (for review, see Gotoh, 2008), but it might be more important in amplifying the pathway, rather than be utterly essential for it (for review, see Gu & Neel, 2003). The adaptor protein Gab-1 which associates with Grb-2 contains a binding site for the p85 subunit of PI3K and thus downstream activation of AKT. In addition to this, Gab-1 has been associated with phospholipase C (for review, see Gu & Neel, 2003). In this way, signalling via RTK can result in the activation of the MAPK pathway, PI3K and phospholipase C, for example see Figure 1.8 for the RTK tropomyosin receptor kinase (Trk) signalling.
1.5 Neuroprotective and neuronal growth inducing factors

There are many factors which have been shown to be involved in the regulation of neuronal protection and neuronal growth. Many of these induce the MAPK pathway, the PI3K pathway or indeed both. These include neurotrophic factors such as the neurotrophins and GDNF, and cytokines.

1.5.1 Neurotrophins

The neurotrophins are a group of neurotrophic factors consisting of BDNF, NGF-β, NT3 and neurotrophin 4/5 (NT4/5). They are all initially made as precursors or pro-neurotrophins which need to be cleaved intracellularly, by furin or pro-convertases, to reveal the mature neurotrophin protein. Additionally, the neurotrophins can be released in the pro-form and cleaved extracellularly by the extracellular endopeptidases tissue-plasminogen activator plasmin cascade or the extracellular matrix-metalloproteinases (for review, see Lessmann & Brigadski, 2009). For example, studies have shown that calcium-dependent release of NGF-β is primarily secreted in the pro-form from cortical neurons and is cleaved to the mature NGF-β protein extracellularly via a complex protease cascade (Bruno & Cuello, 2006). The neurotrophins are released in the CNS in an activity-dependent manner, and the inhibition of neurotrophin signalling can lead to neuronal death (for review, see Chao, 2003). They each bind to two types of receptors; the Trk receptors of which there are three; TrkA, TrkB and TrkC, and the p75 receptor. The Trk receptors show various affinities for the neurotrophins with TrkA preferentially binding to NGF-β, TrkB to BDNF and TrkC to NT-3 (Chao, 2003). The Trk receptors are all RTKs, see section 1.4.3.

1.5.1.1 Neurotrophin Signalling: Trk Receptors

Signalling of the neurotrophins via the Trk receptors is associated with neuronal survival (Chao, 2003). This receptor is activated when two neurotrophin ligands bind to two Trk receptors, resulting in autophosphorylation of tyrosine residues on the Trk receptors and thus the recruitment of various adaptor proteins, such as FRS2 and She (for reviews, see Reichardt, 2006; Gotoh, 2008). Both of these can recruit the Grb-2/SOS complex which leads to the activation of the MAPK pathway via Ras and Raf. Grb-2 can also be in a complex with Gab-1 which leads to the activation of the PI3K pathway (for reviews, see Gu & Neel, 2003; Reichardt, 2006). However, activation of the PI3K pathway via a Trk
receptor may also occur via the adaptor protein IRS-1 (for review, see Reichardt, 2006). Trk receptor signalling often leads to the sustained activation of ERK1/2 which may be associated with the internalisation of the Trk receptor to an endosome bringing the adaptor protein FRS2 close to Rap-1 (Chao, 2003; Reichardt, 2006). Phospholipase C is also recruited to and activated by the RTK leading to the subsequent activation of protein kinase C (for reviews, see Chao, 2003; Reichardt, 2006). There also exists a truncated form of the Trk receptors which lack the intracellular phosphorylation sites and so may act as negative regulators of the Trk receptors. Some reports however show that they may have their own signalling properties (for review, see Cohen-Cory et al., 2010).

![Figure 1.8: Signalling via the Trk Receptors](image)

Two neurotrophin ligands bind to two Trk receptors, leading to the activation of phospholipase C, PI3K and MAPK.
1.5.1.2 Neurotrophin Signalling: p75 Receptor

The p75 receptor is a member of the TNF receptor superfamily and is associated with cellular apoptosis (see Figure 1.9; for review, see Dechant & Barde, 2002). P75 receptor activation leads to the activation of downstream pathways or can also increase the affinity of the neurotrophins for the Trk receptors. Interestingly, the p75 receptor has higher affinity for the pro forms of the neurotrophins which could be a mechanism of control over neurotrophin function as p75 signalling leads to the activation of other signalling pathways such as JNK and NFkB (for review, see Chao, 2003). P75 activation results in the activation of the JNK branch of MAPK signalling via cdc42 and apoptosis signal-regulating kinase I (Ask-1), NFkB activation via TNF receptor associated factor 6 (Traf6) and NFkB inducing kinase (NIK), and the Rho kinases (Reichardt, 2006).

![Diagram of p75 receptor signalling](image)

**Figure 1.9: Signalling via the p75 receptor**

Pro-neurotrophins bind to the p75 receptor and lead to the activation of the NFkB and c-Jun MAPK pathways.
1.5.1.3 NGF-β and neuritic growth

NGF-β is an important potential therapeutic target for protecting neurons following degeneration and for encouraging neuritic growth. Early investigations demonstrated the ability of a factor from a mouse sarcoma, later identified as NGF-β, to induce neuritic growth of sensory neurons (Levi-Montalcini, 1964). Subsequently, much research has shown the ability of NGF-β to induce neuritic growth in both primary neurons and cell lines. For example, NGF-β was found to induce a neuronal-like phenotype in the rat neural crest pheochromocytoma cell, PC12 cells (Greene & Tischler, 1976). This phenomenon lent itself to a large amount of research on the signalling pathways involved in this NGF-β induction of neuritic outgrowth from the PC12 cells. Accordingly, it was then established that the MAPK pathway (Sole et al., 2004), the PI3K pathway (Kimura et al., 1994; Jackson et al., 1996) and NFκB activation (Wood, 1995; Hamanoue et al., 1999) are involved in NGF-β induced outgrowth of PC12 cells. Interestingly, this differentiation into neuronal-like cells does not occur upon epidermal growth factor (EGF) receptor stimulation which has similar signalling to TrkA (for review, see Vaudry et al., 2002). It is believed that this may be due to both sustained MAPK activation and PI3K activation upon NGF-β stimulation of TrkA which does not occur following EGF receptor activation (Qui & Green, 1992; Traverse et al., 1992; York et al., 2000). In relation to the use of NGF-β as a therapeutic agent, ongoing research is investigating the potential of utilising it for delaying cognitive decline during ageing. A promising study by Conner et al found that delivering NGF-β to cholinergic neurons during ageing in the primate attenuates age-associated decreases in cholinergic innervations (Conner et al., 2001). Studies such as this one led to the movement of utilising NGF-β in human trials for AD, a disorder which shows a huge loss of cholinergic innervation. The results of a phase I clinical trial investigating the efficacy of NGF-β gene therapy for patients with mild AD demonstrated safe administration in addition to a suggested attenuation of cognitive decline, warranting the continuation into phase II trials (Tuszynski et al., 2005). The results from the Phase II clinical trial are yet to be finalised, but are due to be completed by May 2012.

1.5.1.4 BDNF and neuritic growth

The ability of BDNF to induce neuritic growth was identified in the 1980’s by a study investigating the impact of the presence of BDNF on the growth of sensory neurons. The study demonstrated that BDNF led to a clear increase in neuritic growth (Davies et al.,
Chapter 1: Introduction

Many other studies have since demonstrated that BDNF can also increase neuritic growth of central neurons such as retinal cells (Thanos et al., 1989), cerebellar granule cells (Segal et al., 1995) and primary cortical neurons (Horch & Katz, 2002). The ability of BDNF to induce neuritic growth, similarly to NGF-β, relies on activation of TrkB (Song et al., 1997), and results in the activation of the MAPK and PI3K pathway with associated downstream effects as described previously (for review, see Cohen-Cory et al., 2010). Furthermore, BDNF is important in developing synapses, and treatment of neurons in vivo with this neurotrophin increases synaptogenesis (Alsina et al., 2001). Due to the widespread use of BDNF in the brain to encourage the growth of many neuronal types, BDNF has been investigated as a therapeutic agent for many CNS disorders which demonstrate neuritic loss, such as AD, PD and Amyotrophic Lateral Sclerosis (ALS) (for review, see Nagahara & Tuszynski, 2011). Clinical trials for the use of BDNF for ALS reached phase III, however, a large phase III trial failed to demonstrate any improvement in patient survival following systemic BDNF administration, however further trials using different delivery methods are ongoing (The BDNF Study Group, 1999; Nagahara & Tuszynski, 2011). In addition to ALS, BDNF has proved beneficial for AD in preclinical animal models. For example, aged primates treated with BDNF expressing lentiviral vectors, demonstrated increased cognitive function in tandem with attenuation of cortical loss (Nagahara et al., 2009). Perhaps future clinical trials for BDNF against AD may demonstrate benefits to patients.

1.5.1.5 The Neurotrophins and NA

NA has previously been shown to induce the expression of neurotrophins in glial cells. An early study demonstrated that β-adrenergic stimulation of C6 glioma cells resulted in the release of NGF-β into the culture medium (Schwartz & Costa, 1977). In addition, Schwann cells increase NGF-β mRNA expression upon treatment with NA or cAMP activators (Matsuoka et al., 1991). There is also much research on the ability of clenbuterol (Clen), a β2-adrenoceptor selective agonist to induce the secretion of NGF-β. For example in vivo Clen treatment results in increased NGF-β mRNA (Follesa & Mocchetti, 1993) and protein (Hayes et al., 1995) in the cerebral cortex of rats. In addition, Clen treatment in vitro of rat hippocampal cells (mixed glia and neurons) results in the release of NGF-β protein which protects the hippocampal cells from glutamate toxicity (Semkova et al., 1996). Furthermore, this protection was attenuated by treatment
with the β-adrenoceptor antagonist propranolol (Prop), or with an antibody against NGF-β (Semkova et al., 1996).

NA has also been shown to induce the expression of BDNF. For example, NA treatment increases BDNF protein in primary hippocampal neurons (Chen et al., 2007), and NA-induced BDNF is known to protect primary neurons against amyloid toxicity (Counts & Mufson, 2010). Furthermore, NA has also been shown to induce the expression of BDNF from primary astrocytes (Zafra et al., 1992).

The ability of NA to induce the expression of NGF-β and BDNF may depend on the NA-induced increase in cAMP with the subsequent activation of PKA and the resultant activation of the transcription factor CREB (Rang & Dale, 2003). CREB then activates the CCAAT/enhancer-binding proteins which have been shown to be involved in NGF-β expression in the rat C6 astrocytoma cell line (Colangelo et al., 1998; McCauslin et al., 2006). Furthermore, an increase in CREB activity has also been demonstrated to result in BDNF expression in cultured cortical neurons (Tao et al., 1998).

1.5.2 Glial-derived neurotrophic factor

GDNF is a neurotrophic factor which was isolated in 1993 by Lin et al. At this time it was shown to enhance cell survival of midbrain dopaminergic neurons and increase dopaminergic neurite outgrowth (Lin et al., 1993). Subsequently GDNF has been found to have many other important roles both within the CNS; and outside the CNS such as kidney development and as a neurotrophic factor for the enteric nervous system (for review, see Baloh et al., 2000). GDNF is not a member of the classical neurotrophin family but rather is a member of the GDNF family ligand (GFL) family; a sub-family of the transforming growth factor-β (TGF-β) superfamily due to the presence of seven repeating cysteine residues, a TGF-β characteristic. The GFL family also includes neurturin (NRTN), artemin (ARTN) and persephin (PSPN) (for review see Airaksinen & Saarma, 2002). All four of the GFLs signal via a multicomponent receptor complex comprising of the RTK rearranged during transfection (RET) and a GDNF family receptor a-component (GFR-α). The GFR-α, of which there are four subtypes, binds the ligand with high affinity but has no downstream signalling mechanisms, instead signalling occurs via the interaction of GFR-α with RET. GDNF preferentially binds to GFR-α1 but there is
also evidence that it can bind to GFR-α2 although functions of this pathway are unknown (for review, see Baloh et al., 2000).

1.5.2.1 GDNF Signalling

As previously mentioned, GDNF primarily signals via the multicomponent complex GFR-α1 and RET (see Figure 1.10). GDNF is secreted as a precursor preproGDNF protein which is cleaved to reveal the signalling sequence. The GDNF binds to the GFR-α which is linked to the plasma membrane via a glycosyl phosphatidylinositol anchor (for review see Airaksinen & Saarma, 2002). The activated GFR-α forms a complex with two RET molecules which activates their intracellular tyrosine kinase domains, inducing homodimerisation and tyrosine autophosphorylation. GFR-α and RET can however bind with low affinity in the absence of GDNF (Eketjall et al., 1999). Soluble forms of the GFR-α receptors also exist which have been shown to bind GDNF in the extracellular space and present it to RET on the cell membrane. Furthermore, GFR-α1 on the cell membrane can bind GDNF and present it to RET on an adjacent cell, and this signal may assist in the formation and maintenance of neuronal connections (Paratcha et al., 2001). Phosphorylated tyrosines on the RET molecule provide docking sites for the adaptor proteins; FRS2, Grb7/10, phospholipase C, Shc and Grb2 (for reviews, see Airaksinen et al., 1999; Gotoh, 2008). Thus activation of RET results in the activation of many signalling pathways, including the ERK1/2, JNK and PI3K pathways (for reviews, see Takahashi, 2001; Gu & Neel, 2003). There is also emerging evidence that GDNF can bind to and signal via the neural cell adhesion molecule (NCAM) receptor. GDNF was shown to increase phosphorylated Fyn, a Src family tyrosine kinase which is associated with the NCAM receptor, an association which requires GFR-α (Paratcha et al., 2003).
Figure 1.10: Signalling of GDNF
GDNF binds to GFR-α which associates with and activates the RET receptor. Activation of RET results in the activation of PKC, PI3K and MAPK pathways.

1.5.2.2 GDNF and Neuritic Growth

The ability of GDNF to impact upon neuritic growth was demonstrated early on in dopaminergic cortical neurons (Lin et al., 1993; Hou et al., 1996) and cerebellar Purkinje cells (Mount et al., 1995). However, the exact mechanism of GDNF-induced neuritic growth is not as clearly defined as for the neurotrophins. Some lines of evidence however suggest that the interaction between GDNF and NCAM is necessary for GDNF-induced neuritic growth (Chao et al., 2003; Ditlevsen et al., 2003; Cao et al., 2008; Nielsen et al., 2009). NCAM has no intracellular signalling capabilities, however the GDNF-induced neuritic growth via NCAM has been shown to involve the FGF-2 receptor (FGFR) (Nielsen et al., 2009). Furthermore, the PI3K pathway is involved in GDNF-induced neuritic growth (Pong et al., 1998; Ditlevsen et al., 2003).

As GDNF is a potent protective factor for dopaminergic neurons, it is a prime candidate for PD therapy where there is profound loss of dopaminergic neurons in the substantia nigra (for review, see Barker, 2009). In two nonhuman primate models of PD, lentiviral GDNF treatment led to increased number of dopaminergic nigral neurons in aged primates and prevented neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
neuronal degeneration (Kordower et al., 2000). These promising results led to the use of GDNF in human clinical trials. However, the clinical trials which have been performed utilising GDNF as a therapy for PD have been inconclusive. Early reports demonstrated efficacy of GDNF administration, however subsequently a larger double-blinded study showed no significant effect of GDNF over placebo (for review, see Barker, 2009). Furthermore, Amgen controversially halted some of its clinical trials prematurely, based on evidence of patients developing antibodies to GDNF and evidence of cerebellar degeneration in nonhuman primate models (Penn et al., 2006).

1.4.2.3 GDNF and NA

At present, there are no reports of an ability of NA to induce the production and secretion of GDNF. However there is some indirect evidence; for example, GDNF mRNA has been detected in areas innervated by LC neurons, but not in the LC itself (Arenas et al., 1995), suggesting perhaps that noradrenergic neurons might stimulate the production of GDNF. Furthermore, NA reuptake inhibitors such as amitriptyline, clomipramine and mianserin lead to an increase in GDNF, but it is unknown how this occurs (Hisaoka et al., 2007). It is also known that GDNF transcription is modulated by members of the CREB family (Baecker et al., 1999; Hisaoka et al., 2008), which is downstream of β2-adrenoceptor activity.

1.5.3 FGF-2

FGF-2 is an 18kDa member of the FGF superfamily, which also includes 22 other ligands, and five receptors. Each FGF ligand contains a heparin binding site, which helps in the formation of a stable interaction between ligand and receptor (Omitz et al., 1996). The mechanism of release of FGF-2 into the extracellular space is somewhat controversial, due to the lack of a typical leader sequence which generally results in secretory proteins being transported to the endoplasmic reticulum and secreted. Early studies suggested that FGF-2 was released only upon cellular damage in an endoplasmic reticulum / Golgi independent manner (for review, see Powers et al., 2000). However, it is now known that FGF-2 is directly translocated to the plasma membrane in a manner that requires both intracellular PIP2 and extracellular heparan sulphate proteoglycans (for review, see Nickel, 2010). Furthermore, FGF-2 is found extracellularly (for review, see Powers et al., 2000), and can be released upon various stimuli (Delgado-Rivera et al., 2009). FGF-2 has also been
shown to be expressed by both neurons and glial cells in the CNS but also displays expression in peripheral tissues (for reviews, see Reuss & von Bohlen und Halbach, 2003; Turner et al., 2006).

1.5.3.1 FGF-2 Signalling

There are four FGF receptors (FGFR1-4) which are all RTKs. There are many splice variants of each receptor which lend to varying affinities of the FGFs to each receptor. The FGF receptors each display a distinct expression pattern, with the FGFR1 most abundantly expressed in the CNS (for review, see Turner et al., 2006). FGF-2 can bind to all four receptor subtypes with varying affinities to each one, for example, FGF-2 has high affinity to the “c” type isoforms of FGFR1-3 and low affinity to the “b” isoforms (Ornitz et al., 1996). Activation of the receptors only occurs when two receptors each with a bound FGF ligand, form a complex linked by a heparan sulphate proteoglycan molecule (for review, see Reuss & von Bohlen und Halbach, 2003). Phosphorylation and receptor activation follows (see Figure 1.11). SH2 domain proteins are known to bind to the activated FGFRs which can then recruit other proteins to the complex. Recruitment to the activated FGFR receptor includes phospholipase C and the adaptor protein FRS2. As described previously, FRS2 recruits Grb-2/SOS, which activates the MAPK pathway via Ras. Gab-1 is also recruited via Grb-2 which activates the PI3K pathway (for review, see Reuss & von Bohlen und Halbach, 2003). It is also important to note a high molecular weight FGF-2 exists which is not secreted and acts independently of the FGFR in the nucleus (for review, see Chlebova et al., 2009).
1.5.3.2 FGF-2 and Neuritic Growth

There is much research demonstrating the ability of FGF-2 to enhance neuritic growth of neurons, for example of rat hippocampal neurons (Walicke et al., 1986; Aoyagi et al., 1994; Patel & McNamara, 1995). In particular, FGF-2 appears to preferentially induce branching of axons and not dendrites (Patel & McNamara, 1995; Szebenyi et al., 2001). Furthermore, the ability of cell adhesion molecules such as NCAM to induce neuritic growth appears to be mediated via the activation of the FGFR (for review see Viollet & Doherty, 1997). Both the MAPK and PI3K pathways have been demonstrated to be involved in FGF-2-induced neuritic growth (Abe et al., 2001; Gilardino et al., 2009). Interestingly, sustained activation of the MAPK is necessary for FGF-2-induced neuritic growth (Abe et al., 2001), similarly to the sustained activity required for NGF-β-induced neuritic growth (Traverse et al., 1992). In terms of therapeutic value, FGF-2 gene therapy has seen some amelioration of AD symptoms such as spatial learning deficits and hippocampal amyloid β deposition, as well as enhancement of neurogenesis, in a mouse model of AD (Kiyota et al., 2011). It remains to be seen if the ability of FGF-2 to induce neuritic growth is also of therapeutic value to humans with AD.
Chapter 1: Introduction

1.5.3.3 FGF-2 and NA

There is limited evidence to show that FGF-2 can be produced upon noradrenergic stimulation. For example, rats injected with Clen show increases in FGF-2 mRNA in the cortex, hippocampus and cerebellum (Follesa & Mocchetti, 1993; Hayes et al., 1995). Furthermore, primary rat cortical, hippocampal and cerebellar astrocytes show increases in FGF-2 mRNA expression and protein production following exposure with isoproterenol, a non-selective β-adrenoceptor agonist (Riva et al., 1996). The ability of NA to induce FGF-2 expression also appears to rely on the increase in cAMP following β-adrenoceptor activation (Riva et al., 1996).

1.5.4 VEGF

Vascular endothelial growth factor (VEGF), also known as VEGFA, belongs to a family which also includes placental growth factor, VEGFB, VEGFC and VEGFD. Alternative splicing of VEGF leads to four main isoforms in humans, all of which have slightly different properties. VEGF₁₆₅, the prototypical VEGF (herein referred to as VEGF), is a glycoprotein which although can be secreted, a large percentage of it also remains bound to the extracellular cell membrane and the extracellular matrix. The main role of VEGF is in angiogenesis, or the production of new blood vessels, therefore it is no surprise that VEGF is induced by hypoxic conditions and is a target for therapeutic relief of tumours (for review, see Ferrara et al., 2003).

1.5.4.1 VEGF Signalling

VEGF has two receptors that it binds to and activates; VEGFR1 and VEGFR2, both of which are RTKs. VEGFR1 (also known as Flt1), undergoes a very weak phosphorylation response upon VEGF activation and thus it has been hypothesised that VEGFR1, as well as an alternatively spliced soluble VEGFR1 both function as decoy receptors to modulate the binding of VEGF to VEGFR2. Despite this, signalling via VEGFR1 has been associated with the recruitment of monocytes amongst other functions. VEGFR2 (also known as Flk1) on the other hand is crucial for the signalling of VEGF to induce vascular growth and induce BBB permeability (for review, see Ferrara et al., 2003). Activation of VEGFR2 results in the phosphorylation of phospholipase-Cγ, PI3K, Ras GTPase-activating protein and Src. It can also activate the ERK1/2 pathway. In addition to these receptors, VEGF associates with two other proteins known as neuropilin 1 (NRP1) and
NRP2, and it is thought that they function by increasing the binding activity of VEGF to VEGFR2 (for review, see Ferrara et al., 2003).

1.5.4.2 VEGF and Neuritic Growth

Many reports have demonstrated the ability of VEGF to induce neuritic growth. For example, primary cortical neurons have been demonstrated to show increased neuritic growth following VEGF exposure (Rosenstein et al., 2003; Khaibullina et al., 2004; Jin et al., 2006). The ability of VEGF to induce neuritic growth has been linked to activation of the VEGFR2 and retrograde transport of VEGF (Sondell et al., 2000; Jin et al., 2006). In addition, the Rho kinases have been implicated in the ability of VEGF to induce neuritic growth in primary cortical neurons (Jin et al., 2006). Furthermore, overexpression of VEGF increased neuritic length and branching of newborn cortical neurons in vivo following an ischemic insult to rats (Wang et al., 2009). Interestingly, a VEGF gene transfer protein has been investigated as a therapeutic agent for ALS. Clinical data from a phase II trial for SB-509 demonstrated the drug was both safe and showed efficacy in ALS patients (Benaim et al., 2010), unfortunately however due to negative results for diabetic neuropathy this drug has been removed from all clinical trials.

1.5.4.3 VEGF and NA

Non-CNS cells have been shown to express VEGF following adrenergic stimulation. For example, brown adipose tissue induces VEGF mRNA following noradrenergic stimulation (Asano et al., 1997), via the increase of cAMP and activation of PKA (Fredriksson et al., 2000). VEGF is also upregulated following NA stimulation in many cancerous cell lines, for example see (Yang et al., 2008). There is however, only one report which has demonstrated an increase in VEGF mRNA following direct NA stimulation in rat astrocytes (Wang & Yang, 2007). A second study however has shown that an increase in cAMP, as occurs downstream of adrenergic stimulation, can also increase VEGF mRNA in neurons in the hippocampus (Lee et al., 2009b).

1.5.5 Interleukin-6

Interleukin-6 (IL-6) was first identified in the mid 1980’s by Hirano and was classified as a cytokine due to its ability to differentiate immature B cells of the immune system to the fully mature antibody-producing cells (Hirano et al., 1986). However, since then, IL-6
has been found to have many diverse functions, including the differentiation and proliferation of many cell types, in particular immune cells, and its involvement in normal metabolism and regulation of the HPA axis, and even a role as a neurotrophic factor (for reviews, see Chalaris et al., 2011; Jones et al., 2011; Spooren et al., 2011). IL-6 is in a cytokine family which also includes CNTF, leukaemia inhibitory factor, oncostatin M, IL-11 and cardiotrophin-1, due to the fact that each signal via gp130 (Marz et al., 1999).

1.5.5.1 IL-6 Signalling

The signalling of IL-6 occurs by two main mechanisms; classical signalling and trans-signalling. Classical signalling involves the interaction of IL-6 with a plasma membrane complex comprised of the non-signalling IL-6 receptor α (IL-6Ra, also known as CD126) and glycoprotein 130 (gp130). IL-6 first interacts with the non-signalling IL-6R, which recruits two molecules of gp130 and facilitates downstream signalling of IL-6 (see Figure 1.12). IL-6 signalling is quite unique in that a soluble IL-6 receptor (sIL-6R) exists in the extracellular space which, upon IL-6 and subsequent gp130 binding, leads to viable downstream signalling. This is the trans-signalling of IL-6. As gp130 is ubiquitously expressed in all cell types, trans-signalling allows cell types which do not express the IL-6R to be activated by IL-6. The sIL-6R is generated by either alternative splicing of the IL-6R mRNA or by shedding of the membrane receptor by metalloproteinases known as A Disintegrin And Metalloproteinase (ADAM) family, in particular ADAM17 appears to be involved in cleaving the IL-6R from the membrane (for review, see Chalaris et al., 2011).

Dimerisation of the gp130 molecules is followed by the recruitment of the Janus Kinases (JAK-1 and JAK-2) which leads to phosphorylation of tyrosine residues on the gp130 cytoplasmic domains and recruitment of STATs (for review, see Spooren et al., 2011). In addition, phosphorylation of a specific tyrosine site on the gp130 molecule by JAK recruits Shp2 which activates the MAPK signalling pathway via Grb2-SOS. Furthermore, Gab-1, and therefore the PI3K pathway, is also activated upon ligand binding (Heinrich et al., 2003).
Figure 1.12: IL-6 Signalling

IL-6 binds to the IL-6 receptor, which leads to the phosphorylation of gp130. This then activates the JAK-STAT pathway. The PI3K and MAPK pathways are also activated upon ligand binding via Gab-1 and Grb-2 respectively.

1.5.5.2 IL-6 and Neuritic Growth

Early in its investigation, IL-6 treatment of PC12 cells was shown to induce a neuronal morphology of the cells in a manner similar to NGF-β treatment (Satoh et al., 1988). This was later shown to occur via the STAT3 pathway (Wu & Bradshaw, 1996). Furthermore, primary hippocampal neurons demonstrate increased neuritic length and branching following IL-6 exposure (Sarder et al., 1996). The ability of IL-6 to induce neuritic growth may be related to the transcription of the atypical Rho kinase RhoU following STAT3 phosphorylation and translocation to the nucleus (Schiavone et al., 2009).
Chapter I: Introduction

1.5.5.3 IL-6 and NA

NA has previously been shown to upregulate both IL-6 mRNA expression and protein production from rat neonatal primary astrocytes. Interestingly, NA was shown in this study to have no effect on the induction of IL-6 from microglia (Norris & Benveniste, 1993). Many other cells have shown modulation of IL-6 following adrenergic stimulation. For example, in the macrophage cell line RAW, adrenergic stimulation via the β2-adrenoceptor agonist salmeterol (Salm) resulted in a significant increase in the release of IL-6 protein from the cells. This ability was blocked by the β2-adrenoceptor selective antagonist ICI 118, 551 but not by a specific β1 or β3 antagonist (Tan et al., 2007). Furthermore, β-adrenergic activation can both enhance (Szabo et al., 1997; Manni et al., 2011) and attenuate (van der Poll et al., 1994) IL-6 production following an inflammatory stimulus. How NA stimulation leads to the induction of IL-6 expression is not known, however one study demonstrated that the ability was independent of PKA or NFκB activation but is mediated via ERK1/2 and p38 MAPK pathways (Tan et al., 2007).
1.6 Objectives of thesis

The major focus of this thesis was to examine the potential of NA, acting on glial β-adrenoceptors, to induce neuritic growth of primary cortical neurons through the release of neurotrophic factors. The specific aims were:

1) To investigate the ability of the monoaminergic neurotransmitters, NA and 5-HT, to induce neuritic growth of primary rat cortical neurons either directly or via an indirect action on glial cells.

2) To determine the glial adrenergic receptor subtype involved in NA-induced neuritic growth of neurons.

3) To determine the glial cell type (astrocyte vs. microglia) involved in NA-induced neuritic growth of neurons.

4) To examine the potential use of the C6 glioma cell line as a model for investigating the ability of glial β-adrenergic stimulation to induce neuritic growth.

5) To determine a role for growth factors as the mechanism for NA-induced neuritic growth of primary cortical neurons.

6) To examine the signalling pathways involved in the regulation of NA-induced neuritic growth, specifically examining the PI3K, the MAPK and STAT3 pathways.
Chapter 2

Materials and Methods
2.1 Materials

2.1.1 Animals

Wistar rats (0-3 days old)  
Bioresources, TCD

2.1.2 Experimental Treatments

Noradrenaline (99%) (NA)  
Sigma-Aldrich, Ireland

STAT3 inhibitor VI, S31-201  
Merck Chemicals, UK

Di-butyryl adenosine cyclic monophosphate (db-cAMP)  
Tocris Bioscience, UK

Goat IgG GDNF neutralizing antibody (GDNF nAB)  
R&D systems, UK

Goat IgG  
Santa-Cruz Inc., USA

LY294002 hydrochloride  
Tocris Bioscience, UK

Mouse IgG1κ fibroblast growth factor 2 neutralizing antibody (FGF-2 nAB)  
Millipore, Ireland

Mouse IgG1κ (isotype control)  
Biolegend, USA

PD98049  
Tocris Bioscience, UK

Phentolamine hydrochloride (Phent)  
Sigma-Aldrich, Ireland

Propranolol hydrochloride (Prop)  
Sigma-Aldrich, Ireland

Rat IgG2bκ CD126 (IL-6 R α chain) antibody  
Biolegend, USA

Rat IgG2b κ, isotype control  
Biolegend, USA

Recombinant rat BDNF  
Biovision, USA

Recombinant rat FGF-2  
Biovision, USA

Recombinant rat GDNF  
R&D Systems, UK

Recombinant rat IL-6  
R&D Systems, UK
Chapter 2: Materials and Methods

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Abbreviation</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amitriptyline</td>
<td>Ami</td>
<td>Serotonin/Noradrenaline reuptake inhibitor</td>
</tr>
<tr>
<td>Clenbuterol</td>
<td>Clen</td>
<td>Agonist of β₂ adrenoceptor</td>
</tr>
<tr>
<td>Dibutryl adenosine cyclic monophosphate</td>
<td>dbcAMP</td>
<td>cAMP analogue</td>
</tr>
<tr>
<td>LY294002</td>
<td>LY</td>
<td>PI3 Kinase Inhibitor</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>NA</td>
<td>Agonist of α and β adrenoceptors</td>
</tr>
<tr>
<td>PD98049</td>
<td>PD</td>
<td>MEK1 Inhibitor</td>
</tr>
<tr>
<td>Phentolamine</td>
<td>Phent</td>
<td>Antagonist of α adrenoceptor</td>
</tr>
<tr>
<td>Propranolol</td>
<td>Prop</td>
<td>Antagonist of β adrenoceptor</td>
</tr>
<tr>
<td>S31-201</td>
<td>S31-201</td>
<td>STAT3 Inhibitor</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>Salb</td>
<td>Agonist of β₁ and β₂ adrenoceptors</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>Salm</td>
<td>Agonist of β₂ adrenoceptor</td>
</tr>
<tr>
<td>Wortmannin</td>
<td>Wort</td>
<td>PI3 Kinase Inhibitor</td>
</tr>
<tr>
<td>Xamoterol hemifumarate (Xam)</td>
<td>Xam</td>
<td>Agonist of β₁ adrenoceptor</td>
</tr>
<tr>
<td>Y1036</td>
<td>Y1036</td>
<td>Neurotrophin antagonist</td>
</tr>
</tbody>
</table>

Table 2.1: Drug Interventions
2.1.3 Cell Culture Materials

Acrodisc syringe filter (0.2\(\mu\)m)  
Biocidal ZF™  
B-27 Supplement  
Cell strainers (40\(\mu\)M)  
Coverslips (plastic, 13mm)  
Coverslips (glass; 13mm, 30mm)  
Dimethyl sulfoxide  
Disposable sterile scalpels  
Dulbecco’s modified Eagle’s medium: F-12 (DMEM)  
Dulbecco’s phosphate buffered saline (PBS) (10X)  
Ethanol, absolute  
Foetal Bovine Serum (FBS)  
Fungiozone  
Glutamax  
Haemocytometer  
Ham’s F12 Nutrient Mixture  
Neurobasal-media  
Penicillin-streptomycin  
Plastic syringe (50ml, 20ml and 1ml)  
Poly-L-lysine  
Poly-D-lysine  
Serological pipette (25ml, 50ml)
Steri-Cycle CO₂ Incubator  
Sterile 6, 24 well plates  
Sterile falcon tubes (15ml, 50ml)  
Sterile microtubes (2ml)  
Sterile Petri dishes  
Sterile transfer pipettes  
Sterile T25cm², T75cm² Flasks  
Trypan Blue  
Trypsin-EDTA

2.1.4 Assay Kits

GDNF Emax® Immunoassay System  
Human BDNF Duoset ELISA  
Human FGF-basic ELISA MAX™ Deluxe Set  
NGF-β Emax® Immunoassay System  
Rat IL-6 ELISA SET  
Rat VEGF Duoset ELISA

2.1.5 Molecular Reagents

96-well optical reaction plates  
Absolute ethanol  
Biosphere filter tips (1000, 100 and 10µl)  
High capacity cDNA archive kit

Chapter 2: Materials and Methods

Bio-Sciences  
Sarstedt, Ireland  
Sarstedt, Ireland  
Sarstedt, Ireland  
Sarstedt, Ireland  
Sigma-Aldrich, Ireland  
Sigma-Aldrich, Ireland  
Promega, UK  
R&D Systems, UK  
Biolegend, USA  
Promega, UK  
BD Biosciences, USA  
R&D Systems, UK  
Applied Biosystems, UK  
Sigma-Aldrich, Ireland  
Sarstedt, Ireland  
Applied Biosystems
Molecular grade water  
Optical adhesive covers  
PCR tubes  
RNase-free 1.5ml and 2ml microfuge tubes  
RNase Zap wipes  
Total RNA isolation kit  
TaqMan gene expression assays (see Table 2.2)  
TaqMan universal PCR master mix  

2.1.6 General Laboratory Plastics  
Laboratory rolls  
Parafilm  
Microtest 96-well flat bottomed plates  
Microtubes (1.5ml)  
Microtubes (0.5ml)  
Pipette tips  
Plastic transfer pipettes  
Plastic syringe (1ml)  
F96 Maxisorp immunoplates for ELISA  

2.1.7 General Laboratory Chemicals  
2-Propanol  

Chapter 2: Materials and Methods  
Sigma-Aldrich, Ireland  
Applied Biosystems, UK  
Sarstedt, Ireland  
Ambion, UK  
Ambion, UK  
Macherey-Nagel GmbH & Co., Germany  
Applied Biosystems, UK  
Applied Biosystems, UK  
Fisher Scientific  
Fisher Scientific  
Sarstedt, Ireland  
Sarstedt, Ireland  
Sarstedt, Ireland  
Sarstedt, Ireland  
Sarstedt, Ireland  
Becton Dickenson  
Sarstedt, Ireland  
Sigma-Aldrich, Ireland  
43
<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute ethanol (EtOH)</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Acrylamide</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Ammonium Persulfate (APS)</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>β-Mercaptoethanol</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Bovine Serum Albumin (BSA)</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Bromophenol Blue</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Disodium hydrogen orthophosphate (Na$_2$HPO$_4$)</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Glycerol</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Glycine</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Hydrochloric acid (HCl)</td>
<td>VWR Int., Ireland</td>
</tr>
<tr>
<td>N,N,N',N'-Tetramethylethylendiamine (TEMED)</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>N'N' Bis Acrylamide</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Normal goat serum</td>
<td>Vector, UK</td>
</tr>
<tr>
<td>NP-40 (([Octy]phenoxy)polyethoxyethanol)</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Methanol (MeOH)</td>
<td>VWR Int., Ireland</td>
</tr>
<tr>
<td>Orthophosphoric acid</td>
<td>VWR Int., Ireland</td>
</tr>
<tr>
<td>Phosphatase inhibitor cocktail I &amp; II</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Potassium dihydrogen orthophosphate (KH$_2$PO$_4$)</td>
<td>VWR Int., Ireland</td>
</tr>
<tr>
<td>Potassium chloride (KCl)</td>
<td>Merck</td>
</tr>
<tr>
<td>Protease inhibitor cocktail</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
<tr>
<td>Sodium bicarbonate (NaHCO$_3$)</td>
<td>VWR Int., Ireland</td>
</tr>
<tr>
<td>Sodium carbonate (Na$_2$CO$_3$)</td>
<td>VWR Int., Ireland</td>
</tr>
<tr>
<td>Sodium Chloride (NaCl)</td>
<td>VWR Int., Ireland</td>
</tr>
<tr>
<td>Sodium dodecyl sulphate (SDS) 99%</td>
<td>Sigma-Aldrich, Ireland</td>
</tr>
</tbody>
</table>
Chapter 2: Materials and Methods

Sodium hydroxide (NaOH) Sigma-Aldrich, Ireland
Sodium phosphate monobasic monohydrate (NaH$_2$PO$_4$) Sigma-Aldrich, Ireland
Sulphuric acid (H$_2$SO$_4$) 98% BDH
Triton X-100 Sigma-Aldrich, Ireland
Trizma Base Sigma-Aldrich, Ireland
Tris-HCl Sigma-Aldrich, Ireland
Triton-X Sigma-Aldrich, Ireland
Tween-20 Sigma-Aldrich, Ireland

2.1.8 Western Blotting and Staining reagents and antibodies

AKT Antibody Cell Signalling, USA
Anti-mouse IgG Sigma-Aldrich, Ireland
Anti-rabbit IgG Amersham, UK
Anti-βIII-tubulin IgG Promega, UK
β-actin antibody Santa-Cruz Inc., USA
β$_2$-adrenoceptor antibody Santa-Cruz Inc., USA
Broadrange molecular weight marker Biorad, USA
CD11b antibody Millipore, Ireland
ECL Western Blotting Substrate Pierce, USA
GFAP antibody Dako
Goat anti-rabbit Alexa 488 Invitrogen, USA
Goat anti-mouse Alexa 633 Invitrogen, USA
Goat anti-rabbit Alexa 546 Invitrogen, USA
Chapter 2: Materials and Methods

Hoescht
Normal goat serum (NGS)
Polyvinylidene (PVDF)
Re-blot plus
STAT-3 Antibody
Phospho-AKT Antibody
Phospho-p42/44 (ERK) Antibody
Phospho-STAT-3 Antibody

Invitrogen, USA
Sigma-Aldrich, Ireland
Millipore, Ireland
Millipore, Ireland
Cell Signalling, USA
Cell Signalling USA
Cell Signalling, USA
Cell Signalling, USA

2.2 Methods

2.2.1 Aseptic Technique

Aseptic techniques were used during all cell culture work and also in the preparation of cell culture reagents to maintain a sterile environment which was free from fungal, bacterial and viral infections. This was necessary as infections can interfere with normal cellular function. Pipette tips and dH2O were sterilised by autoclaving at 121°C for 20min prior to use in cell culture. Sterile disposable plastics were also utilised to ensure asepsis. Dissection equipment was cleaned with Virkon and then baked for a minimum of 1h at 200°C to ensure sterility. All cell culture work was carried out in a laminar flow hood (Hera Safe, category 2). This prevents contamination with airborne pathogens by only allowing filtered air to come into contact with cells. The interior of the hood was sterilized with 70% ethanol (EtOH; 30% ddH2O and 70% EtOH v/v) before and after use. The hood surface was also exposed to ultraviolet (UV) light for 30min after use. Any items taken into the flow hood were lightly sprayed with 70% EtOH to prevent introduction of any pathogens to the hood work area. Disposable latex gloves were worn and sprayed with EtOH before use. Gloves were changed regularly during cell culture work. Cells were maintained in a sterile incubator (humidified 5% CO2: 95% air environment at 37°C) and any items put in the incubator were lightly sprayed with EtOH to prevent contamination with any pathogens. Both the incubator and laminar flow hood were regularly cleaned with Biocidal ZFT™, Mycoplasm off, virkon and EtOH to maintain a sterile environment.
2.2.2 Preparation of Culture Media and Test Compounds

_Glial Culture Media:_ The glial culture media of 10% (v/v) heat-inactivated Fetal Bovine Serum (FBS), 1% (v/v) Penicillin-Streptomycin (P/S) in Dulbecco's modified Eagle's medium (DMEM:F12) and 0.1% (v/v) Fungizone was prepared by filter-sterilising 5ml P/S, 50ml FBS through a 0.2mm syringe filter into a 500ml bottle of DMEM:F12 and adding 500μl of Fungizone. This complete DMEM (cDMEM) was used in all glial preparations unless otherwise specified.

_Neurobasal media:_ The neuronal culture media of 1% (v/v) P/S, 1% (v/v) Glutamax and 0.1% (v/v) Fungizone in neurobasal media (NBM, Invitrogen) was prepared by filter-sterilising 5ml P/S and 5ml glutamax through a 0.2mm syringe filter into a 500ml of NBM followed by addition of 500μl of Fungizone. When required, a working solution was prepared by adding 500μl of 100 X B-27 growth supplement to 50ml of complete-NBM.

_Phaspate buffered saline (PBS):_ A working 1 X solution of PBS was prepared by adding 1ml Dulbecco’s sterile 10 X PBS to 9ml ddH₂O.

_Noradrenaline (NA):_ A 10mM stock solution was prepared by dissolving 0.034g NA (Formula weight 337g/mol) in 1ml NBM. This was then filter-sterilised using a 0.2mm syringe filter. NA was prepared fresh for each experiment.

_Salbutamol:_ A 100mM stock solution was prepared by dissolving 25mg of salbutamol (β-AR agonist; Formula weight 228.35g/mol) in 1.71ml ddH₂O. Stock solution was frozen at -20°C in 15μl aliquots. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter.

_Salmeterol:_ A 100mM stock solution was prepared by dissolving 10mg salmeterol (selective β₂-AR agonist; Formula weight 415.57g/mol) in 240.6μl DMSO. Stock solution was frozen at -20 °C in 12μl aliquots. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter.

_Xamoterol:_ A 50mM stock solution was prepared by dissolving 10mg xamoterol (selective β₁-AR agonist; Formula weight 397.43g/mol) in 503.2μl ddH₂O. Stock solution was frozen at -20 °C in 12μl aliquots. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter and.
**Di-butyryl adenosine 3', 5'-cyclic monophosphate (db-cAMP):** A 50mM stock solution was prepared by dissolving 25mg of db-cAMP (cyclic AMP analogue; Formula weight 491.4g/mol) in 1ml ddH2O. Stock solution was frozen at -20 °C in 15μl aliquots. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter.

**Phentolamine:** A 50mM stock solution of phentolamine (non-selective α-adrenoceptor antagonist; Formula weight 317.8g/mol) was prepared by adding 50mg to 3.38ml of ddH2O. This solution was vortexed and filter-sterilised by using a 0.2μm syringe filter. Stock solution was frozen at -20 °C in 50μl aliquots for future use.

**Propranolol:** A 50mM stock solution was prepared by dissolving 50mg propranolol (non-selective β-AR antagonist; Formula weight 295.8g/mol) in 3.38ml ddH2O. This was then filter-sterilised using a 0.2mm syringe filter. Stock solution was frozen at -20°C in 50μl aliquots for future use.

**Alamar Blue (Resazurin):** A 440μM stock solution of alamar blue was prepared by dissolving 25mg resazurin (C12H6NNaO4, Formula weight 251.17g/mol) in 226.214ml ddH2O. Stock solution was stored in a dark bottle for future use.

**Wortmannin:** A 10mM stock concentration of wortmannin was prepared by dissolving 1mg wortmannin (Formula weight 428.44g/mol) in 233.4μl of DMSO. Stock solution was frozen at -20°C in 5μl aliquots for future use. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter.

**LY294002:** A 10mM stock concentration of LY294002 was prepared by dissolving 5mg LY294002 (Formula weight 343.81g/mol) in 1.45ml DMSO. Stock solution was frozen at -20°C in 15μl aliquots for future use. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter.

**PD98059:** A 10mM stock concentration of PD98059 was prepared by dissolving 1mg PD98059 (Formula weight 267.28g/mol) in 374.14μl DMSO. Stock solution was frozen at
-20°C in 15μl aliquots for future use. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter.

**STAT3 Inhibitor VI, S31-201:** A 10mM stock concentration of S31-201 was prepared by dissolving 10mg of S31-201 (Formula weight 365.4g/mol) in 2.74ml DMSO. Stock solution was frozen at -20°C in 15μl aliquots for future use. Before use it was diluted to a working concentration in pre-warmed media and filter-sterilised using a 0.2mm syringe filter.

### 2.2.3 Preparation of coverslips

Poly-L-lysine was firstly reconstituted with 3ml of sterile dH₂O and thoroughly mixed with a vortex. A further 22ml of sterile dH₂O was added to give a stock concentration of 1mg/ml. This solution was then filter-sterilised using a 0.2mm syringe filter and frozen at -20°C in 1ml aliquots for future use. When required, this 1ml aliquot was diluted 1:25 by the addition of 24ml dH₂O to a final concentration of 40μg/ml. Poly-D-lysine was prepared by reconstituting 5mg with 50ml sterile dH₂O to make a stock concentration of 0.1mg/ml. This solution was then filter sterilized using a 0.2mm syringe filter and frozen at -20°C in 5ml aliquots for future use. When required the aliquot was further diluted by addition of 5ml dH₂O to a working concentration of 50μg/ml. Glass coverslips were sterilised by baking at 200°C for at least 2h. Coverslips were then placed into sterile plates (24-well plates or 6-well plates) using a clean and sterile forceps and placed under the UV light for 30min for further sterilisation. A drop of 110μl (13mm diameter) or 1.5ml (25mm diameter) of poly-D-lysine (50μg/ml) or poly-L-lysine (40μg/ml) was added onto the centre of each coverslip and incubated at 37°C for at least 30min. The poly-D-lysine or poly-L-lysine was then aspirated and kept at 4°C to be re-used up to three times. The coverslips were then rinsed gently twice with sterile dH₂O and any residual dH₂O was discarded. The plates were left to fully dry for at least 2h at 37°C until use.

### 2.2.4 Preparation of Primary Cultures

Primary cultures for mixed glial cells, enriched astrocytes, enriched microglia and primary cortical neurons were prepared as described previously (McNamee et al., 2010b) and see below.
2.2.4.1 Primary Mixed Glial Cells

Primary rat glial cells are prepared by dissection of the brain tissue and dissociation of the area of interest to obtain a glia enriched cell culture. The cells are allowed to grow and mature for between 10 – 14d and then used in experimental procedures. Glial cultures prepared in this manner generally contain astrocytes and microglia at 70% and 30% of total cell population respectively. Primary cultures are beneficial to use as they are untransformed cells, and are thus more representative of the natural brain environment.

The mixed glial enriched cultures were prepared from the brains of newborn Wistar rat pups (postnatal day 2-3), under sterile conditions, in the laminar flow hood. The pups were decapitated using a large sharp scissors. A smaller scissors was then used to cut the skin down the midline to reveal the skull which was then carefully cut on each side at ear level. A curved forceps was then used to gently pull away the skull to reveal the exposed brain. A straight fine toothed forceps was used to remove and discard the meninges. The cortical tissue on both hemispheres was then removed and placed into a drop of pre-warmed cDMEM. The cortical tissue from 3 pups was pooled and cross-chopped using a scalpel and any blood vessels were removed. The finely-chopped tissue was then transferred into a 50ml falcon tube with 6ml of pre-warmed cDMEM and incubated for 20min. After the incubation, the tissue was triturated until all visible clumps were removed, passed through a sterile mesh filter (40μm) and centrifuged at 2000 x RPM for 3min at 20°C. The supernatant was discarded and the pellet was re-suspended in 1ml pre-warmed cDMEM by gently triturating until a homogenous cellular suspension was obtained. At this stage the cell suspension was counted by the trypan blue exclusion method. 10μl of cell suspension was diluted with 90μl of trypan blue and viable cells were counted using a haemocytometer. The cell suspension was then diluted to approximately 5 x 10⁶cells/ml and 5ml of this suspension was added into T75 flasks. The flasks were placed into an incubator (5% CO₂, 95% air at 37°C) for 2h to allow adherence to the bottom of the flask and then were flooded with 10ml cDMEM. Media was replaced after 3d and there-after every 4-6d.

For conditioned media studies, the T75 flasks were gently trypsinised by rinsing the cells with 1 X PBS, followed by addition of 5ml of trypsin-EDTA. The flasks were incubated at 37°C for approximately 10min, during which time the flasks were periodically checked under an inverted microscope to assess level of cell adherence to the plate. When approximately 95% of the cells were non-adherant, cDMEM was added to the flasks as the
FBS contains trypsin inhibitors. The resultant suspension was then centrifuged at 2000 x RPM for 3 min at 20°C. The supernatant was discarded and the pellet was re-suspended in 1ml pre-warmed cDMEM by gently triturating until a homogenous cellular suspension was obtained. This cell suspension was diluted with a further 35ml cDMEM and re-plated into uncoated 6-well plates. Re-plated glial cells were treated at least 3d post trypsinisation and when cells were confluent.

For staining of primary glial cells, 75% of the cell suspension (approximately 1 x 10^5 cells/ml) following trypsinization and centrifugation was plated onto poly-l-lysine pre-coated glass coverslips. After 2h to allow for cell adherence, 350μl of cDMEM was gently added.

2.2.4.2 Primary enriched astrocyte and microglia

Primary mixed glial cells were prepared as described before, with the exception that cultures for microglia were treated with GM-CSF (10ng/ml) and M-CSF (10ng/ml) to encourage microglial proliferation. When flasks reached confluency (approx d10-14), the flask caps were wrapped in parafilm and placed onto an orbital shaker for 2h at 110rpm to remove the loosely adherent microglial cells from the astrocytic monolayer. After which time, the flasks were brought back into the laminar flow, and tapped 10 times to encourage microglia to fully detach. The resultant suspension was centrifuged at 2000 X RPM for 5 min at 20°C. The supernatant was discarded and the pellet resuspended in 1ml cDMEM and counted by the trypan blue method. Cells were plated at a density of at least 1 x 10^6 cells/ml on poly-l-lysin pre-coated glass coverslips in 24-well plates and treated at least 2d post separation. Several coverslips were stained by fluorescent immunocytochemistry for CD11b, a marker for microglia, to assess for microglial purity. Cells prepared in this way yielded 95% pure microglia.

Mixed glial cultures for enriched astrocytes were not treated with GM-CSF or M-CSF. After 10-14d, microglia were removed as described above. The remaining astrocyte monolayer in the T75 flasks was then gently trypsinised and plated onto uncoated 6-well plates for treatments or poly-l-lysin pre-coated glass coverslips for fluorescent immunocytochemistry.
2.2.4.3 Primary Cortical Neurons

The cortex was dissected from 1d old Wistar rat pups as described previously. The tissue was finely cross-chopped in pre-warmed NBM and then transferred into 5ml of trypsin-EDTA, and incubated for 2min at 37°C. CDMEM (5ml) was then added and the tissue was triturated twice, followed by centrifugation at 2000 x RPM for 4min at 20°C. The resultant supernatant was discarded and the pellet re-suspended in 5ml cDMEM. This cell suspension was triturated until no visible clumps remained, passed through a sterile mesh filter (40μm) and centrifuged at 2000 x RPM for 3 min at 20 °C. The supernatant was discarded and the pellet was re-suspended in 1ml pre-warmed cNBM by gently triturating until a homogenous cellular suspension was obtained. The cell suspension was counted by the trypan blue exclusion method. For all Sholl analysis experiments, the cell suspension was diluted to 5 x 10^5 cells/ml and 75μl of this was gently pipetted onto the centre of a poly-d-coated coverslip in 24-well plates. The plate was placed into an incubator (5% CO₂, 95% air at 37°C) for 2h to allow adherence and then flooded with 300μl cNBM. For Western Immunoblotting experiments, the cell suspension was diluted to a concentration of 1 x 10^5 cells/ml, and 750μl of this was plated onto poly-d-coated coverslips in 6-well plates and allowed to adhere for 2h until the addition of 1.2ml cNBM. Neurons were treated after 3d in vitro (DIV).

2.2.5 Preparation of C6 glioma cells

C6 glioma cells (Banca Biologica e Cell Factory, Genova, Italy; passage 4; Figure 2.1) were first awakened by addition of 1ml pre-warmed Hams-F12 media to the vial, followed by a further 4ml and immediate transfer to a T-25 cm² flask and incubated at 37°C with 5% CO₂. All further experiments and re-animation of cells were performed in cDMEM. Upon reaching confluency (80-90%), the cells were trypsinised, and re-passaged into T-75cm² flasks or frozen down for future use. Briefly, the old media was discarded and the adherent cells were washed in pre-warmed sterile PBS. Trypsin (1:3 ratio in PBS) was added for 5min at 37°C. The trypsin was deactivated with cDMEM and the resultant cell suspension was centrifuged for 3min at 2000 x RPM at 20°C, to pellet the cells. The supernatant was removed, and the cells gently resuspended in cDMEM. Cells were counted using the haemocytomter. Aliquots of at least 1 x 10^6 cells/ml were frozen using the Nalgene Mr. Frosty box at -80°C for 24h and then transferred to a liquid nitrogen canister for future use. Cell suspensions were re-passaged into either T75cm² flasks (10ml of 1x10⁵ cells/ml) for continued growth of the cell line, 6-well plates (2ml of
Chapter 2: Materials and Methods

5x10^4 cells/ml) for cell treatments or glass coverslipped 24-well plates (75μl of 1x10^5 cells/ml followed by 300μl after 2h). Cells were incubated for at least 24h prior to the addition of treatments.

Figure 2.1 C6 Glioma Cells growth and morphology
C6 glioma cells immediately following re-animation (A), after 1 DIV (B), 2 DIV (C) and 3 DIV (D). Scale bar is equal to 200μm in each case.

2.2.6 Cell culture treatments
For each experiment, 6-well tissue culture plates were prepared with mixed glial cultures as described in section 2.2.4. Each well was considered as n=1, and treated with 1.2ml of drug. Pre-treatments were administered 30min prior to post-treatment. Cell cultures were incubated at 37 °C with 5% CO_2 with the various drug treatments for either 6h to assess gene expression, or 24h for CM experiments, for protein production or cell viability. For CM experiments, after 24h, the CM was removed and filtered through a 0.2mm syringe filter to remove cells and cellular debris. A full CM transfer was then performed on the neurons. B-27 supplement was added to every well after CM transfer. Neurons for cell viability and Sholl experiments were treated for 24h, neurons for Western Immunoblotting were treated for 5min. Control cultures were always treated with the addition of vehicle included in the drug treatments, e.g. DMSO. Cell numbers of glia (mixed glia, astrocytes
or microglia) for CM experiments were kept at approximately the same numbers across experiments (approx 1 x 10^6 cells/well). Where this was not possible (e.g. for enriched microglial cultures), CM volume was adjusted appropriately.

2.2.7 Harvesting glial cultures for mRNA analysis
The fume hood, equipment and gloves were wiped with RNase Away wipes prior to use to prevent RNA contamination. After 6h treatment, the supernatant from the 6-well plates was removed and the cells were lysed and then harvested using 350μl Lysis buffer (RA1 (Macherey-Nagel, Germany), 1% β-mercaptoethanol) per well. Samples were then frozen at -80°C to be extracted at a later time.

2.2.8 Preparation of neuronal cultures for Western Immunoblotting
Primary cortical neurons were prepared and treated as outlined previously. The treatments were removed by aspiration and cells rinsed gently in 1 x PBS at room temperature. 60μl of ice-cold lysis buffer (50mM Tris-HCl, pH8; 150mM NaCl; 1% ([Octyl]phenoxy)polyethoxyethanol (NP-40)) containing 1% protease and phosphatase inhibitors was added per well. Cells were scraped off using a clean pipette tip and collected in an ice-cold 1.5ml microtube. The samples were then centrifuged at 12,000 x RPM at 4°C for 10min. The supernatant was transferred to a clean ice-cold 1.5ml microtube and frozen at -80°C until later use. A 1:2 dilution of the supernatant was prepared and a protein assay was carried as outlined in section 2.2.12.1. Protein concentrations of samples were equalised to 1mg/ml using lysis buffer. Samples were then stored at -80°C until use for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and western immunoblotting as described in section 2.2.12.

2.2.9 RNA Analysis

2.2.9.1 RNA extraction
RNA was extracted from the cells using a NucleoSpin RNA II kit (Macherey-Nagel, Germany) according to the kit protocol. Standard precautions were taken to keep reagents, consumables and equipment free from RNAses. The lysate, as collected during cell harvesting (section 2.2.8), was filtered through the violet NucleoSpin Filter columns and centrifuged for 1min at 11,000 x g. 70% ethanol was then added to the lysate and mixed by gentle pipetting. This was then loaded into a NucleoSpin RNA II Column and centrifuged for 30sec at 11,000 x g. This membrane was then desalted using membrane desalting buffer and again centrifuged at 11,000 x g for 30sec. 95μl of Dnase reaction mixture was then added to the membrane and incubated for 15min to degrade any
contaminating DNA. The membrane was washed with buffer RA2 to inactivate the Dnase and centrifuged at 11,000 x g for 30sec. The column was placed in a new tube and the membrane was dried by the addition of 600μl RA3 and centrifuged at 11000 x g for 30sec, then 250μl RA3 was added and centrifuged at 11000 x g for 2min. The column was placed into a clean collection tube and the RNA was eluted using RNase-free water and centrifuged at 11,000 x g for 1min. The eluted RNA was reapplied to the column for a second elution step at 11,000 x g for 1min. The eluted RNA was then quantified using a nanospectrophotometer. The RNA was stored at -80 °C until RNA equalisation.

2.2.9.2 Measuring RNA concentration and Equalising RNA
The RNA concentration of each sample was measured using a NanoDrop® ND1000 spectrophotometer. Purity was demonstrated by the A260/280 ratio. RNA samples (20 μl) were equalised to the lowest concentration of RNA detected by addition of RNase-free H₂O.

2.2.9.3 cDNA Preparation
C omplete mentary DNA (cDNA), was reverse transcribed from the equalised RNA using ABI High Capacity cDNA archive kit according to the manufacturers protocol. Briefly an equal volume of RNA was mixed with cDNA Mastermix (containing RT Buffer (Reverse Transcriptase), dNTPs, random primers, multiscribe RT and RNase-free H₂O). The samples were mixed, briefly centrifuged and placed into a Thermal Cycler (PTC-200 Peltier Thermal Cycler DNA Engine) on the ABI-RT programme. The samples were kept at 25°C for 10min and then for 120min at 37 °C. Upon completion of the programme, the samples were removed, diluted 1:4 with RNAse-free H₂O and frozen at -20°C until needed for further polymerase chain reaction (PCR) analysis.

2.2.9.4 Multi-target (Multiplex) quantitative Real Time-PCR (RT-PCR)
Quantitative PCR was performed on Applied Biosystems ABI Prism 7300 Sequence Detection System v1.3.1 in 96-well format and 25μl reaction volume per well as described previously (Boyle & Connor, 2007). Each sample included the target probe (see table 2.2) and the endogenous marker β-actin (VIC-labelled MGB Taqman probe, Applied Biosystems), to allow for normalisation of gene expression between samples. RT-PCR was performed using Taqman Gene Expression Assays (Applied Biosystems) which contain forward and reverse primers, and a FAM-labelled MGB Taqman probe to each gene of interest.
A 10 µl volume of diluted cDNA was added to each well and 15 µl of reaction mix (12.5 µl Taqman Universal PCR Mastermix, 1.25 µl β-actin primer, 1.25 µl target primer) was added to give a final reaction volume of 25 µl. Electronic pipettes (EDP3 2-20 µl, 10-100 µl and 20-200 µl) were used to ensure pipetting accuracy. Samples were run on the ABI Prism 7300 Sequence Detection System (Applied Biosystems, Germany) for either 40 or 45 cycles. The samples were first heated to 95°C for 10 min to start the process before the cycles began. The samples were heated to 95°C for 15 sec to allow denaturation of the double-stranded cDNA. The temperature was then decreased to 60°C to allow annealing and extension of the cDNA. The data were analysed using Applied Biosystems relative quantification software.

2.2.9.5 Realtime-PCR analysis

The ΔΔCt method (Applied Biosystems RQ software, Applied Biosystems, UK) was used to assess gene expression, as calculated relative to the endogenous control β-actin, and the control samples to give a Relative Quantification value (RQ) (2^{-ΔΔCt}, where Ct is the threshold cycle). This method compares gene expression of treated samples to an untreated control sample instead of quantifying the exact copy number of the gene. This means that the fold-difference (increase or decrease) can be assessed between treated and untreated samples. The fold-difference is assessed using the cycle number (CT) difference between samples. A threshold for fluorescence is set, against which CT is measured. To accurately assess differences between gene expression, the threshold is set when the PCR reaction is in the exponential phase, when the PCR reaction is optimal or 100% efficient. Samples with low CT readings demonstrate high fluorescence, indicating greater amplification and thus greater gene expression. To measure this fold-difference relative to control, the CT of the endogenous control (β-actin) is subtracted from the CT of the target gene for each sample, thus accounting for any difference in cDNA quantity that may exist. This normalised CT value is called the CT difference (ΔCT). The ΔCT of the control is subtracted from itself to give 0, and subtracted from all other samples, this is the ΔΔCT value (cycle difference corrected for β-actin). The ΔΔCT is then converted into a fold-difference. As a one-cycle difference corresponds to a two-fold increase or decrease relative to control, the fold-difference in gene expression between the control and treated samples is given by 2 to the power of the -ΔΔCT. Thus when PCR is 100% efficient a five-cycle difference between samples means a 5-fold difference is a 32-fold difference (2^{5}). The control sample always has a ΔΔCT value of 0, thus 2^{0} gives a 2^{ΔΔCT} of 1, against which all other samples are referenced.
### Chapter 2: Materials and Methods

#### 2.2.10 Fluorescent Immunocytochemistry and Sholl Analysis

**2.2.10.1 General fluorescent immunocytochemistry**

Fluorescent immunocytochemistry was performed on both mixed glial cells and neurons grown on glass coverslips. Primary antibodies used were as follows; GFAP (1:2000), Cd11B (1:1000), βIII-tubulin (1:850), S100β (1:1000). All primary antibodies were diluted in 2.5% normal goat serum in PBS. Secondary antibodies used were; goat anti-rabbit Alexa Fluor 488, goat anti-mouse Alexa Fluor 633. All secondary antibodies were diluted in 2.5% normal goat serum in PBS.

Cells grown on glass coverslips were washed under sterile conditions twice with PBS. The cells were then fixed with ice-cold methanol for 15min at -20°C, and again washed twice with PBS. After the fixation step, all subsequent steps were performed on the normal

---

<table>
<thead>
<tr>
<th>Target</th>
<th>Primer Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-actin (VIC)</td>
<td>4352340E</td>
</tr>
<tr>
<td>BDNF</td>
<td>Rn00560868_m1</td>
</tr>
<tr>
<td>CNTF</td>
<td>Rn00755092_m1</td>
</tr>
<tr>
<td>FGF-2</td>
<td>Rn00570809_m1</td>
</tr>
<tr>
<td>GDNF</td>
<td>RN00755092_m1</td>
</tr>
<tr>
<td>IGF-1</td>
<td>Rn00710306_m1</td>
</tr>
<tr>
<td>IL-10</td>
<td>Rn00563409_m1</td>
</tr>
<tr>
<td>IL-6</td>
<td>Rn00561420_m1</td>
</tr>
<tr>
<td>NGF-β</td>
<td>Rn01533872_m1</td>
</tr>
<tr>
<td>NT3</td>
<td>Rn00579280_m1</td>
</tr>
<tr>
<td>NT4/5</td>
<td>RN00566076_s1</td>
</tr>
<tr>
<td>TGF-beta 1</td>
<td>Rn00572010_m1</td>
</tr>
<tr>
<td>VEGF</td>
<td>Rn01511601_m1</td>
</tr>
</tbody>
</table>

**Table 2.2 List of primers for PCR**
Chapter 2: Materials and Methods

laboratory bench. Non-reactive sites were blocked for 2h at room temperature (RT) in blocking buffer (10% normal goat serum in PBS). The blocking buffer was removed and the primary antibody was immediately added. The cells were incubated in primary antibody overnight at 4°C. Cells were again washed three times in PBS. Cells were then incubated with an appropriate secondary antibody in a light protected environment for 2h at RT. The cells were again washed three times in PBS. The glass coverslips were then removed and mounted onto glass slides onto Vectashield fluorescent mounting media with DAPI. Each coverslip was sealed with nail varnish and stored in the dark at 4°C until viewed. All pictures were taken on epifluorescent microscope with AxioVision Rel 8 Software (Carl Zeiss MicroImaging).

2.2.10.2 Sholl Analysis

The Sholl analysis procedure was adapted from Gutierrez and Davies (2007). For the analysis, βIII tubulin stained neuronal coverslips were viewed at 200 X on the epifluorescent microscope. For a coverslip to be utilised in Sholl analysis, the neurons must display a healthy network phenotype, following this, individual neurons, which were not in contact with any other neurons, were imaged at random. Five individual neurons from each coverslip were imaged, analysed and averaged for Sholl analysis. Where possible, groups were blinded. Neuronal images were imported into Microsoft PowerPoint where a calibrated image of concentric circles at 10μm distances (up to 165μm) was superimposed onto the cell body of the nucleus of the neuron (Figure 2.2). Primary neurites, neuritic branches and neurite termination points were all counted within each circle. Primary neurites were classified as those directly stemming from the cell body within circle number 1, while a branch was counted if a neurite clearly divides in two for at least 5μm (or half a circle width). The longest neurite was utilised as the neuritic length. If a neurite extended outside of the superimposed circles, the extended length was measured, however no further branches were recorded. Sholl analysis results were displayed for the number of primary neurites, the number of neuritic branches and the neuritic length. Furthermore, the Sholl profile was also displayed. For this, the total number of neurites for any segment was plotted against the distance from the cell soma.
The total number of neurites for any segment was calculated as follows:

\[ X_i = X_{i-1} + B_i - T_i \]

Where \( X_i \) = the number of neurites for the “ith” segment

\( B_i \) = the number of branching events occurring in the “ith” segment

\( T_i \) = the number of branching terminations occurring in the “ith” segment

![Neuron stained with βIII tubulin and Hoescht (A) with overlaying Sholl analysis concentric circles (B)](image)

Figure 2.2: Neuron stained with βIII tubulin and Hoescht (A) with overlaying Sholl analysis concentric circles (B)

Figure shows a neuron which has been stained with βIII tubulin (white) with the cell body stained with Hoescht (blue). In this example, the neuron is considered to have six primary neurites (indicated with yellow stars), with three bifurcations between circles 1 and 2 (red arrows) and two more bifurcations between 2 and 3. The longest neurite terminates between circles 5 and 6 (green arrow). Scale bar = 30μm

As this was the first time Sholl analysis was performed in this laboratory it was important to examine the Sholl profile of the primary cortical neurons. As such the number of neuritic branches for untreated neurons was plotted against the distance from the cell soma to generate the Sholl profile. The resulting graph (Figure 2.3) shows a stereotypical Sholl profile as described in the literature (Gutierrez & Davies, 2007). Thus the Sholl analysis was utilised in subsequent studies.
Figure 2.3: Sholl profile of untreated rat primary cortical neurons

A scatter plot of the number of branches plotted against the distance from the cell soma for control neurons demonstrate a stereotypical "Sholl profile".
2.2.11 Cell Viability assay: Alamar Blue

The alamar blue assay is a metabolic assay for assessing the ability of living cells to convert a redox dye (resazurin, C_{12}H_{6}NNaO_{4}) into a fluorescent end product (resorufin). Viable cells can reduce resazurin into resorufin via mitochondrial metabolism. A 440μM solution of Alamar Blue dye was made by dissolving Resazurin in ddH_{2}O. Neurons were treated as required. Following treatment, medium was removed from the cultures and Alamar Blue dye in fresh NBM (As; 1:10 ratio, e.g. 30μl into 270μl) and incubated at 37°C and 5% CO_{2} was added for 3h. The dye was also added to empty wells (Am) and untreated control cultures (Ac). When colour change had occurred, 200μl of supernatant was transferred to 96 well plates. Absorbance was read at 600nm using a microtitre plate reader (Elx 800 Bio-Tek instruments Inc.). Results were calculated as follows:

\[
\text{Am} = \text{Average absorbance of wells containing Media only}
\]
\[
\text{Ac} = \text{Average absorbance of wells containing Cells without treatments}
\]
\[
\text{As} = \text{Absorbance of a particular sample}
\]
\[
\% \text{ Viability} = ((\text{Am} - \text{As})/(\text{Am} - \text{Ac})) \times 100
\]

2.2.12 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Immunoblotting

SDS-PAGE and Western Immunoblotting was performed as described previously (McNamee et al., 2010a; McNamee et al., 2010b).

2.2.12.1 Bradford Protein Assay

Protein concentration was determined by the Bradford assay method (Bradford, 1976). Standard protein concentrations (0-1000μg/ml) of Bovine Serum Albumin (BSA) were made. 5μl of standard and sample was pipetted into a 96-well plate in duplicate. 195μl of dye reagent was added on top of the standard and sample and the plate was incubated for 5 minutes at room temperature. After 5min, the plate was read using a standard plate reader (Bio-Tek microplate reader, BioTek Instruments, USA) and protein concentration was calculated.
2.2.12.2 Gel Preparation and SDS-Page

Samples to be analysed by western immunoblotting were added in a 4:1 v/v ratio to 4× Laemmli sample buffer (1M Tris-HCL, pH 6.8; 25% (w/v) sodium dodecyl sulphate; 50% (v/v) glycerol; 10% (v/v) β-mercaptoethanol; 2% (w/v) bromophenol blue) and were boiled at 60°C for 5min prior to loading on gels for SDS-PAGE. Electrophoresis was performed using SDS-polyacrylamide gels (10% separating gel: 4% stacking gel). Briefly, gels were prepared, mixed by pipetting and quickly pipetted between two glass plates held firmly together with a casting frame. A layer of 2-propanol was poured on top of the gel to prevent evaporation. This separating gel was allowed to set for approximately 30min after which time the 2-propanol was removed and the top of the gel was rinsed with dH2O. The stacking gel was then prepared and poured on top of the separating gel and a 10-well comb was placed into the gel to allow wells for loading to form. The stacking gel was left to set for 30min. The glass plates with gel were then removed from the casting frame and placed into an electrode assembly and clamped into place. This was then put into the gel rig. The inner and the bottom of the outer gel rig were filled with 1× electrode running buffer (125mM Tris-Base, pH 8.3; 960mM glycine; 0.5% SDS) and the combs were removed. 30μl of sample was loaded per well. 5μl of Broadrange Molecular Marker was loaded onto gels alongside samples. Proteins were separated by applying a constant current of 33milliamps per gel for 60min or until the blue dye from the sample buffer had run to the bottom of the gel.

2.2.12.3 Semi-dry transfer

Following electrophoresis, separated proteins were transferred onto polyvinylidene fluoride (PVDF) membranes using a semi-dry blotter at a constant current of 225mA for 70min. Briefly, gels were removed from the glass plates and placed within a sandwich of filter paper and PVDF membrane. The PVDF was first activated by soaking the membrane in methanol for 30sec followed by soaking in dH2O for 2min. To make the sandwich, two pieces of filter paper soaked in anode buffer I (0.3M Tris-Base, 10% methanol) were placed onto the anode (+) plate of the semi-dry blotter, one piece of filter paper soaked in anode buffer II (25mM Tris-Base, 10% methanol) was placed on top of this. The activated PVDF membrane was placed on next, followed by the gel. Lastly, three pieces of filter paper soaked in cathode buffer ((25mM Tris-Base, 40mM glycine, 10% methanol) was placed on top. Any bubbles which may have been present were removed by gently rolling a pasteur pipette over the top of the sandwich. The cathode (-) plate was then placed on top of the sandwich and the current was applied at 225mA for 70min. In this set-up the
proteins will migrate from the gel towards the anode plate and hence into the PVDF membrane.

2.2.12.4 Western Immunoblotting
Following transfer, membranes were immediately blocked in 5% milk in TSB-Tween20 (TBS-T) for 1h. The membrane was then washed 3 x 5min in 15ml TBS-T. The membrane was incubated with the primary antibody at the appropriate dilution (see Table 2.3) in 10ml of 5% BSA in TBS-T overnight at 4°C on a rocker-roller. The membrane was washed 3 x 10min in 15ml TBS-T and then the secondary antibody was applied to the membrane at the appropriate dilution (see Table 2.3) and incubated for 1h at RT. The membrane was washed 3 x 10min in 15ml TBS-T. The membrane was then exposed to ECL chemilumiscent solution and developed on Fujifilm Luminescent Image Analyzer LAS-3000. Blots were stripped in 10ml re-store Western blot Stripping Solution for 15min and then washed 3 x 10 min in 15ml TBS-T. After this, blots were ready to be re-blocked and re-probed with another antibody. Protein bands were quantified using ImageJ software, NIH.

<table>
<thead>
<tr>
<th>Target</th>
<th>M. Wt (kDa)</th>
<th>Primary Antibody Conc</th>
<th>Secondary Antibody Conc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akt</td>
<td>60</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
<tr>
<td>p-Akt</td>
<td>60</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
<tr>
<td>STAT3</td>
<td>79, 86</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
<tr>
<td>p-STAT3</td>
<td>79, 86</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
<tr>
<td>Erk</td>
<td>42, 44</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
<tr>
<td>P-Erk</td>
<td>42, 44</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
<tr>
<td>B2-adrenoceptor</td>
<td>55</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
<tr>
<td>B-actin</td>
<td>43</td>
<td>1:1000</td>
<td>1:2000</td>
</tr>
</tbody>
</table>

Table 2.3 Antibody dilutions for western immunoblotting
2.2.13 Enzyme-linked Immunosorbent assays (ELISA)

Protein concentrations were measured in the glial CM by ELISA. Each kit was chosen based on previous reports demonstrating successful protein quantification from primary rat astrocytes or rat brain homogenate (Park et al., 2000; Hisaoka et al., 2007; Griffin et al., 2009; Guo et al., 2009; Lee et al., 2009a). Each ELISA was followed as per the manufacturers guidelines supplied in the kit (see table 2.4). Briefly, 50μl of the diluted capture antibody was added to each well of a 96-well plate and incubated for the appropriate amount of time. Following this, plates were washed with wash buffer and then blocked with block buffer to block any non-specific binding sites. The block was removed and the samples and diluted standards were then added to the plates (50μl) and incubated for the appropriate amount of time. Plates were washed again with wash buffer and the detection antibody (50μl) was added for the appropriate amount of time. The plates were again washed. Following this, the HRP-conjugated antibody (50μl) was added, incubated and then another wash was performed. TMB solution was then added (50μl) and colour development occurred. The reaction was stopped with stop solution (50μl) and absorbance was read at 450nm. Protein concentrations were calculated from the standard curve.
## Chapter 2: Materials and Methods

### ELISA FGF-2, NGF-β, GDNF

<table>
<thead>
<tr>
<th>ELISA</th>
<th>FGF-2</th>
<th>NGF-β</th>
<th>GDNF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capture Antibody</strong></td>
<td>Diluted in coating buffer (supplied in kit), overnight at 4°C</td>
<td>NGF-β polyclonal antibody, diluted in coating buffer (0.025M NaHCO3, 0.025M Na2CO3, pH 9.7), overnight at 4°C</td>
<td>GDNF monoclonal antibody, diluted in coating buffer (0.025M NaHCO3, 0.025M Na2CO3, pH 9.7), overnight at 4°C</td>
</tr>
<tr>
<td><strong>Block</strong></td>
<td>Supplied in kit, 1h at RT</td>
<td>Supplied in kit, 1h at RT</td>
<td>Supplied in kit, 1h at RT</td>
</tr>
<tr>
<td><strong>Standards and Samples</strong></td>
<td>0-500pg/ml of standards, 2h at RT</td>
<td>0-250pg/ml of standards, 6h at RT</td>
<td>0-2000pg/ml of standards, 6h at RT</td>
</tr>
<tr>
<td><strong>Detection Antibody</strong></td>
<td>Diluted in blocking buffer, 1h RT</td>
<td>Anti-NGF-β monoclonal antibody, diluted in blocking buffer, overnight at 4°C</td>
<td>Anti-human GDNF polyclonal antibody, diluted in blocking buffer, overnight at 4°C</td>
</tr>
<tr>
<td><strong>HRP-conjugated antibody</strong></td>
<td>Avidin-HRP, diluted in blocking buffer, 30min RT</td>
<td>Anti-rat IgG-HRP, diluted in blocking buffer, 2.5h at RT</td>
<td>Anti-chicken IgY-HRP, diluted in blocking buffer, 2.5h at RT</td>
</tr>
<tr>
<td><strong>Stop Solution</strong></td>
<td>PBS + 0.05% Tween-20</td>
<td>TBS + 0.05% Tween-20</td>
<td>TBS + 0.05% Tween-20</td>
</tr>
</tbody>
</table>

### ELISA IL-6, BDNF, VEGF

<table>
<thead>
<tr>
<th>ELISA</th>
<th>IL-6</th>
<th>BDNF</th>
<th>VEGF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capture Antibody</strong></td>
<td>Diluted in coating buffer (0.1M NaHCO3, pH 9.5)</td>
<td>Mouse anti-human BDNF diluted in PBS, overnight at RT</td>
<td>Mouse anti-rat VEGF diluted in PBS, overnight at RT</td>
</tr>
<tr>
<td><strong>Block</strong></td>
<td>PBS + 10% FBS, 1h at RT</td>
<td>PBS + 1% BSA, 1h at RT</td>
<td>PBS + 1% BSA, 1h at RT</td>
</tr>
<tr>
<td><strong>Standards and Samples</strong></td>
<td>0-5000pg/ml of standards, 2h at RT</td>
<td>0-1500pg/ml of standards, 2h at RT</td>
<td>0-1000pg/ml of standards, 2h at RT</td>
</tr>
<tr>
<td><strong>Detection Antibody</strong></td>
<td>IL-6 monoclonal antibody diluted in blocking buffer, 1h at RT</td>
<td>Anti-human BDNF diluted in blocking buffer, 2h at RT</td>
<td>Anti-rat VEGF diluted in blocking buffer, 2h at RT</td>
</tr>
<tr>
<td><strong>HRP-conjugated antibody</strong></td>
<td>streptavidin-HRP, 30min at RT</td>
<td>streptavidin-HRP, 20min at RT</td>
<td>streptavidin-HRP, 20min at RT</td>
</tr>
<tr>
<td><strong>Stop Solution</strong></td>
<td>2N H2SO4</td>
<td>2N H2SO4</td>
<td>2N H2SO4</td>
</tr>
<tr>
<td><strong>Wash Buffer</strong></td>
<td>PBS + 0.05% Tween-20</td>
<td>PBS + 0.05% Tween-20</td>
<td>PBS + 0.05% Tween-20</td>
</tr>
</tbody>
</table>

Table 2.4 ELISA antibodies and procedures
2.2.14 Statistical Analysis

All data was analysed in GB-stat [Dynamic Microsystems Inc.] and all graphs created in Prism 4 (GraphPad Prism, California, USA). Analysis of variance (ANOVA), or student t tests were performed where appropriate. All Sholl profile graphs were analysed using a repeated measures ANOVA (two, or three-way where appropriate). If significant changes were observed, the data was further analysed using Newman-Keuls or Fisher’s LSD post-hoc test as appropriate. A p value of less than 0.05 was deemed significant and all data are expressed as means + or ± standard error of the mean.
Chapter 3

Results
3.1 Examination of the impact of neurotransmitters on neuronal complexity

Monoaminergic neurotransmitters, which include noradrenaline and serotonin, are classical transmitters which are released from nerve terminals to modulate post-synaptic signal transduction in neurons (Rang & Dale, 2003). However, both serotonin and noradrenaline have previously been shown to have extra-synaptic actions on glial cells and can promote the production of neurotrophic factors (for review, see Kimelberg, 1995). Much work has been performed to assess the roles of the monoamines in providing neuronal protection, however, there is little research examining monoamine-induced changes in neuronal outgrowth which could prove important for encouraging neuronal regeneration following brain injury, disease or neurodegeneration.

Therefore, the aims of these studies were as follows:

1) To determine if noradrenaline or serotonin promotes neurite outgrowth in primary rat cortical neurons either directly or via an indirect action on glial cells.

2) To determine if the antidepressant and NA/5-HT reuptake inhibitor, amitriptyline, promotes neuronal outgrowth in primary cortical neurons either directly or via an indirect action on glial cells.
3.1.1 Effect of noradrenaline on neuronal complexity: A role for glial cells

Noradrenaline is known to have extra-synaptic actions on glial cells, stimulating the release of supporting factors for neurons (for example (Madrigal et al., 2009). The purpose of these studies therefore was to determine if noradrenaline, via an action on glial cells, would provide a more trophic environment for primary cortical neurons. For that reason confluent primary mixed glial cells from P2-3 rat cortex were treated with control (complete neurobasal media (NBM)) or noradrenaline (NA; 10μM for viability assay, 1, 5, 10μM for Sholl analysis) in NBM. The cells were treated for 24h after which time the conditioned media (CM) was collected, filtered and then used to treat for 24h, primary cortical neurons which had been cultured for 4DIV. The neurons were then assessed for neuronal viability by the Alamar blue assay and for neuronal morphological changes by Sholl analysis.

3.1.1.1 NA CM increases neuronal viability

A Student’s t-test demonstrated that CM from NA-treated cultures (NA CM) significantly increased neuronal viability when compared with control CM (p=0.0097, t=2.893, d.f.=18), while NA had no direct effect on neuronal viability (p=0.0775, t=1.968, d.f.=10). [Figure 3.1].

![Figure 3.1: NA CM, but not a directly applied NA, increases neuronal viability](image-url)

Primary cortical neurons were treated for 24h with either NA CM from glial cells or directly with NA (10μM for both). The Alamar blue assay was then performed. NA CM significantly increased neuronal viability as compared to control CM. Direct NA had no effect on neuronal viability. Data expressed as mean + SEM, n=6-10. **p<0.01 vs. control CM (Student’s t-test).
3.1.1.2 NA CM increases all measures of neuronal complexity of primary cortical neurons

**Primary Neurites**
A one-way ANOVA demonstrated a significant effect of NA CM on the number of primary neurites \( F_{(3,24)}=5.086, p=0.0072 \). Post-hoc analysis revealed that all doses of NA CM increased the number of primary neurites extending from the cell soma as compared to control CM treated neurons (p<0.05 for 1μM and 5μM, p<0.01 for 10μM). [Figure 3.2a, Newman-Keuls, n=7].

**Neuritic Branches**
A one-way ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches \( F_{(3,24)}=6.113, p=0.0031 \). Post-hoc analysis revealed that all doses of NA CM increased the number of neuritic branches compared to control CM treated neurons (p<0.05 for 5μM, p<0.01 for 1μM, 10μM). [Figure 3.2b, Newman-Keuls, n=7].

**Neuritic Length**
A one-way ANOVA demonstrated a significant effect of NA CM on the neuritic length \( F_{(3,24)}=12.82, p<0.0001 \). Post-hoc analysis revealed that all doses of NA CM significantly increased the neuritic length compared to control CM treated neurons (p<0.01). [Figure 3.2c, Newman-Keuls, n=7].
Figure 3.2: NA CM increases all measures of neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with NA CM from glial cells. Sholl analysis was then performed on the neurons. All doses of NA CM significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean ± SEM, n=7. *p<0.05, **p<0.01 vs. control CM (One-way ANOVA followed by post-hoc Newman-Keuls).
3.1.1.3 Representative neurons for primary cortical neurons treated with NA CM

Primary cortical neurons were treated for 24h with NA CM from glial cells. Cells were then stained using fluorescent immunocytochemistry for the neuronal structural protein βIII-tubulin and counter-stained with the cell body marker DAPI. Figure 3.3 shows representative images for neurons treated with control CM (A) and NA CM (B-D).

Figure 3.3: Representative neurons for primary cortical neurons treated with NA CM

Primary cortical neurons treated with NA CM from glial cells were stained using fluorescent immunocytochemistry for the neuronal structural protein βIII-tubulin (white) and the cell body marker DAPI (blue). All neurons were imaged by 200X magnification. Pictures correspond to representative images for (A) control neuron treated with control CM and neurons treated with NA CM at 1μM (B), 5μM (C) and 10μM (D). Scale bars in each diagram are equal to 50μm.
3.1.1.4 NA CM increases the Sholl profile of primary cortical neurons

A two-way repeated measures ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches at specific distances from the neuronal cell soma \[F_{(3,384)}=14.306, \ p<0.0001\]. ANOVA also demonstrated a significant effect of distance \[F_{(16,384)}=362.21, \ p<0.0001\] and a significant distance by treatment interaction \[F_{(48,384)}=1.84, \ p=0.0009\]. Furthermore post-hoc analysis revealed that neurons treated with all doses of NA CM had significantly more branches than neurons treated with control CM at 5, 15 and 25\(\mu\)m (\(p<0.01\)) from the cell soma while neurons treated with 1\(\mu\)M NA also had significantly more branches at 35\(\mu\)m (\(p<0.05\)). [Figure 3.4, Newman-Keuls, \(n=7\)].

![Figure 3.4: NA CM increases the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24 h with NA CM from glial cells. Sholl analysis was then performed on the neurons. NA CM (5\(\mu\)M, 10\(\mu\)M) significantly increased the number of branches at 5, 15 and 25\(\mu\)M from the cell soma while NA CM (1\(\mu\)M) significantly increased the number of branches at 5, 15, 25 and 35\(\mu\)M from the cell soma compared to control CM. Data expressed as means \(\pm\) SEM, \(n=7\). **\(p<0.01\) NA CM 1\(\mu\)M vs. control CM, \#\(p<0.05\), \\#\#\(p<0.01\) NA CM 5\(\mu\)M vs. control CM, ++\(p<0.01\) NA CM 10\(\mu\)M vs. control CM (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.1.2 NA has no effect on neuronal complexity of primary cortical neurons

As primary cortical neurons are known to express the noradrenergic receptors (for review, see Gu, 2002), it was important to establish if a direct treatment of primary cortical neurons with NA can also lead to increases in morphological complexity. Therefore primary neurons were treated for 24h with control NBM or with NA (1μM, 5μM or 10μM) in NBM. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.1.2.1 Direct treatment of primary cortical neurons with NA does not alter neuronal complexity

**Primary Neurites**

A one-way ANOVA showed no significant effect of NA on the number of primary neurites \[F(3,24)=1.386, p=0.2712\]. [Figure 3.5a, \(n=7\)].

**Neuritic Branches**

A one-way ANOVA showed no significant effect of NA on the number of neuritic branches \[F(3,24)=1.675, p=0.1988\]. [Figure 3.5b, \(n=7\)].

**Neuritic Length**

A one-way ANOVA showed no significant effect of NA on the neuritic length \[F(3,24)=2.075, p=0.1302\]. [Figure 3.5c, \(n=7\)].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.5: Direct treatment of primary cortical neurons with NA does not alter neuronal complexity

Primary cortical neurons were treated for 24h with NA. Sholl analysis was then performed on the neurons. NA treatment had no effect on (a) number of primary neurites, (b) number of neuritic branches or (c) the neuritic length of the neurons. Data expressed as mean + SEM, n=7. (One-way ANOVA).
3.1.2.2 NA reduces the Sholl profile of primary cortical neurons

A repeated measures ANOVA demonstrated a significant effect of NA on the number of neuritic branches at specific distances from cell soma \( [F(3,384)=3.34, p=0.036] \). ANOVA also demonstrated a significant effect of distance \( [F(16,384)=217.9, p<0.0001] \) and a significant distance by treatment interaction \( [F(48,384)=1.75, p=0.0023] \). Furthermore, post-hoc analysis revealed that NA (1\( \mu \)M) treated neurons had significantly less branches than control treated neurons at 15 (\( p<0.05 \)), 25 and 35\( \mu \)m (\( p<0.01 \)) from the cell soma while NA (10\( \mu \)M) treated neurons had significantly less branches than control treated neurons at 15, 25, 35 (\( p<0.01 \)) and 45\( \mu \)m (\( p<0.05 \)) from the cell soma. \[Figure 3.6, Newman-Keuls, \( n=7 \)].

![Figure 3.6: Direct treatment of primary cortical neurons with NA alters neuronal complexity](image)

Primary cortical neurons were treated for 24h with noradrenaline. Sholl analysis was then performed on the neurons. NA (1\( \mu \)M) had significantly less branches than control at 15, 25 and 35\( \mu \)m from the cell soma while NA (10\( \mu \)M) had significantly less branches than control at 15, 25, 35 and 45\( \mu \)m from the cell soma.

\( *p<0.05 \), \( **p<0.01 \) NA 1\( \mu \)M vs. control, \( #p<0.05 \), \( ##p<0.01 \) NA 10\( \mu \)M vs. control. Data expressed as means \( \pm \) SEM, \( n=7 \). (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.1.2.3 Representative neurons for primary cortical neurons treated with NA

Primary cortical neurons were treated for 24h with NA. Cells were then stained using fluorescent immunocytochemistry for the neuronal structural protein βIII-tubulin and counter-stained with the cell body marker DAPI. Figure 3.7 shows representative images for neurons treated with control (A) and NA (B).

![Figure 3.7: Representative images of primary cortical neurons treated with NA](image)

Primary cortical neurons treated with NA were stained using fluorescent immunocytochemistry for the neuronal structural protein βIII-tubulin (white) and the cell body marker DAPI (blue). All neurons were imaged by 200X magnification. Pictures correspond to representative images for (A) control neuron (B) NA (10µM). Scale bars in each diagram are equal to 50µm.
3.1.3 5-HT CM has no effect on the morphology of primary cortical neurons

As 5-HT has been shown to influence the expression of neurotrophic factors in glial cells, it was of interest to determine if 5-HT could impact upon the morphology of primary cortical neurons. Confluent primary mixed glial cells were treated with control NBM or serotonin (1μM, 5μM or 10μM) in NBM. The cells were treated for 24h after which time the CM was collected, filtered and then used to treat 4 DIV primary cortical neurons for 24h. The neurons were then stained using fluorescent immunocytochemistry for βIII tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.1.3.1 5-HT CM has no effect on measures of neuronal complexity of primary cortical neurons

**Primary Neurites**

A one-way ANOVA demonstrated no effect of 5-HT CM on the number of primary neurites \([F(3,24)=1.653, p=0.2037]\). (Figure 3.8a, \(n=7\)).

**Neuritic Branches**

A one-way ANOVA demonstrated no effect of 5-HT CM on the number of neuritic branches \([F(3,24)=2.275, p=0.1056]\). (Figure 3.8b, \(n=7\)).

**Neuritic Length**

A one-way ANOVA demonstrated no effect of 5-HT CM on the neuritic length \([F(3,24)=1.425, p=0.26]\). (Figure 3.8c, \(n=7\)).
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.8: 5-HT CM has no effect on measures of neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with 5-HT CM from glial cells. Sholl analysis was then performed on the neurons. 5-HT CM had no effect on (a) number of primary neurites (b) number of neuritic branches or the (c) neuritic length. Data expressed as means ± SEM, n=7. (One-way ANOVA).
3.1.3.2 5-HT CM increases the Sholl profile of primary cortical neurons

A repeated measures ANOVA demonstrated no significant effect of 5-HT CM on the number of neuritic branches at specific distances from cell soma \([F(3,384)=2.62, p=0.074]\). ANOVA demonstrated a significant effect of distance \([F(16,384)=246.24, p<0.0001]\) with no significant distance by treatment interaction \([F(48,384)=0.82, p=0.798]\). Post-hoc analysis revealed that 5-HT CM (1μM) treated neurons had significantly more branches than control CM treated neurons at 25 (p<0.05) and 35μm (p<0.01) while 5-HT (5μM) CM treated neurons had significantly more branches than control CM treated neurons at 25, 35 and 45μm (p<0.05) and 5-HT (10μM) CM treated neurons had significantly more branches than control CM treated neurons at 5, 35 (p<0.05) and 15μm (p<0.01) from the cell soma. [Figure 3.9, Newman-Keuls, n=7].

![Figure 3.9: 5-HT CM increases the Sholl profile of primary cortical neurons.](image)

Primary cortical neurons were treated for 24h with 5-HT CM from glial cells. Sholl analysis was then performed on the neurons. 5-HT CM (1μM) had significantly more branches than control at 25 and 35μm, while 5-HT CM (5μM) had significantly more branches than control at 25, 35 and 45μm, and 5-HT CM (10μM) had significantly more branches than control at 5, 15 and 35μm from the cell soma. *p<0.05, **p<0.01 5-HT CM (1μM) vs. control CM, #p<0.05, 5-HT CM (5μM) vs. control CM. $p<0.05, $$p<0.01 5-HT CM (10μM) vs. control CM. Data expressed as means ± SEM, n=7. (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.1.4 5-HT has no effect on neuronal complexity of primary cortical neurons

Although serotonin CM had no effect on neuronal morphology, it was still important to assess any effect a direct treatment of 5-HT might have on neuronal morphology as neurons express the 5-HT receptors (for review, see Gu, 2002). Therefore neurons were treated for 24h with control NBM or with 5-HT (1µM, 5µM or 10µM) in NBM. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.1.4.1 5-HT has no effect on neuronal complexity of primary cortical neurons

**Primary Neurites**

A one-way ANOVA demonstrated no effect of 5-HT on the number of primary neurites \[F(3,20)=1.006, p=0.4109\]. [Figure 3.10a, n=6].

**Neuritic Branches**

A one-way ANOVA demonstrated no effect of 5-HT on the number of neuritic branches \[F(3,20)=1.218, p=0.3289\]. [Figure 3.10 b, n=6].

**Neuritic Length**

A one-way ANOVA demonstrated no effect of 5-HT on the neuritic length \[F(3,20)=0.318, p=0.7676\]. [Figure 3.10c, n=6].
(a) Primary Neurites

![Bar graph showing the number of primary neurites for different concentrations of 5-HT.]

(b) Neuritic Branches

![Bar graph showing the number of neuritic branches for different concentrations of 5-HT.]

(c) Neuritic Length

![Bar graph showing the neuritic length for different concentrations of 5-HT.]

Figure 3.10: 5-HT has no effect on neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with 5-HT. Sholl analysis was then performed on the neurons. 5-HT treatment had no effect on (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM, n=6. (One-way ANOVA).
3.1.4.2 5-HT increases the Sholl profile of primary cortical neurons

A repeated measures ANOVA demonstrated no effect of 5-HT on the number of neuritic branches at specific distances from cell soma \( F(3,320)=2.57, p=0.0822 \). ANOVA demonstrated a significant effect of distance \( F(16,320)=216.64, p<0.0001 \) and a significant distance by treatment interaction \( F(48,320)=1.618, p=0.0086 \). Post-hoc analysis revealed that 5-HT (5\( \mu \)M) had significantly more branches than control at 15, 25 (\( p<0.01 \)) and 35\( \mu \)m (\( p<0.05 \)) from the cell soma. [Figure 3.11, Newman-Keuls, \( n=6 \)].

![Figure 3.11: 5-HT increases the Sholl profile of primary cortical neurons.](image)

Primary cortical neurons were treated for 24h with 5-HT. Sholl analysis was then performed on the neurons. 5-HT (5\( \mu \)M only) treated neurons had significantly more branches than control at 15, 25 and 35\( \mu \)m from the cell soma. Data expressed as means ± SEM, \( n=6 \). **\( p<0.01 \), *\( p<0.05 \) 5-HT (5\( \mu \)M) vs. control (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls.)
3.1.5 Amitriptyline CM increases some measures of neuronal morphology

Amitriptyline (AMI), a tricyclic antidepressant, functions as both a serotonin and noradrenaline reuptake inhibitor (Iversen, 2006). Therefore, the ability of AMI to enhance neuronal complexity via actions on glial cells was assessed. Confluent primary mixed glial cells were treated with control NBM or AMI (1μM, 5μM or 25μM) in NBM. The cells were treated for 24h after which time the CM was collected, filtered and then used to treat 4 DIV primary cortical neurons for 24h. The neurons were then stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.1.5.1 AMI CM increases the number of primary neurites and neuritic length but not branch number of primary cortical neurons

Primary Neurites

A one-way ANOVA demonstrated a significant effect of AMI CM on the number of primary neurites \(F(3,28)=7.356, p=0.0009\). Post-hoc analysis revealed that AMI CM (5μM) increased the number of primary neurites extending from the cell soma as compared to control CM treated neurons \((p<0.01)\). [Figure 3.12a, Newman-Keuls, \(n=8\)].

Neuritic Branches

A one-way ANOVA demonstrated a significant effect of AMI CM on the number of neuritic branches \(F(3,28)=3.363, p=0.0326\). Post-hoc analysis revealed no significant effect of AMI CM on the number of neuritic branches. [Figure 3.12b, Newman-Keuls, \(n=8\)].

Neuritic Length

A one-way ANOVA demonstrated a significant effect of AMI CM on the neuritic length \(F(3,28)=4.976, p=0.0068\). Post-hoc analysis revealed that AMI CM (5μM) significantly increases the neuritic length compared to control CM treated neurons \((p<0.01)\). [Figure 3.12c, Newman-Keuls, \(n=8\)].
Chapter 3: Results

(a) Primary Neurites

![Bar chart showing the number of primary neurites for different AMI CM (μM) concentrations.](image1)

(b) Neuritic Branches

![Bar chart showing the number of neuritic branches for different AMI CM (μM) concentrations.](image2)

(c) Neuritic Length

![Bar chart showing the neuritic length for different AMI CM (μM) concentrations.](image3)

Figure 3.12: AMI CM increases the number of primary neurites and neuritic length but not branch number of primary cortical neurons

Primary cortical neurons were treated for 24h with the AMI CM from glial cells. Sholl analysis was then performed on the neurons. AMI CM (5μM) significantly increased (a) number of primary neurites and (c) neuritic length but not (b) number of neuritic branches. Data expressed as mean + SEM, n=8. **p<0.01 vs. control CM (One-way ANOVA followed by post-hoc Newman-Keuls).
3.1.5.2 AMI CM increases the Sholl profile of primary cortical neurons

A repeated measures ANOVA demonstrated a significant effect of AMI CM on the number of neuritic branches at specific distances from cell soma \( F(3,448)=8.606, p=0.003 \). ANOVA also demonstrated a significant effect of distance \( F(16,448)=246.79, p<0.0001 \) and a significant distance by treatment interaction \( F(48,448)=1.614, p=0.0076 \). Furthermore post-hoc analysis revealed that AMI CM (5\( \mu \)M) had significantly more branches than control at 5, 15 and 25\( \mu \)m from the cell soma while AMI CM (25\( \mu \)M) had significantly less branches than control at 25\( \mu \)m from the cell soma. [Figure 3.13, Newman-Keuls, \( n=8 \)].

Figure 3.13: AMI CM increases the Sholl profile of primary cortical neurons.

Primary cortical neurons were treated for 24h with AMI CM from glial cells. Sholl analysis was then performed on the neurons. AMI CM (5\( \mu \)M) significantly increased the number of branches at 5, 15 and 25\( \mu \)m from the cell soma while AMI CM (25\( \mu \)M) significantly reduced the number of branches at 25\( \mu \)m from the cell soma compared to control CM. Data expressed as means ± SEM, \( n=8 \). **\( p<0.01 \) AMI CM 5\( \mu \)M vs. control CM, \#\( p<0.05 \) AMI CM 25\( \mu \)M vs. control CM (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.1.6 Direct Amitriptyline treatment increases neuronal complexity

As AMI CM was shown to induce some morphological changes within the primary cortical neurons it was then important to assess if a direct treatment of primary cortical neurons with AMI could also induce morphological changes in the neurons or whether the glial cells were vital for this ability. Therefore primary neurons were treated for 24h with control NBM or with AMI (1\mu M, 5\mu M or 25\mu M) in NBM. As before, the neurons were stained using fluorescent immunocytochemistry for \beta III-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.1.6.1 Direct AMI increases all measures of neuronal complexity of primary cortical neurons

**Primary Neurites**

A one-way ANOVA demonstrated a significant effect of AMI on the number of primary neurites \([F(3,20)=5.774, p=0.0052]\). Post-hoc analysis revealed that AMI (1\mu M, p<0.05) and (5\mu M, p<0.01) significantly increased the number of primary neurites extending from the cell soma as compared to control treated neurons. [Figure 3.14a, Newman Keuls, \(n=6\)].

**Neuritic Branches**

A one-way ANOVA demonstrated a significant effect of AMI on the number of neuritic branches \([F(3,20)=6.838, p=0.0024]\). Post-hoc analysis revealed that AMI (1\mu M) increased the number of neuritic branches compared to control neurons (p<0.01). [Figure 3.14b, Newman Keuls, \(n=6\)].

**Neuritic Length**

A one-way ANOVA demonstrated a significant effect of AMI on the neuritic length \([F(3,20)=3.181, p=0.0463]\). Post-hoc analysis revealed that AMI (1\mu M) increased the neuritic length compared to control treated neurons (p<0.05). [Figure 3.14c, Fishers LSD, \(n=6\)]
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.14: Direct AMI increases all measures of neuronal complexity of primary cortical neurons
Primary cortical neurons were treated for 24h with AMI. Sholl analysis was then performed on the neurons. AMI significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM, n=6. *p<0.05, **p<0.01 vs. control (One-way ANOVA followed by post-hoc Newman Keuls [a and b] Fishers LSD [c]).
3.1.6.2 Direct AMI increases the Sholl profile of primary cortical neurons

A repeated measures ANOVA demonstrated a significant effect of AMI on the number of neuritic branches at specific distances from cell soma \([F(3,320)=7.214, p=0.0018]\). ANOVA also demonstrated a significant effect of distance \([F(16,320)=256.26, p<0.0001]\) and a significant distance by treatment interaction \([F(48,320)=2.11, p<0.0001]\). Furthermore post-hoc analysis revealed that AMI (1\(\mu\)M) treated neurons had significantly more branches than control treated neurons at 5, 35 (\(p<0.05\)), 15 and 25\(\mu\)m (\(p<0.01\)) from the cell soma while AMI (5\(\mu\)M) treated neurons had significantly more branches at 5, 15, 25 and 35\(\mu\)m from the cell soma. AMI (25\(\mu\)M) treated neurons were not significantly different to control treated neurons. [Figure 3.15, Newman-Keuls, \(n=6\)].

![Figure 3.15: Direct AMI increases the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24h with AMI. Sholl analysis was then performed on the neurons. AMI (1\(\mu\)M and 5\(\mu\)M) treated neurons had significantly more branches at 5, 15, 25 and 35\(\mu\)m from the cell soma compared to control treated neurons. Data expressed as means ± SEM, \(n=6\), \#\(p<0.05\), ##\(p<0.01\) AMI (1\(\mu\)M) vs. control, \**p<0.01\) AMI (5\(\mu\)M) vs. control. (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.2 Examination of the glial adrenoceptor subtype involved in noradrenaline mediated neuronal morphology changes

As NA elicited the most profound effect on neuronal morphology the remainder of the studies in this thesis are focused on the mechanisms and mediators that underlie the ability of CM from NA-treated glial cells to enhance neuronal morphology. NA can bind to either α- or β-adrenoceptor subtypes, both of which are present on glial cells (for review, see Kimelberg, 1995). Literature suggests that the neuroprotective properties of adrenergic stimulation are mediated mainly via the β-adrenoceptor subtype (Semkova et al., 1996). Therefore, it was important to determine which glial adrenoceptor subtype was mediating the noradrenaline-induced effects on neuronal morphology in an attempt to understand the underlying mechanisms.

Therefore the aims of these studies were as follows:

1) To examine the ability of antagonism of the glial α- and β-adrenoceptors to attenuate NA CM-induced increases in complexity of primary cortical neurons.
2) To examine the ability of the non-selective β-adrenoceptor agonist, salbutamol, to induce morphological changes in neurons via an action on glial cells.
3) To examine the abilities of the specific β₁-adrenoceptor agonist; xamoterol, and the specific β₂-adrenoceptor agonists; clenbuterol and salmeterol, to induce morphological changes in neurons via an action on glial cells.
4) To examine the ability of the cell permeable cAMP analogue; dbcAMP, to induce morphological changes in neurons via an action on glial cells.
3.2.1 NA CM-induced increases in neuronal morphology are primarily attributed to the \( \beta \)-adrenoceptor

Propranolol (Prop, \( \beta \)-adrenoceptor antagonist) and phentolamine (Phent, \( \alpha \)-adrenoceptor antagonist) were utilised in this study to block the ability of NA to bind to the \( \beta \) and \( \alpha \) adrenoceptors respectively. Glial cells were pre-treated for 30min with Prop (10\( \mu \)M), Phent (10\( \mu \)M) or control followed by stimulation with NA (10\( \mu \)M) for 24h. This CM was then used to treat neurons for 24h, followed by Sholl analysis as before.

3.2.1.1 Antagonism of the \( \beta \)-adrenoceptor blocks all NA CM-induced increases in neuronal complexity while antagonism of the \( \alpha \)-adrenoceptor attenuates NA CM-induced increases in neuritic length

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the number of primary neurites \([F(1,42)=18.45, p=0.0001]\). There was also a significant effect of antagonist treatment \([F(2,42)=5.37, p=0.0084]\) but no significant interaction \([F(2,42)=1.51, p=0.2325]\). Post-hoc analysis revealed that NA CM had significantly more primary neurites compared to control CM (p<0.01) and that Prop in combination with NA CM had significantly less primary neurites compared to NA CM alone (p<0.05). Phent had no effect on NA CM-induced increases in the number of primary neurites [Figure 3.16a, Newman Keuls \( n=8 \)].

**Neuritic Branching**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the number of neuritic branches \([F(1,42)=28.83, p<0.0001]\). There was also a significant effect of antagonist treatment \([F(2,42)=3.93, p=0.0273]\) and a significant NA by antagonist interaction \([F(2,42)=3.61, p=0.036]\). Post-hoc analysis revealed that NA CM treatment significantly increased the number of neuritic branches compared to control CM treated neurons (p<0.01) and that Prop with NA CM had significantly less neuritic branches compared to NA CM alone (p<0.01). Phent had no effect on NA CM-induced increases in the number of neuritic branches. [Figure 3.16b, Newman Keuls, \( n=8 \)].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the neuritic length \([F(1,42)=23.56, p<0.0001]\). There was also a significant effect of antagonist treatment \([F(2,42)=4.93, p=0.0119]\) and a significant NA by antagonist interaction \([F(2,42)=6.92, p=0.0025]\). Post-hoc analysis revealed that NA CM treatment significantly increased the neuritic length compared to control treated neurons (p<0.01), while both Prop and Phent with NA CM had significantly reduced neuritic length compared to NA CM alone (p<0.01). [Figure 3.16c, Newman Keuls \( n=8 \)].
Chapter 3: Results

(a) Primary Neurites

![Graph showing the number of primary neurites for Control, Prop, and Phent conditions.]

(b) Neuritic Branches

![Graph showing the number of neuritic branches for Control, Prop, and Phent conditions.]

(c) Neuritic Length

![Graph showing the neuritic length in micrometers (µm) for Control, Prop, and Phent conditions.]

Figure 3.16: Antagonism of the β-adrenoceptor blocks all NA CM-induced increases in neuronal complexity while antagonism of the α-adrenoceptor attenuates NA CM-induced increases in neuritic length.

Primary cortical neurons were treated for 24h with the CM from glial cells pre-treated for 30 min with Prop (10µM) or Phent (10µM) followed by NA (10µM) stimulation for 24h. Sholl analysis was then performed. Prop significantly reduced the NA CM-induced increases in (a) number of primary neurites, (b) number of neuritic branches and (c) neuritic length. While Phent significantly reduced the NA CM-induced increases in (c) neuritic length. Data expressed as mean ± SEM, n=8. **p<0.01 vs. control CM, #p<0.05, ##p<0.01 vs. NA CM alone. (Two-way ANOVA followed by post-hoc Newman-Keuls).
3.2.1.2 Antagonism of the β-adrenoceptor blocks all NA CM-induced increases in the Sholl profile of primary cortical neurons

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM [$F(1,224)=30.09, p<0.0001$] on the number of neuritic branches at specific distances from the cell soma. ANOVA also demonstrated a significant effect of Prop [$F(1,224)=30.11, p<0.0001$] and of distance [$F(16,224)=239.07, p<0.0001$]. Significant interactions were also found between NA CM and distance [$F(16,224)=8.5, p<0.0001$], Prop and distance [$F(16,224)=4.07, p<0.0001$], and between NA CM and Prop [$F(1,224)=14.76, p=0.0018$]. Furthermore post-hoc analysis revealed that NA CM treated neurons had significantly more branches than control CM treated neurons at 5, 15, 25, 34 and 45µm ($p<0.01$) from the cell soma. Prop with NA CM treated neurons had significantly less branches than NA CM treated neurons alone at 5, 15, 25, 35 ($p<0.01$) and 45µm ($p<0.05$) from the cell soma. [Figure 3.17, Newman-Keuls, $n=8$].

Figure 3.17: Antagonism of the β-adrenoceptor blocks all NA CM-induced increases in the Sholl profile of primary cortical neurons

Primary cortical neurons were treated for 24h with the CM from glial cells pre-treated for 30 min with Prop (10µM) followed by NA (10µM) stimulation for 24h. Sholl analysis was then performed. NA CM treated neurons had significantly more branches than control CM treated neurons at 5, 15, 25, 34 and 45µm from the cell soma. Prop with NA CM treated neurons had significantly less branches than NA CM treated neurons alone at 5, 15, 25, 35 and 45µm from the cell soma. Data expressed as means ± SEM, $n=8$. **$p<0.01$ NA CM vs. control CM, #p<0.05, ##p<0.01 NA CM + Prop vs. NA CM. (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.2.1.3 Antagonism of the α-adrenoceptor does not attenuate the NA CM-induced increases in the Sholl profile of primary cortical neurons

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM \( F(1,224)=58.45, \ p<0.0001 \) but no significant effect of Phent on the number of neuritic branches at specific distances from the cell soma. ANOVA also demonstrated a significant effect of distance \( F(16,224)=357.38, \ p<0.0001 \) and a significant distance by NA CM treatment interaction \( F(16,224)=7.26, \ p<0.0001 \). Furthermore post-hoc analysis revealed that NA CM treated neurons had significantly more branches than control at 5, 15, 25, 35 (\( p<0.01 \)) and 45\( \mu \text{m} \) (\( p<0.05 \)) from the cell soma. Phent treated neurons alone had significantly more branches than control CM treated neurons at 25\( \mu \text{m} \) from the cell soma (\( p<0.05 \)). Importantly, there were no significant differences between NA CM in combination with Phent with NA CM treated neurons alone. [Figure 3.18, Newman-Keuls, \( n=8 \)].

![Figure 3.18: Antagonism of the α-adrenoceptor does not attenuate NA CM-induced increases in the Sholl profile of cortical neurons](image)

Primary cortical neurons were treated for 24h with the CM from glial cells pre-treated with Phent (10\( \mu \text{M} \)) followed by NA (10\( \mu \text{M} \)) stimulation for 24h. Sholl analysis was then performed. NA CM treated neurons had significantly more branches than control CM treated neurons at 5, 15, 25, 34 and 45\( \mu \text{m} \) from the cell soma. Phent alone treated neurons had significantly more branches than control CM treated neurons at 25\( \mu \text{m} \) from the cell soma. There were no significant differences between NA CM alone and Phent with NA CM treated neurons. Data expressed as means ± SEM, \( n=8 \). **\( p<0.01 \) NA CM vs. control CM, +\( p<0.05 \) Phent vs. control CM (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.2.2 Salbutamol CM increases measures of neuronal morphology

Noradrenaline can signal via two main β-adrenoceptors, the β₁-adrenoceptor and the β₂-adrenoceptor (Rang & Dale, 2003). To assess the ability of activation of the glial β-adrenoceptors in enhancing neuronal complexity, the non-selective β-adrenoceptor agonist, Salbutamol (Salb), was utilised. As before, confluent primary mixed glial cells were treated with control NBM or Salb (5μM or 10μM) in NBM. The cells were treated for 24h after which time the CM was collected, filtered and then used to treat 4 DIV primary cortical neurons for 24h. The neurons were then stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.2.2.1 Salb CM increases all measures of neuronal complexity of primary cortical neurons

**Primary Neurites**

A one-way ANOVA demonstrated a significant effect of Salb CM on the number of primary neurites \( [F(2,15)=4.534, p=0.0288] \). Post-hoc analysis revealed that both doses of Salb CM increased the number of primary neurites extending from the cell soma as compared to control CM treated neurons \( (p<0.05) \). [Figure 3.19a, Newman-Keuls, \( n=6 \)].

**Neuritic Branches**

A one-way ANOVA demonstrated a significant effect of Salb CM on the number of neuritic branches \( [F(2,15)=4.594, p=0.0278] \). Post-hoc analysis revealed that both doses of Salb CM increased the number of neuritic branches compared to control CM treated neurons \( (p<0.05) \). [Figure 3.19 b, Newman-Keuls, \( n=6 \)].

**Neuritic Length**

A one-way ANOVA demonstrated a significant effect of Salb CM on the neuritic length \( [F(2,15)=7.367, p=0.0059] \). Post-hoc analysis revealed that both doses of Salb CM significantly increased the neuritic length compared to control CM treated neurons \( (p<0.01 \) for 5μM and \( p<0.05 \) for 10μM). [Figure 3.19c, Newman-Keuls, \( n=6 \)].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.19: Salb CM increases all measures of neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with Salb CM (5, 10μM) from glial cell. Sholl analysis was then performed on the neurons. Salb CM significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM, n=6. *p<0.05, **p<0.01 vs. control CM. (One-way ANOVA followed by post-hoc Newman-Keuls).
3.2.2.2 *Salb CM increases the Sholl profile of primary cortical neurons*

A repeated measures two-way ANOVA demonstrated a significant effect of Salb CM on the number of neuritic branches at specific distances from cell soma \(F(2,240)=7.187, p=0.0065\). ANOVA also demonstrated a significant effect of distance \(F(16,240)=182.99\), but no significant distance by treatment interaction \(F(32,240)=1.41, p=0.0755\). Furthermore *post-hoc* analysis revealed that both doses of Salb CM treated neurons had significantly more branches than control CM treated neurons at 5, 15, 25 and 35μm (\(p<0.01\)) from the cell soma while Salb CM (5μM) treated neurons in addition had significantly more branches at 45 and 55μm (\(p<0.01\)). [Figure 3.20, Newman-Keuls, \(n=6\)].

![Figure 3.20: Salb CM increases the Sholl profile of primary cortical neurons](image_url)

Primary cortical neurons were treated for 24h with Salb CM (5, 10μM) from glial cells. Sholl analysis was then performed on the neurons. Salb CM (5μM) treated neurons significantly increased the number of branches at 5, 15, 25, 35, 45 and 55μm from the cell soma while Salb CM (10μM) treated neurons had significantly more branches at 5, 15, 25 and 35μm from the cell soma compared to control CM. Data expressed as means ± SEM, \(n=6\). **\(p<0.01\) Salb CM (5μM) vs. control CM, ###\(p<0.01\) Salb CM (10μM) vs. control CM (Two-way repeated measures ANOVA followed by *post-hoc* Newman-Keuls).
Chapter 3: Results

3.2.3 The $\beta$2-adrenoceptor agonists, salmeterol and clenbuterol, but not the $\beta$1-adrenoceptor agonist, xamoterol, increases measures of neuronal morphology

Salmeterol is considered both a $\beta_1$ and $\beta_2$-adrenoceptor agonist; therefore it was important to further dissociate the ability of the $\beta$-adrenoceptors to induce morphological changes in the neurons. Therefore, the highly selective $\beta_2$-adrenoceptor agonists salmeterol (Salm; 1µM) and clenbuterol (Clen; 1µM), and the highly selective $\beta_1$-adrenoceptor agonist, xamoterol (Xam; 1µM) were utilised to treat primary mixed glial cells and thus the CM on primary neuronal cells. Sholl analysis was performed as before.

3.2.3.1 Salm CM and Clen CM but not Xam CM increase all measures of neuronal complexity of primary cortical neurons

Primary Neurites

A one-way ANOVA demonstrated a significant effect of treatment on the number of primary neurites $[F(3,21)=6.664, p=0.0025]$. Post-hoc analysis revealed that Salm CM ($p<0.05$) and Clen CM ($p<0.01$) increased the number of primary neurites extending from the cell soma as compared to control CM treated neurons. Xam CM had no effect on the number of primary neurites. [Figure 3.21a, Newman-Keuls, $n=5-7$].

Neuritic Branches

A one-way ANOVA demonstrated a significant effect of treatment on the number of neuritic branches $[F(3,21)=6.271, p=0.0033]$. Post-hoc analysis revealed that Salm CM ($p<0.01$) and Clen CM ($p<0.05$) increased the number of neuritic branches compared to control CM treated neurons. Xam CM had no effect on the number of neuritic branches. [Figure 3.21b, Newman-Keuls, $n=5-7$].

Neuritic Length

A one-way ANOVA demonstrated a significant effect of treatment on the neuritic length $[F(3,20)=9.867, p=0.0003]$. Post-hoc analysis revealed that Salm CM ($p<0.01$) and Clen CM ($p<0.01$) increased the neuritic length compared to control CM treated neurons. Xam CM had no effect on the neuritic length. [Figure 3.21c, Newman-Keuls, $n=5-7$].

99
Figure 3.21: Salm CM and Clen CM but not Xam CM increase all measures of neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with the CM from glial cells treated with Salm (1μM), Clen (1μM) or Xam (1μM) for 24h. Sholl analysis was then performed on the neurons. Both Salm CM and Clen CM treated neurons significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Xam CM treatment of neurons had no effect on any parameter. Data expressed as mean ± SEM, n=5-7. *p<0.05, **p<0.01 vs. control CM (One-way ANOVA followed by post-hoc Newman-Keuls).
3.2.3.2 Salm CM and Clen CM but not Xam CM increases the Sholl profile of primary cortical neurons

A repeated measures two-way ANOVA demonstrated a significant effect of treatment on the number of neuritic branches at specific distances from cell soma \( [F(3,336)=10.96, p=0.0002] \). ANOVA also demonstrated a significant effect of distance \( [F(16,336)=157.53, p<0.0001] \) and a significant distance by treatment interaction \( [F(48, 336)=2.748, p<0.0001] \). Furthermore post-hoc analysis revealed that Clen CM had significantly more branches at 5, 15, 25 and 35μm from the cell soma than control CM treated neurons while Salm CM treated neurons had significantly more branches at 5, 15, 25, 35 and 45μm from the cell soma. [Figure 3.22, Newman-Keuls, \( n=5-7 \)].

![Figure 3.22: Salm CM and Clen CM but not Xam CM increases the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24h with the CM from glial cells treated with Salm (1μM), Clen (1μM) or Xam (1μM) for 24h. Sholl analysis was then performed on the neurons. Clen CM had significantly more branches at 5, 15, 25 and 35μm from the cell soma than control CM treated neurons while Salm CM treated neurons had significantly more branches at 5, 15, 25, 35 and 45μm from the cell soma. Data expressed as means ± SEM, \( n=5-7 \), **\( p<0.01 \) Salm CM vs. control CM, ***\( p<0.01 \) Clen CM vs. control CM (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.2.4 The cAMP analogue, dbcAMP, CM increases neuronal complexity

Stimulation of the β2-adrenoceptor activates adenylate cyclase resulting in the subsequent production of cAMP (for review, see Johnson, 2001). To assess if an increase in the intracellular concentration of cAMP in glial cells is sufficient for the CM to enhance primary neuronal complexity, the cell-permeable cAMP analogue dbcAMP was utilised. Primary glial cells were treated with dbcAMP (300μM) for 24h after which time the CM was collected and used to treat neurons. Sholl analysis was performed as before.

3.2.4.1 DbcAMP CM increases all measures of neuronal complexity of primary cortical neurons

Primary Neurites
A Student’s t-test demonstrated a significant effect of dbcAMP CM on the number of primary neurites compared to control CM treated neurons \([t=3.367, \text{d.f.}=9, p=0.0083]\). (Figure 3.23a).

Neuritic Branching
A Student’s t-test demonstrated a significant effect of dbcAMP CM on the number of neuritic branches compared to control CM treated neurons \([t=2.727, \text{d.f.}=9, p=0.0023]\). (Figure 3.23b).

Neuritic Length
A Student’s t-test demonstrated a significant effect of dbcAMP CM on the neuritic length compared to control CM treated neurons \([t=2.481, \text{d.f.}=9, p=0.0348]\). (Figure 3.23c).
(a) **Primary Neurites**

![Graph showing the number of primary neurites for control and dbcAMP treated neurons. The graph shows that dbcAMP significantly increased the number of primary neurites compared to control.]

(b) **Neuritic Branches**

![Graph showing the number of neuritic branches for control and dbcAMP treated neurons. The graph shows that dbcAMP significantly increased the number of neuritic branches compared to control.]

(c) **Neuritic Length**

![Graph showing the neuritic length for control CM and dbcAMP CM treated neurons. The graph shows that dbcAMP CM significantly increased neuritic length compared to control CM.]

**Figure 3.23: DbcAMP CM increases all measures of neuronal complexity of primary cortical neurons**

Primary cortical neurons were treated for 24h with dbcAMP CM (300µM) from glial cells. Sholl analysis was then performed on the neurons. DbcAMP CM significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length compared to control CM treated neurons Data expressed as mean + SEM, n=5-6. *p<0.05, **p<0.01 vs. control CM (Student's t-test).
3.2.4.2 DbcAMP CM increases the Sholl profile of primary cortical neurons

A repeated measures two-way ANOVA demonstrated a significant effect of dbcAMP CM on the number of neuritic branches at specific distances from cell soma \( F(1,144)=18.16, p=0.0021 \). ANOVA also demonstrated a significant effect of distance \( F(16,144)=73.51, p<0.0001 \) and a significant distance by treatment interaction \( F(16,144)=3.45, p<0.0001 \). Furthermore post-hoc analysis revealed that dbcAMP CM had significantly more branches than control at 5, 15, 25, 35, 45\( \mu \)m (\( p<0.01 \)) and 55\( \mu \)m (\( p<0.05 \)) from the cell soma. [Figure 3.24, Newman-Keuls, \( n=5-6 \)].

![Figure 3.24: DbcAMP CM increases the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24h with dbcAMP CM (300\( \mu \)M) from glial cells. Sholl analysis was then performed on the neurons. DbcAMP CM significantly increased the number of branches at 5, 15, 25, 35, 45 and 55\( \mu \)m from the cell soma compared to control CM treated neurons. Data expressed as means ± SEM, \( n=5-6 \). **\( p<0.01 \), *\( p<0.05 \) vs. control CM (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.2.4.3 Representative images for primary cortical neurons treated with dbcAMP CM

Primary cortical neurons were treated for 24h with dbcAMP CM from glial cells. Cells were then stained using fluorescent immunocytochemistry for the neuronal structural protein βIII-tubulin and counter-stained with the cell body marker DAPI. Images (figure 3.25) show representative images for the dbcAMP CM experiment.

Figure 3.25: Representative images for primary cortical neurons treated with dbcAMP CM

Fluorescent immunocytochemistry with the neuronal structural protein βIII-tubulin (white) and the cell body marker DAPI (blue) was carried out on primary cortical neurons treated with the CM from dbcAMP (300μM) treated mixed glial cells. All neurons were imaged by 200X magnification. Pictures correspond to representative images for (A) control neuron treated with control CM and neurons treated with dbcAMP CM (B), Scale bar is equal to 50μm.
3.3 NA stimulation of astrocytic β-adrenoceptors are responsible for the NA CM-induced increases in neuronal complexity

Primary mixed glial preparations are primarily composed of astrocytes (80-90%) and microglia (10-20%). As both cell types have been shown to express the β2-adrenoceptor (Kimelberg, 1995; Mori et al., 2002), it was important to assess the roles of each cell type in enhancing neuronal complexity via the β2-adrenoceptor.

The aims of these studies were as follows:

1) To assess the ability of NA CM from cultures enriched in astrocytes and cultures enriched in microglia to induce morphological changes in primary cortical neurons.

2) To assess the ability of Salb CM and dbcAMP CM from enriched astrocytes to induce morphological changes in primary cortical neurons.
3.3.1 **NA CM from enriched astrocytes increases neuronal complexity**

Primary mixed glial cells were prepared as before. When cells reached confluency, the microglia were removed as described in the methods. Confluent astrocytes were then treated with control NBM or NA (10μM) in NBM. The cells were treated for 24h after which time the CM was collected, filtered and then used to treat 4 DIV primary cortical neurons for 24h. The neurons were then stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to examine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite. In addition, cultures were stained using fluorescent immunocytochemistry for GFAP, to assess for astrocytic purity [figure 3.26].

3.3.1.2 **NA CM from enriched astrocytes increases all measures of neuronal complexity of primary cortical neurons**

**Primary Neurites**

A Student’s t-test demonstrated a significant effect of NA CM on the number of primary neurites compared to control CM (t=3.979, d.f.=14, p=0.0014). [Figure 3.27a].

**Neuritic Branching**

A Student’s t-test demonstrated a significant effect of NA CM on the number of neuritic branches compared to control CM (t=3.711, d.f.=14, p=0.0023). [Figure 3.27b].

**Neuritic Length**

A Student’s t-test demonstrated a significant effect of NA CM on the neuritic length compared to control CM (t=7.841, d.f.=14, p<0.0001). [Figure 3.27c].
3.3.1.1 Representative images for enriched astrocyte culture

Primary enriched astrocytes were prepared as described in the methods. Cells were then stained using fluorescent immunocytochemistry for the astrocytic marker GFAP, the microglial marker CD11b and counter-stained with the cell body marker DAPI. No positive staining for CD11b was seen. Figure 3.26 shows representative images for enriched astrocytes.

Figure 3.26: Representative images for enriched astrocyte culture

Primary enriched astrocytes were stained using fluorescent immunocytochemistry for the astrocytic marker GFAP (A, green) and counter-stained with DAPI (B, blue). Merged image C. Scale bar is equal to 50μm.
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.27: NA CM from enriched astrocytes increases all measures of neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with NA (10μM) CM from astrocytes. Sholl analysis was then performed on the neurons. NA CM significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length compared to control CM treated neurons. Data are expressed as mean ± SEM, n=8, **p<0.01 vs. control CM (Student’s t-test).
3.3.1.3 **NA CM from enriched astrocytes increases the Sholl profile of primary cortical neurons**

A two-way repeated measures ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches at specific distances from cell soma \([F(1,224)=25.988, p=0.0002]\). ANOVA also demonstrated a significant effect of distance \([F(16,224)=200.339, p<0.0001]\) and a significant distance by treatment interaction \([F(48, 224)=3.455, p<0.0001]\). Furthermore, *post-hoc* analysis revealed that NA CM had significantly more branches than control CM treated neurons at 5, 15, 25\(\mu\)m (\(p<0.01\)) and 35\(\mu\)m (\(p<0.05\)) from the cell soma. [Figure 3.28, Newman-Keuls, \(n=8\)].

*Figure 3.28: NA CM from enriched astrocytes increases the Sholl profile of primary cortical neurons*

Primary cortical neurons were treated for 24h with NA (10\(\mu\)M) CM from astrocytes. Sholl analysis was then performed on the neurons. NA CM significantly increased the number of branches at 5, 15, 25\(\mu\)m and 35\(\mu\)m from the cell soma compared to control CM treated neurons. Data expressed as means ± SEM, \(n=8\), **\(p<0.01\), *\(p<0.05\) vs. control CM (Two-way repeated measures ANOVA followed by *post-hoc* Newman-Keuls).
3.3.4 NA CM from enriched microglia does not increase neuronal morphology

The previous section demonstrated that NA CM from enriched astrocytes enhanced the complexity of primary cortical neurons similarly to NA CM from a mixed glial culture. It was then important to establish if the microglia in a mixed glial culture are also involved in the enhancement of neuritic growth by NA CM. Therefore, purified primary microglia were prepared as described in the methods. Purified microglia were then treated with control or NA (10μM) in NBM. The cells were treated for 24h after which time the CM was collected, filtered and then used to treat 4 DIV primary cortical neurons for 24h. The neurons were then stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to examine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.3.4.1 NA CM from enriched microglia had no effect on the number of neuritic branches or neuritic length and reduced the number of primary neurites of primary cortical neurons

**Primary Neurites**

A Student’s t-test demonstrated a significant effect of NA CM on (A) number of primary neurites (t=3.088, d.f.=14, p=0.0081). [Figure 3.29a].

**Neuritic Branching**

A Student’s t-test demonstrated no significant effect of NA CM (B) number of neuritic branches (t=0.5246, d.f.=14, p=0.608). [Figure 3.29b].

**Neuritic Length**

A Student’s t-test demonstrated no significant effect of NA CM neuritic length (t=0.004408, d.f.=14, p=9965). [Figure 3.29c].
Chapter 3: Results

(a) Primary Neurites

\[
\begin{align*}
\text{Control CM} & \quad 4 \\
\text{NA CM} & \quad **
\end{align*}
\]

(b) Neuritic Branches

\[
\begin{align*}
\text{Control CM} & \quad 4 \\
\text{NA CM} & \quad 2
\end{align*}
\]

(c) Neuritic Length

\[
\begin{align*}
\text{Control CM} & \quad 150 \\
\text{NA CM} & \quad 100
\end{align*}
\]

Figure 3.29: NA CM from enriched microglia had no effect on the number of neuritic branches or neuritic length and reduced the number of primary neurites of primary cortical neurons.

Primary cortical neurons were treated for 24h with the NA CM (10μM) from microglia. Sholl analysis was then performed on the neurons. NA CM significantly reduced the number of primary neurites and had no effect on the number of neuritic branches or the neuritic length. Data are expressed as mean ± SEM, n=8 (Student’s t-test).
3.3.4.2 NA CM from enriched microglia significantly reduced the Sholl profile of primary cortical neurons

A two-way repeated measures ANOVA demonstrated no significant effect of NA [F(1, 224) = 2.5148, p = 0.1351] but a significant effect of distance [F(16, 224) = 195.7, p < 0.0001]. There was no significant interaction between the two. Furthermore, post-hoc analysis revealed that NA CM had significantly less branches than control CM at 5 and 15μm (p < 0.01) from the cell soma. [Figure 3.30, Newman-Keuls, n = 8].

![Graph](image)

Figure 3.30: NA CM from enriched microglia significantly reduced the Sholl profile of primary cortical neurons

Primary cortical neurons were treated for 24h with NA CM (10μM) from enriched microglia. Sholl analysis was then performed on the neurons. NA CM significantly reduced the number of neuritic branches at 5 and 15μm from the cell soma compared to control. Data are expressed as mean ± SEM, n = 8 (Two-way repeated measures ANOVA followed by post-hoc Newman Keuls).
3.3.2 *Salbutamol CM from enriched astrocytes increases neuronal complexity*

Primary enriched astrocytes were prepared as described in the methods. Confluent astrocytes were then treated with control or Salb (10μM) in NBM. The cells were treated for 24h after which time the CM was collected, filtered and then used to treat 4 DIV primary cortical neurons for 24h. The neurons were then stained using fluorescent immunocytochemistry for βIII tubulin and after image acquisition, were analysed by Sholl analysis specifically to examine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.3.2.1 *Salb CM from enriched astrocytes increases the neuritic branching and neuritic length but not primary neurites of primary cortical neurons*

**Primary Neurites**

A Student’s t-test demonstrated no significant effect of Salb CM on the number of primary neurites compared to control CM (t=1.45, d.f.=14, p=0.1692). [Figure 3.31a].

**Neuritic Branching**

A Student’s t-test demonstrated a significant effect of Salb CM on the number of neuritic branches compared to control CM (t=2.388, d.f.=14, p=0.0316). [Figure 3.31b].

**Neuritic Length**

A Student’s t-test demonstrated a significant effect of Salb CM on the neuritic length compared to control CM (t=3.712, d.f.=14, p=0.0023). [Figure 3.31c].
Primary cortical neurons were treated for 24h with Salb (10μM) CM from astrocytes. Sholl analysis was then performed on the neurons. Salb CM significantly increased (b) number of neuritic branches and (c) neuritic length, but not (a) number of primary neurites. Data are expressed as mean + SEM, n=8, **p<0.01, *p<0.05 vs. control CM (Student’s t-test).
3.3.2.2 *Salb CM from enriched astrocytes increases the Sholl profile of primary cortical neurons*

A two-way repeated measures ANOVA demonstrated a significant effect of Salb (10μM) CM on the number of neuritic branches at specific points from the cell soma \( F(3,224)=12.195, \ p=0.0036 \). ANOVA also showed that distance was significant \( F(16,224)=99.58, \ p<0.0001 \) but no significant distance by treatment interaction \( F(16,224)=1.215, \ p=0.2571 \). Furthermore *post-hoc* analysis revealed that Salb CM had significantly more branches than control CM treated neurons at 5 (p<0.05), 15, 25, 35 and 45μm (p<0.01) from the cell soma. [Figure 3.32, Newman-Keuls, n=8].

![Figure 3.32: Salb CM from enriched astrocytes increases the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24h with Salb (10μM) CM from enriched astrocytes. Sholl analysis was then performed on the neurons. Salb CM had significantly more branches than control CM treated neurons at 5, 15, 25, 35 and 45μm from the cell soma. Data are expressed as mean ± SEM, n=8, *p<0.05, **p<0.01 vs. control CM (Two way repeated measures ANOVA followed by *post-hoc* Newman-Keuls).
3.3.3 *DbcAMP CM from enriched astrocytes increases neuronal complexity*

Primary astrocytes were prepared as described in the methods. Confluent astrocytes were then treated with control or dbcAMP (300μM) in NBM. The cells were treated for 24h after which time the CM was collected, filtered and then used to treat 4 DIV primary cortical neurons for 24h. The neurons were then stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to examine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.3.3.1 *DbcAMP CM from enriched astrocytes increases all measures of neuronal complexity of primary cortical neurons*

**Primary Neurites**

A Student’s *t*-test demonstrated a significant effect of dbcAMP CM on the number of primary neurites (*t*=4.511, d.f.=14, *p*=0.0005). [Figure 3.33a].

**Neuritic Branching**

A Student’s *t*-test demonstrated a significant effect of dbcAMP CM on the number of neuritic branches (*t*=3.853, d.f.=14, *p*=0.0018). [Figure 3.33b].

**Neuritic Length**

A Student’s *t*-test demonstrated a significant effect of dbcAMP CM on the neuritic length (*t*=6.009, d.f.=14, *p*<0.0001). [Figure 3.33c].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.33: DbcAMP CM from enriched astrocytes increases all measures of neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with dbcAMP (300μM) CM from enriched astrocytes. Sholl analysis was then performed on the neurons. DbcAMP CM significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length compared to control CM treated neurons. Data expressed as mean + SEM, n=8. **p<0.01 vs. control CM (Student’s t-test).
3.3.2.2 *DbcAMP CM from enriched astrocytes increases the Sholl profile of primary cortical neurons*

A two-way repeated measures ANOVA demonstrated a significant effect of dbcAMP (300\(\mu\)M) on the number of neuritic branches at specific points from the cell soma \([F(1,224)=41.958, \ p<0.0001]\). ANOVA also demonstrated a significant effect of distance \([F(16,224)=148.566, \ p<0.0001]\) and a significant distance by treatment interaction \([F(16,224)=5.44, \ p<0.0001]\). Furthermore, *post-hoc* analysis revealed that dbcAMP CM had significantly more branches than control CM treated neurons at 5, 15, 25, 35 (\(p<0.01\)) and 45\(\mu\)m (\(p<0.05\)) from the cell soma. [Figure 3.34, Newman-Keuls, \(n=8\)].

![Figure 3.34: DbcAMP CM from enriched astrocytes increases the Sholl profile of primary cortical neurons](image)

*Figure 3.34: DbcAMP CM from enriched astrocytes increases the Sholl profile of primary cortical neurons*

Primary cortical neurons were treated for 24h withdbcAMP (300\(\mu\)M) CM from enriched astrocytes. Sholl analysis was then performed on the neurons. DbcAMP CM had significantly more branches than control at 5, 15, 25, 35 and 45\(\mu\)m from the cell soma compared to control CM treated neurons. Data are expressed as mean \(\pm\) SEM, \(n=8\), *\(p<0.05\), **\(p<0.01\) vs. control CM (Two-way repeated measures ANOVA followed by *post-hoc* Newman-Keuls).
3.4 C6 glioma cells as a model of primary astrocytes

The previous section demonstrated that astrocytes in primary mixed glial culture are responsible for the ability of NA to induce morphological changes in primary cortical neurons. Therefore use of the C6 glioma cell line was examined as an alternative to primary astrocytes for studying the impact of β₂-adrenoceptor activation on neuronal morphology.

The aims of these studies were as follows:

1) To assess the expression of the astrocytic markers S100β and GFAP in the C6 glioma cell line.
2) To assess the expression of the β₂-adrenoceptor in C6 glioma cells.
3) To assess the ability of NA CM from C6 glioma cells to induce morphological changes in primary cortical neurons.
3.4.1 C6 glioma cells express the astrocytic markers S100β and GFAP

C6 glioma cells were fixed in methanol and stained using fluorescent immunocytochemistry for S100β, GFAP and the nuclear marker DAPI. C6 glioma cells were shown to strongly express both S100β and GFAP [Figure 3.35].

![Figure 3.35: C6 glioma cells expression of S100β and GFAP](image)

C6 glioma cells were stained using fluorescent immunocytochemistry with S100β (A, C), GFAP (D, F) and DAPI (B, C, E, F). C6 cells were shown to express the astrocytic marker S100β. (A) S100β, red (B) DAPI, blue and (C) co-localisation of S100β and DAPI in C6 cells. Scale bar is equal to 50 μm.

Figure 3.35: C6 glioma cells expression of S100β and GFAP

C6 glioma cells were stained using fluorescent immunocytochemistry with S100β (A, C), GFAP (D, F) and DAPI (B, C, E, F). C6 cells were shown to express the astrocytic marker S100β. (A) S100β, red (B) DAPI, blue and (C) co-localisation of S100β and DAPI in C6 cells. Scale bar is equal to 50 μm.
3.4.2 The C6 glioma cells express the β2-adrenoceptor

As the C6 cells were to be used to measure NA-induced morphological changes in neurons via the β2-adrenoceptor, it was imperative to examine if they express the β2-adrenoceptor. Therefore, C6 cells were grown in serum-free DMEM for 48h. Following this, the cells were harvested and prepared for Western blotting as described in the methods. Western immunoblot visualisation clearly shows the expression of the β2-adrenoceptor in all C6 glioma cell line samples at the 55kDa mark. β-actin was also clearly expressed at 43kDa. [Figure 3.36].

![Western blot analysis of C6 glioma cell lysates showing expression of β2-adrenoceptor and β-actin](image)

**Figure 3.36: C6 glioma cells express the β2-adrenoceptor**

Western blot analysis of C6 glioma cell lysates show that the β2 adrenoceptor was expressed by the cells. β-actin was also expressed. \((n=4)\).
3.4.3 *NA CM from C6 glioma cells shows no effect on neuronal morphology*

As with the primary astrocytes, the C6 cells were treated with NA (1, 10μM) for 24h. Following this, the CM was removed, filtered and used to treat primary cortical neurons for 24h. The neurons were then stained and assessed for changes in neuronal morphology by Sholl analysis.

**Primary Neurites**

A one-way ANOVA demonstrated no significant effect of NA treatment on the number of primary neurites extending from the cell soma \( F(2,13)=1.019, p=0.388 \). [Figure 3.37a, \( n=5-6 \)].

**Neuritic Branches**

A one-way ANOVA demonstrated no significant effect of NA treatment on the number of neuritic branches \( F(2,13)=0.469, p=0.636 \). [Figure 3.37b, \( n=5-6 \)].

**Neuritic Length**

A one-way ANOVA demonstrated no significant effect of NA treatment on the neuritic length \( F(2,13)=0.95, p=0.4117 \). [Figure 3.37c, \( n=5-6 \)].
Figure 3.37: NA CM from C6 cells had no effect on neuronal morphology

Primary cortical neurons were treated for 24h with the CM from C6 cells treated with NA (1, 10μM) for 24h. Sholl analysis was then performed on the neurons. NA CM had no effect of (a) Primary neurites, (b) neuritic branches or (c) neuritic length compared to control CM treated neurons. Data are expressed as mean + SEM, n=5-6. (One-way ANOVA).
3.5 A role for glial-derived growth factors in mediating the effects of NA CM on neuronal morphology

As the previous sections have described, NA treatment of primary glial cells via an action on the astrocytic β2-adrenoceptor, results in the release of soluble factors which induces morphological changes in primary cortical neurons. It was therefore important to examine potential mediators which might be resulting in these changes, to assess if the mediators could directly stimulate neuronal growth, and to see if neutralisation of these mediators could prevent NA CM-induced morphological changes.

The aims of these studies were as follows:

1) To examine the expression of a range of neuronal growth factors in glial cells following treatment with NA and the β-adrenoceptor agonist, salbutamol.
2) To examine the ability of a direct treatment of the selected growth factors to mimic the morphological changes induced by β-adrenoceptor activation.
3) To assess if neutralization of these growth factors in the NA CM could attenuate NA CM-induced increases in neuronal morphology.
3.5.1 NA and Salb treatment of glial cells induce the expression of growth factors

Examination of any changes in mRNA levels of a particular protein is a rapid method of assessing the potential of a particular stimulus to increase the production of a protein (Guo et al., 2008). Therefore, primary mixed glial cells were treated for 6h with NA or Salb and then harvested for mRNA expression as described in the methods.

3.5.1.1 NA treatment of glial cells leads to the increase in mRNA expression of several growth factors

A Student’s $t$-test demonstrated a significant increase in the expression of GDNF ($t=5.263$, $p=0.0004$, d.f.=10), NGF-$\beta$ ($t=4.518$, $p=0.0011$, d.f.=10), BDNF ($t=4.897$, $p=0.0006$, d.f.=10), FGF-2 ($t=6.534$, $p<0.0001$), VEGF ($t=8.68$, $p<0.0001$, d.f.=10) and IL-6 ($t=5.258$, $p=0.0005$, d.f.=9) and a significant decrease in expression of NT3 ($t=3.73$, $p=0.0039$, d.f.=10) and IGF-1 ($t=2.564$, $p=0.0282$, d.f.=10) in NA treated glial cells. No significant effect of NA treatment was found in NT4/5 ($t=0.7674$, $p=0.4606$, d.f.=10), TGF-$\beta$1 ($t=0.2518$, $p=0.8063$, d.f.=10), CNTF ($t=2.031$, $p=0.0768$, d.f.=8) or IL-10 ($t=1.898$, $p=0.0869$, d.f.=10). [Figure 3.38, $n=5$-6].
Figure 3.38: NA treatment of glial cells leads to the increase in mRNA expression of several growth factors

Glial cells were treated for 6h with noradrenaline and then harvested for mRNA expression. NA increased the expression of GDNF, NGF-β, BDNF (a) and FGF-2, VEGF and IL-6 (b). NA significantly reduced mRNA expression of NT3 (a) and IGF-1 (b). NT4/5, TGF-β1, CNTF and IL-10 remained unchanged. Data expressed as means ± SEM, n=5-6, *p<0.05 vs. control, **p<0.01 vs. control (Student’s t-test).
3.5.1.2 Salb treatment of glial cells leads to the increase in mRNA expression of several growth factors

A Student’s t-test demonstrated a significant increase in the expression of GDNF (t=8.865, p<0.0001, d.f.=10), NGF-β (t=7.624, p<0.0001, d.f.=10), BDNF (t=5.809, p=0.0003, d.f.=10) FGF-2 (t=4.171, p=0.0019), VEGF (t=10.28, p<0.0001, d.f.=10) and IL-6 (t=4.799, p=0.001, d.f.=9) and a significant decrease in the expression of IGF-1 (t=2.37, p=0.0392, d.f.=10) in Salb treated glial cells. No significant effect of Salb treatment was found in NT3 (t=1.553, p=0.1514, d.f.=10), NT4/5 (t=0.0624, p=0.9515, d.f.=10), TGF-β1 (t=2.195, p=0.0529, d.f.=10), CNTF (t=1.732, p=0.1215, d.f.=8) or IL-10 (t=1.193, p=0.2605, d.f.=10). [Figure 3.39, n=5-6].
Figure 3.39: Salb treatment of glial cells leads to the increase in mRNA expression of several growth factors
Glial cells were treated for 6h with Salbutamol and then harvested for mRNA expression by qPCR. Salb increased the expression of GDNF, NGF-β, BDNF (a) and FGF-2, VEGF and IL-6 (b). Salb significantly reduced mRNA expression of IGF-1 (b). NT3, NT4/5, TGF-β1, CNTF and IL-10 remained unchanged. Data expressed as means ± SEM (n=5-6). *p<0.05 vs. control, **p<0.01 vs. control (Student’s t-test).
3.5.2 NA increases the release of growth factors from glial cells

In the previous sections, the growth factors GDNF, FGF-2, IL-6, NGF-β and BDNF were all shown to have increased mRNA expression following NA stimulation of primary mixed glial cells, it was therefore vital to ascertain whether NA stimulation of glial cells could induce the production of these factors for release into the CM. Therefore, glial cells were treated with NA (10μM) for 24h, after which time the CM was collected and analysed by ELISA for GDNF, NGF-β, IL-6, FGF-2, VEGF and BDNF.

3.5.2 NA stimulation enhances release of GDNF, FGF-2 and IL-6 from glial cells

A Student’s t-test demonstrated a significant effect of NA on GDNF \( p=0.0065, t=3.422, \) d.f.=10\], FGF-2 \( p=0.0048, t=3.448, \) d.f.=12\]. IL-6 was not detected in control cultures, but clearly increased upon NA stimulation. There was no significant effect of NGF-β release \( p=0.1947, t=1.374, \) d.f.=12\] or VEGF release \( p=0.0893, t=1.848, \) d.f.=12\], while BDNF was undetected in both control and NA CM. [Figure 3.40].

![Figure 3.40: NA stimulation enhances release of GDNF, FGF-2 and IL-6 from glial cells](image)

Glial cells were treated for 24h with NA (10μM), after which time the CM was analysed for protein release by ELISA. NA significantly increased the release of GDNF, IL-6 and FGF-2 from glial cells. There was no effect of NA on NGF-β or VEGF, and BDNF was undetected in the samples. Data expressed as means + SEM, \( n=6-7 \). **p<0.01 vs. own control. ND=not detected. (Student's t-test).
Chapter 3: Results

3.5.3 GDNF increases neuronal complexity of primary cortical neurons

GDNF mRNA expression was significantly increased by both NA and Salb treatment of primary mixed glial cells. Therefore, the ability of GDNF to induce morphological changes in primary cortical neurons was assessed. Primary cortical neurons were treated with GDNF (1, 5, 10ng/ml) for 24h. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.5.3.1 GDNF increases all measures of neuronal complexity of primary cortical neurons

Primary Neurites

A one-way ANOVA demonstrated a significant effect of GDNF treatment on the number of primary neurites [F(3,28)=3.048, p=0.045]. Post-hoc analysis revealed that GDNF 5ng/ml, (p<0.01) and 10ng/ml (p<0.05) treatment significantly increased the number of primary neurites extending from the cell soma as compared to control treated neurons. [Figure 3.41a, Fishers LSD, n=8].

Neuritic Branches

A one-way ANOVA demonstrated a significant effect of GDNF treatment on the number of neuritic branches [F(3,28)=3.96, p=0.018]. Post-hoc analysis revealed that all doses of GDNF treatment significantly increased the number of neuritic branches compared to control treated neurons (p<0.05). [Figure 3.41b, Newman-Keuls, n=8].

Neuritic Length

A one-way ANOVA demonstrated a significant effect of GDNF treatment on the neuritic length [F(3,28)=11.41, p<0.0001]. Post-hoc analysis revealed that all doses of GDNF treatment significantly increased the neuritic length compared to control treated neurons (p<0.01). [Figure 3.41c, Newman-Keuls, n=8].
(a) Primary Neurites

Figure 3.41: GDNF increases all measures of neuronal complexity of primary cortical neurons
Primary cortical neurons were treated for 24h GDNF (1ng/ml, 5ng/ml, 10ng/ml). Sholl analysis was then performed on the neurons. GDNF significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM (n=8). *p<0.05, **p<0.01 vs. control (One-way ANOVA followed by post-hoc Newman-Keuls [b and c] or Fishers LSD [a]).
3.5.3.2 GDNF increases the Sholl profile of primary cortical neurons

A repeated measures two-way ANOVA demonstrated a significant effect of GDNF on the number of neuritic branches at specific distances from cell soma \( [F(3,448)=6.57, p=0.0017] \). ANOVA also demonstrated a significant effect of distance \( [F(16,448)=245.77, p<0.0001] \) but no significant distance by treatment interaction. Furthermore, post-hoc analysis revealed that all doses of GDNF had significantly more branches (p<0.05 for 1ng/ml, p<0.01 for 5ng/ml and 10ng/ml) at 5, 15 and 25μm from the cell soma. In addition, GDNF (1ng/ml) had significantly more (p<0.01) branches at 35μm from the cell soma compared to control treated neurons. [Figure 3.42, Newman-Keuls, n=8].

Figure 3.42: GDNF increases the Sholl profile of primary cortical neurons

Primary cortical neurons were treated for 24h with GDNF. Sholl analysis was then performed on the neurons. All doses of GDNF had significantly more branches at 5, 15 and 25μm from the cell soma. In addition, GDNF (1ng/ml) had significantly more branches at 35μm from the cell soma compared to control treated neurons. **p<0.01 GDNF 5ng/ml and 10ng/ml vs. control, #p<0.05 GDNF 1ng/ml vs. control, ##p<0.01 GDNF 1ng/ml vs. control. Data expressed as means ± SEM, n=8 (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.5.4 NGF-β increases neuronal complexity of primary cortical neurons

NGF-β mRNA expression was significantly increased by both NA and Salb treatment of primary mixed glial cells. Therefore, the ability of NGF-β to induce morphological changes in primary cortical neurons was assessed. Primary cortical neurons were treated with NGF-β (1, 5, 10ng/ml) for 24h. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.5.4.1 NGF-β increases all measures of neuronal complexity of primary cortical neurons

** Primary Neurites

A one-way ANOVA demonstrated a significant effect of NGF-β treatment on the number of primary neurites \(F(3,27)=3.85, p=0.0205\). *Post-hoc* analysis revealed that all doses of NGF-β treatment increased the number of primary neurites extending from the cell soma as compared to control treated neurons (p<0.05). [Figure 3.43a, Newman-Keuls, \(n=7-8\)].

** Neuritic Branching

A one-way ANOVA demonstrated a significant effect of NGF-β treatment on the number of neuritic branches \(F(3,27)=5.907, p=0.0026\). *Post-hoc* analysis revealed that all doses of NGF-β treatment increased the number of neuritic branches compared to control treated neurons (p<0.05). [Figure 3.43b, Newman-Keuls, \(n=7-8\)].

** Neuritic Length

A one-way ANOVA demonstrated a significant effect of NGF-β treatment on the neuritic length \(F(3,27)=5.052, p=0.0066\). *Post-hoc* analysis revealed that all doses of NGF-β treatment significantly increased the neuritic length compared to control treated neurons (p<0.05). [Figure 3.43c, Newman-Keuls, \(n=7-8\)].
Chapter 3: Results

(a) **Primary Neurites**

(b) **Neuritic Branches**

(c) **Neuritic Length**

Figure 3.43: NGF-β increases the complexity of primary cortical neurons

Primary cortical neurons were treated for 24h NGF-β (1ng/ml, 5ng/ml, 10ng/ml). Sholl analysis was then performed on the neurons. NGF-β significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM (n=7-8). *p<0.05 vs. control (One-way ANOVA followed by post-hoc Newman-Keuls).
3.5.4.2 NGF-β increases the Sholl profile of primary cortical neurons

A repeated measures two-way ANOVA demonstrated a significant effect of NGF-β on the number of neuritic branches at specific distances from cell soma \(F_{(3,432)}=11.33, p<0.0001\). ANOVA also demonstrated a significant effect of distance \(F_{(16,432)}=286.79, p<0.0001\] and a significant distance by treatment interaction \(F_{(48, 432)}=4.75, p<0.0001\]. Furthermore post-hoc analysis revealed that all doses of NGF-β had significantly more branches than control at 5, 15, 25, 35 and 45μm \((p<0.01)\) from the cell soma while NGF-β \((10\text{ng/ml})\) in addition had significantly more branches at 55μm \((p<0.05)\) from the cell soma. [Figure 3.44, Newman-Keuls, \(n=7-8\)].

![Figure 3.44: NGF-β treatment of neurons leads to an increase in Sholl profile complexity](image)

Primary cortical neurons were treated for 24h with NGF-β. Sholl analysis was then performed on the neurons. All doses of NGF-β had significantly more branches at 5, 15, 25, 35 and 45μm from the cell soma while NGF-β \((10\text{ng/ml})\) had significantly more branches in addition at 55μm from the cell soma. Data expressed as means ± SEM, \(n=7-8\). \#p<0.05 NGF-β \((1\text{ng/ml})\) vs. control, \***p<0.01 NGF-β \((5\text{ng/ml})\) vs. control, \$p<0.05 NGF-β \((10\text{ng/ml})\) vs. control. (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
Chapter 3: Results

3.5.5 *BDNF increases neuronal complexity of primary cortical neurons*

BDNF mRNA expression was significantly increased by both NA and Salb treatment of primary mixed glial cells. Therefore, the ability of BDNF to induce morphological changes in primary cortical neurons was assessed. Primary cortical neurons were treated with BDNF (1, 5, 10ng/ml) for 24h. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.5.5.1 *BDNF increases all measures of neuronal complexity of primary cortical neurons*

**Primary Neurites**

A one-way ANOVA demonstrated a significant effect of BDNF treatment on the number of primary neurites \[F(3,20)=12.93, p<0.0001\]. *Post-hoc* analysis revealed that all doses of IL-6 treatment (p<0.05 for 1ng/ml, p<0.01 for 5 and 10ng/ml) increased the number of neuritic branches compared to control treated neurons. [Figure 3.45a, Newman-Keuls, \(n=6\)].

**Neuritic Branching**

A one-way ANOVA demonstrated a significant effect of BDNF treatment on the number of neuritic branches \[F(3,20)=3.53, p=0.0335\]. *Post-hoc* analysis revealed that IL-6 (5ng/ml) treatment significantly increased the number of neuritic branches compared to control treated neurons (p<0.05). [Figure 3.45b, Newman-Keuls, \(n=6\)].

**Neuritic Length**

A one-way ANOVA demonstrated a significant effect of BDNF treatment on the neuritic length \[F(3,20)=8.86, p=0.0006\]. *Post-hoc* analysis revealed that all doses of IL-6 treatment significantly increased the neuritic length compared to control treated neurons (p<0.01). [Figure 3.45c, Newman-Keuls, \(n=6\)].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.45: BDNF increases all measures of neuronal complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with BDNF (1ng/ml, 5ng/ml, 10ng/ml). Sholl analysis was then performed on the neurons. BDNF significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM, n=6. **p<0.01, *p<0.05 vs. control (One-way ANOVA followed by post-hoc Newman-Keuls).
3.5.5.2 BDNF increases the Sholl profile of primary cortical neurons

A repeated measures two-way ANOVA demonstrated a significant effect of BDNF on the number of neuritic branches at specific distances from cell soma \([F(3,320)=8.826, p=0.0006]\). ANOVA also demonstrated a significant effect of distance \([F(16,320)=434.289, p<0.0001]\) and a significant distance by treatment interaction \([F(48,320)=3.928, p<0.0001]\). Furthermore post-hoc analysis revealed that all doses of BDNF had significantly more branches than control at 5, 15 and 25µm \((p<0.01)\) from the cell soma while BDNF (1ng/ml and 5ng/ml) in addition had significantly more branches at 35µm \((p<0.01)\) and 45µm \((p<0.05)\) from the cell soma. [Figure 3.46, Newman-Keuls, \(n=6\)].

![Figure 3.46: BDNF treatment of neurons leads to an increase in Sholl profile complexity](image)

Primary cortical neurons were treated for 24h with BDNF. Sholl analysis was then performed on the neurons. All doses of BDNF had significantly more branches at 5, 15 and 25µm, from the cell soma while BDNF (1ng/ml and 5ng/ml) also had significantly more branches at 35µm and 45µm from the cell soma. Data expressed as means ± SEM \((n=6)\), *\(p<0.05\), **\(p<0.01\) BDNF 1ng/ml and 5ng/ml vs. control, ##\(p<0.01\) BDNF 10ng/ml vs. control (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.5.6 FGF-2 increases neuronal complexity of primary cortical neurons

FGF-2 mRNA expression was significantly increased by both NA and Salb treatment of primary mixed glial cells. Therefore, the ability of FGF-2 to induce morphological changes in primary cortical neurons was assessed. Primary cortical neurons were treated with FGF-2 (1, 5, 10ng/ml) for 24h. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.5.6.1 FGF-2 increases all measures of neuronal complexity of primary cortical neurons

**Primary Neurites**

A one-way ANOVA demonstrated a significant effect of FGF-2 treatment on the number of primary neurites \( F(3,20) = 9.395, p = 0.0004 \). Post-hoc analysis revealed that all doses of FGF-2 treatment increased the number of neuritic branches compared to control treated neurons \( p<0.01 \). [Figure 3.47a, Newman-Keuls \( n=6 \)].

**Neuritic Branching**

A one-way ANOVA demonstrated a significant effect of FGF-2 treatment on the number of neuritic branches \( F(3,20) = 4.369, p = 0.0161 \). Post-hoc analysis revealed that all doses of FGF-2 treatment significantly increased the number of neuritic branches compared to control treated neurons \( p<0.05 \). [Figure 3.47b, Newman-Keuls, \( n=6 \)].

**Neuritic Length**

A one-way ANOVA demonstrated a significant effect of FGF-2 treatment on the neuritic length \( F(3,20) = 4.318, p = 0.0168 \). Post-hoc analysis revealed that all doses of FGF-2 treatment significantly increased the neuritic length compared to control treated neurons \( p<0.05 \). [Figure 3.47c, Newman-Keuls, \( n=6 \)].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.47: Direct treatment of neurons with FGF-2 increases the complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with FGF-2 (1ng/ml, 5ng/ml, 10ng/ml). Sholl analysis was then performed on the neurons. FGF-2 significantly increased (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM (n=6). **p<0.01, *p<0.05 vs. control (One-way ANOVA followed by post-hoc Newman-Keuls).
3.5.6.2 *FGF-2 increases the Sholl profile of primary cortical neurons*

A repeated measures two-way ANOVA demonstrated a significant effect of FGF-2 on the number of neuritic branches at specific distances from cell soma \([F(3,320)=4.622, p=0.013]\). ANOVA also demonstrated a significant effect of distance \([F(16,320)=322.54, p<0.0001]\) and a significant distance by treatment interaction \([F(48, 320)=3.23, p<0.0001]\). Furthermore, *post-hoc* analysis revealed that all doses of FGF-2 had significantly more branches than control at 5, 15, 25 and 35\(\mu\)m from the cell soma \((p<0.01)\), in addition FGF-2 had significantly more branches than control at 45\(\mu\)m for both 1ng/ml \((p<0.05)\) and 5ng/ml \((p<0.01)\). [Figure 3.48, Newman-Keuls, \(n=6\)].

![Figure 3.48: FGF-2 treatment of neurons show an enhanced Sholl profile](image)

Primary cortical neurons were treated for 24h with FGF-2. Sholl analysis was then performed on the neurons. All doses of FGF-2 had significantly more branches at 5, 15, 25 and 35\(\mu\)m from the cell soma, in addition 1ng/ml and 5ng/ml had significantly more branches than control at 45\(\mu\)m from the cell soma. *\(p<0.05\), **\(p<0.01\) FGF-2 1ng/ml vs. control, ##\(p<0.01\) FGF-2 5ng/ml vs. control, ++\(p<0.01\) FGF-2 10ng/ml vs. control. Data expressed as means ± SEM, \(n=6\) (Two-way repeated measures ANOVA followed by *post-hoc* Newman-Keuls).
3.5.7 VEGF does not increase neuronal complexity of primary cortical neurons

VEGF mRNA expression was significantly increased by both NA and Salb treatment of primary mixed glial cells. Therefore, the ability of VEGF to induce morphological changes in primary cortical neurons was assessed. Primary cortical neurons were treated with VEGF (1, 5, 10ng/ml) for 24h. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition, were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.5.6.1 VEGF has no effect on the neuronal complexity of primary cortical neurons

**Primary Neurites**

A one-way ANOVA demonstrated no significant effect of VEGF treatment on the number of primary neurites \( F(3,20)=2.08, p=0.135 \). [Figure 3.49a, \( n=6 \)].

**Neuritic Branching**

A one-way ANOVA demonstrated no significant effect of VEGF treatment on the number of neuritic branches \( F(3,20)=1.138, p=0.357 \). [Figure 3.49b, \( n=6 \)].

**Neuritic Length**

A one-way ANOVA demonstrated no significant effect of VEGF treatment on the neuritic length \( F(3,20)=1.81, p=0.178 \). [Figure 3.49c, \( n=6 \)].
(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.49: Direct treatment of neurons with VEGF has no effect on the complexity of primary cortical neurons

Primary cortical neurons were treated for 24h with VEGF (1ng/ml, 5ng/ml, 10ng/ml). Sholl analysis was then performed on the neurons. VEGF had no effect on (a) number of primary neurites (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM, n=6 (One-way ANOVA).
3.5.7.2 VEGF increases the Sholl profile of primary cortical neurons

A repeated measures two-way ANOVA demonstrated no significant effect of VEGF on the number of neuritic branches at specific distances from cell soma [F(3,320)=0.905, p=0.4561]. ANOVA demonstrated a significant effect of distance [F(16,320)=215.25, p<0.0001] but no significant distance by treatment interaction. Furthermore, post-hoc analysis revealed that 1ng/ml VEGF had significantly more branches than control at 5μm from the cell soma (p<0.05), 5ng/ml VEGF had significantly more branches than control at 5μm (p<0.05) and 25μm (p<0.01) from the cell soma, while 10ng/ml VEGF had significantly more branches than control at 25μm (p<0.01) and 35μm (p<0.05) from the cell soma. [Figure 3.50, Newman-Keuls, n=6].

![Figure 3.50: VEGF increases the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24h with VEGF. Sholl analysis was then performed on the neurons. 1ng/ml VEGF had significantly more branches than control at 5μm from the cell soma, 5ng/ml VEGF had significantly more branches than control at 5μm and 25μm from the cell soma, while 10ng/ml VEGF had significantly more branches than control at 25μm and 35μm from the cell soma. *p<0.01 VEGF 1ng/ml vs. control, #p<0.05, ##p<0.01 VEGF 5ng/ml vs. control, +p<0.05, ++p<0.01 VEGF 10ng/ml vs. control. Data expressed as means ± SEM, n=6 (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.5.8 IL-6 increases neuronal complexity of primary cortical neurons

IL-6 mRNA expression was significantly increased by both NA and Salb treatment of primary mixed glial cells. Therefore, the ability of IL-6 to induce morphological changes in primary cortical neurons was assessed. Primary cortical neurons were treated with IL-6 (1, 5, 10ng/ml) for 24h. As before, the neurons were stained using fluorescent immunocytochemistry for βIII-tubulin and after image acquisition were analysed by Sholl analysis specifically to determine the number of primary neurites extending from the cell soma, the number of neuritic branches and the length of the longest neurite.

3.5.8.1 IL-6 increases neuritic branching and neuritic length of primary cortical neurons

Primary Neurites

A one-way ANOVA revealed no effect of IL-6 treatment on the number of primary neurites \([F(3,20)=1.019, p=0.405]\). [Figure 3.51a, \(n=6\)].

Neuritic Branching

A one-way ANOVA demonstrated a significant effect of IL-6 treatment on the number of neuritic branches \([F(3,20)=12.28, p<0.0001]\). Post-hoc analysis revealed that all doses of IL-6 treatment increased the number of neuritic branches compared to control treated neurons \((p<0.01)\). [Figure 3.51b, Newman-Keuls, \(n=6\)].

Neuritic Length

A one-way ANOVA demonstrated a significant effect of IL-6 treatment on the neuritic length \([F(3,20)=11.09, p=0.0002]\). Post-hoc analysis revealed that all doses of IL-6 treatment significantly increased the neuritic length compared to control treated neurons \((p<0.01)\). [Figure 3.51c, Newman-Keuls, \(n=6\)].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.51: IL-6 increases neuritic branching and neuritic length of primary cortical neurons
Primary cortical neurons were treated for 24h IL-6 (1ng/ml, 5ng/ml, 10ng/ml). Sholl analysis was then performed on the neurons. IL-6 had no effect on the number of neuritic branches (a) but significantly increased (b) number of neuritic branches and (c) neuritic length. Data expressed as mean ± SEM, n=6. **p<0.01, *p<0.05 vs. control. (One-way ANOVA followed by post-hoc Newman-Keuls).
3.5.8.2 IL-6 increases the Sholl profile of primary cortical neurons

A repeated measures two-way ANOVA demonstrated a significant effect of IL-6 on the number of neuritic branches at specific distances from cell soma \[F(3,320)=8.25, p=0.0009\]. ANOVA also demonstrated a significant effect of distance \[F(16,320)=362.106, p<0.0001\] and a significant distance by treatment interaction \[F(48, 320)=2.72, p<0.0001\]. Furthermore post-hoc analysis revealed that IL-6 (1 and 5ng/ml) had significantly more branches at 15, 25, 35μm (p<0.01) and 45μm (1ng/ml at p<0.05, 5ng/ml at p<0.01) from the cell soma compared to control while IL-6 (10ng/ml) also had significantly more branches at 15, 25, 35 and 45μm (p<0.01) as well as at 95, 105, 115μm (p<0.05) from the cell soma compared to control neurons. [Figure 3.52, Newman-Keuls, n=6].

![Figure 3.52: IL-6 increases the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24h with IL-6. Sholl analysis was then performed on the neurons. All doses of IL-6 had significantly more branches at 15, 25, 35 and 45μm from the cell soma while IL-6 (10ng/ml) also had significantly more branches at 95, 105 and 115μm from the cell soma. Data expressed as means ± SEM (n=6), #p<0.05, ##p<0.01 IL-6 (1ng/ml) vs. control, $$$p<0.01$ IL-6 (5ng/ml) vs. control, *p<0.05, **p<0.01 IL-6 (10ng/ml) vs. control. (Two-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.5.9 Neutralization of GDNF attenuates some NA CM-induced increases in measures of neuronal complexity

As shown previously, GDNF treatment of primary cortical neurons enhanced neuronal complexity. In addition, NA stimulation of glial cells increases GDNF mRNA expression. To assess if GDNF was important for inducing NA CM-induced increases in neuronal complexity, a GDNF neutralizing antibody (nAB, 0.5μg/ml), or normal goat IgG (0.5μg/ml), was added to the CM for 30min. Neurons were then treated with the CM plus nAB or IgG for 24h, Sholl analysis was performed as before.

3.5.9.1 GDNF nAB attenuates NA CM-induced increases in neuritic length but not primary neurites or neuritic branching

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of primary neurites [F(1,28)=9.85, p=0.004] but no significant effect of the GDNF nAB or any significant interaction between the two. *Post-hoc* analysis revealed that NA CM had significantly more primary neurites compared to control CM (p<0.05). GDNF nAB had no effect on the number of primary neurites either alone or in combination with NA CM. [Figure 3.53a, Fishers LSD, n=8].

**Neuritic Branching**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches [F(1,28)=6.79, p=0.0145] but no significant effect of the GDNF nAB or any significant interaction between the two. *Post-hoc* analysis revealed that NA CM had significantly more neuritic branches compared to control CM (p<0.05). GDNF nAB had no effect on the number of neuritic branches either alone or in combination with NA CM. [Figure 3.53b, Fishers LSD, n=8].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM on the neuritic length [F(1,28)=35.63, p<0.0001]. The GDNF nAb did not quite reach significance [F(1,28)=4.156, p=0.051], however there was a significant interaction between the two [F(1,28)=4.32, p=0.0469]. *Post-hoc* analysis revealed that NA CM had significantly longer neurites compared to control CM (p<0.01) while the GDNF nAb in combination with NA CM had significantly shorter neurites compared to NA CM alone (p<0.01). [Figure 3.53c, Newman-Keuls, n=8]
Figure 3.53: GDNF nAB attenuates NA CM-induced increases in neuritic length but not primary neurites or neuritic branching

Primary cortical neurons were treated for 24h with NA CM (10μM) which had been incubated for 30min with the GDNF nAB (0.5μg/ml) or normal goat IgG (0.5μg/ml). Sholl analysis was then performed. NA CM significantly increased (a) primary neurites, (b) number of neuritic branches and (c) neuritic length. The GDNF nAB attenuated NA CM-induced increases in neuritic length (c) but not primary neurites or neuritic branching. Data expressed as means + SEM, n=8. **p<0.01 vs. control CM, ##p<0.01 vs. NA CM alone (Two-way ANOVA followed by post-hoc Newman-Keuls (c) or Fishers LSD (a, b)).
3.5.9.2 **GDNF nAB attenuates some NA CM-induced increases in the Sholl profile of primary cortical neurons**

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM treatment \([F(1,224)=26.89, p=0.0001]\) and distance \([F(16,224)=221.57, p<0.0001]\) but no significant effect of the GDNF nAB on the number of neuritic branches at points from cell the soma. ANOVA also demonstrated a significant treatment by distance interaction \([F(16,224)=5.13, p=0.0001]\). In addition, post-hoc analysis revealed that NA CM had significantly more branches compared to control CM treated neurons at 5\(\mu\)M (\(p<0.05\)), 15, 25 and 35\(\mu\)M (\(p<0.01\)) from the cell soma and GDNF nAB + NA CM treatment had significantly less branches than NA CM alone treated neurons at 15\(\mu\)m (\(p<0.05\)). [Figure 3.54, Newman-Keuls, \(n=8\)].

![Figure 3.54: The GDNF nAB attenuates some NA CM-induced increases in the Sholl profile of primary cortical neurons](image)

Primary cortical neurons were treated for 24h with NA CM (10\(\mu\)M) which had been incubated for 30min with the GDNF nAB (0.5\(\mu\)g/ml) or normal goat IgG (0.5\(\mu\)g/ml). Sholl analysis was then performed. NA CM had significantly more branches than control at 5, 15, 25 and 35\(\mu\)m from the cell soma. In addition, the GDNF nAB in combination with NA CM had significantly less branches than NA CM alone at 15\(\mu\)m from the cell soma. Data expressed as means ± SEM, \(n=8\). *\(p<0.05\), **\(p<0.01\) NA CM vs. Control CM, #\(p<0.05\) GDNF nAB + NA CM vs. NA CM alone. (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.5.10 Inhibition of NGF-β and BDNF signalling blocks NA CM-induced increases in neuronal complexity

As shown previously, NGF-β and BDNF treatment of primary cortical neurons enhanced neuronal complexity. In addition, NA stimulation of glial cells increases both NGF-β and BDNF mRNA expression. To assess if these neurotrophins were important for inducing NA CM-induced increases in neuronal complexity, a neurotrophin antagonist, Y1036 (40μM), was added to the CM for 30min. Y1036 is a small molecule inhibitor which binds both NGF-β ($K_D=3|J\mu M$) and BDNF ($K_D=3.5|J\mu M$) and prevents their binding to either Trk or p75 receptors (Eibl et al., 2010). Neurons were then treated with the CM plus Y1036 for 24h and Sholl analysis was performed as before.

3.5.10.1 The neurotrophin antagonist, Y1036, blocks all NA CM-induced increases in neuronal complexity

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of primary neurites [$F(1,26)=5.83$, $p=0.023$] but no significant effect of Y1036 or any significant NA by Y1036 interaction. Post-hoc analysis revealed that NA CM had significantly more primary neurites compared to control CM ($p<0.05$) and that Y1036 in combination with NA CM had significantly less primary neurites compared to NA CM alone ($p<0.05$). [Figure 3.55a, Newman-Keuls, $n=7-8$].

**Neuritic Branches**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches [$F(1,26)=11.21$, $p=0.0025$], a significant effect of Y1036 [$F(1,26)=6.21$, $p=0.0193$] and a significant NA CM by Y1036 interaction [$F(1,26)=11.08$, $p=0.0026$]. Post-hoc analysis revealed that NA CM had significantly more neuritic branches compared to control CM ($p<0.01$) and that Y1036 in combination with NA CM had significantly less neuritic branches compared to NA CM alone ($p<0.01$). [Figure 3.55b, Newman-Keuls, $n=7-8$].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM on the neuritic length [$F(1,26)=11.88$, $p=0.0019$], a significant effect of Y1036 [$F(1,26)=9.27$, $p=0.0053$] with no significant NA CM by Y1036 interaction. Post-hoc analysis revealed that NA CM had significantly longer neurites compared to control CM ($p<0.05$) while Y1036 in combination with NA CM had significantly shorter neurites compared to NA CM alone ($p<0.01$). [Figure 3.55c, Newman-Keuls, $n=7-8$].
(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.55: The neurotrophin antagonist, Y1036, blocks all NA CM-induced increases in neuronal complexity

Primary cortical neurons were treated for 24h with NA CM (10μM) which had been incubated for 30min with Y1036 (40μM). Sholl analysis was then performed. NA CM significantly increased (a) primary neurites, (b) number of neuritic branches and (c) neuritic length. Y1036 attenuated all NA CM-induced increases in complexity. Data expressed as means + SEM, n=8. *p<0.05, **p<0.01 NA CM vs. control CM, #p<0.05, ##p<0.01 vs. NA CM alone (Two-way ANOVA followed by post-hoc Newman-Keuls).
3.5.10.2 Neurotrophin antagonist, Y1036, blocks the NA CM induces increases in the Sholl profile

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM treatment \([F(1,208)=23.85, p=0.0003]\), Y1036 treatment \([F(1,208)=10.23, p=0.007]\) and distance \([F(16,224)=221.57, p<0.0001]\) with significant interactions between NA CM and Y1036; \([F(1,208)=8.56, p=0.0118]\), NA CM and distance \([F(16,208)=2.43, p=0.0022]\), NA CM with Y1036 and distance \([F(16,208)=3.95, p<0.0001]\). In addition, post-hoc analysis revealed that NA CM had significantly more branches compared to control CM at 5, 15, 25 and 35\(\mu\)m \((p<0.01)\) from the cell soma while Y1036 in combination with NA CM had significantly less branches than NA CM alone at 5, 15, 25 and 35\(\mu\)m from the cell soma \((p<0.01)\). [Figure 3.56, Newman-Keuls, \(n=8\)].

![Figure 3.56: The neurotrophin antagonist, Y1036, blocks the NA CM-induced increases in the Sholl profile](image)

Primary cortical neurons were treated for 24h with NA CM (10\(\mu\)M) which had been incubated for 30min with Y1036 (40\(\mu\)M). Sholl analysis was then performed. NA CM had significantly more branches than control at 5, 15, 25 and 35\(\mu\)m from the cell soma. In addition, Y1036 in combination with NA had significantly less branches than NA CM alone at 5, 15, 25 and 35\(\mu\)m from the cell soma. Data expressed as means ± SEM, \(n=7-8\). **\(p<0.01\) NA vs. control, ##\(p<0.01\) Y1036 + NA CM vs. NA CM alone. (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.5.11 Neutralization of FGF-2 attenuates NA CM-induced increases in neuronal complexity

As shown previously, FGF-2 treatment of primary cortical neurons enhanced neuronal complexity. In addition, NA stimulation of glial cells increases FGF-2 mRNA expression. To assess if FGF-2 was important for inducing NA CM-induced increases in neuronal complexity, an FGF-2 neutralizing antibody (nAB, 2.5μg/ml), or the isotype control; mouse IgG1κ (2.5μg/ml), has added to the CM for 30min. Neurons were then treated with the CM plus nAB or IgG for 24h, Sholl analysis was performed as before.

3.5.11.1 FGF-2 nAB reduces NA CM-induced increases in number of primary neurites and the neuritic length but not the number of branches

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the number of primary neurites \( [F(1,27)=38.6, p<0.0001] \). There was no significant effect of the FGF-2 nAB \( [F(1,27)=2.82, p=0.1043] \) or an interaction between the two \( [F(1,27)=3.77, p=0.063] \). Post-hoc analysis revealed that NA CM had significantly more primary neurites compared to control CM (p<0.01) and that the FGF-2 nAB in combination with NA CM had significantly less primary neurites compared to NA CM alone (p<0.05). [Figure 3.57a, Newman-Keuls, n=7-8].

**Neuritic Branching**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the number of neuritic branches \( [F(1,27)=59.25, p<0.0001] \). There was no significant effect of the FGF-2 nAB \( [F(1,27)=0.416, p=0.524] \) or an interaction between the two \( [F(1,27)=2.42, p=0.13] \). Post-hoc analysis revealed that NA CM treatment significantly increased the number of neuritic branches compared to control CM treated neurons (p<0.01). [Figure 3.57b, Newman-Keuls, n=7-8].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the neuritic length \( [F(1,27)=53.07, p<0.0001] \). There was no significant effect of the FGF-2 nAB \( [F(1,27)=3.92, p=0.058] \). There was a significant interaction between the two \( [F(1,27)=7.52, p=0.0107] \). Post-hoc analysis revealed that NA CM treatment significantly increased the neuritic length compared to control treated neurons (p<0.01), while the FGF-2 nAB in combination with NA CM had significantly reduced neuritic length compared to NA CM alone (p<0.01). [Figure 3.57c, Newman-Keuls, n=7-8].
(a) Primary Neurites

![Graph showing the number of primary neurites for Control CM and NA CM.](image)

(b) Neuritic Branches

![Graph showing the number of neuritic branches for Control CM and NA CM.](image)

(c) Neuritic Length

![Graph showing the neuritic length for Control CM and NA CM.](image)

**Figure 3.57: FGF-2 nAB reduces NA CM-induced increases in number of primary neurites and the neuritic length but not the number of branches**

Primary cortical neurons were treated for 24h with NA CM (10μM) which had been incubated for 30min with mouse IgG1κ (2.5μg/ml) or the FGF-2 nAB (2.5μg/ml) for 30min, and then placed onto neurons. Sholl analysis was then performed. NA CM significantly increased (a) primary neurites, (b) number of neuritic branches and (c) neuritic length. The FGF-2 nAB attenuated NA CM-induced increases in (a) primary neurites and (c) neuritic length but not (b) neuritic branching. Data expressed as means + SEM, n=6. **p<0.01 vs. control CM, #p<0.05, ##p<0.01 vs. NA CM alone (Two-way ANOVA followed by post-hoc Newman-Keuls).
3.5.11.2 FGF-2 nAB attenuates some NA CM-induced increases in the Sholl profile of primary cortical neurons

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches at specific points from the cell soma \([F(1,224)=70.7, p<0.0001]\). There was no significant effect of FGF-2 nAB but there was a significant NA CM by FGF-2 nAB interaction \([F(1,224)=4.99, p=0.0423]\). There was also a significant effect of distance \([F(16,224)=603.07, p<0.0001]\) and a significant distance by NA CM interaction \([F(16,224)=6.74, p<0.0001]\). Furthermore post-hoc analysis revealed that NA CM had significantly more branches than control CM at 5, 15, 25 (p<0.01) and 35\(\mu\)m (p<0.05) from the cell soma. The FGF-2 nAB in combination with NA CM had significantly less branches than NA CM alone at 15\(\mu\)m from the cell soma (p<0.05). [Figure 3.58, Newman-Keuls, n=6].

Figure 3.58: FGF-2 nAB attenuates some NA CM-induced increases in the Sholl profile of primary cortical neurons

Primary cortical neurons were treated for 24h with NA CM (10\(\mu\)M) which had been incubated for 30min with mouse IgG1k (2.5\(\mu\)g/ml) or the FGF-2 nAB (2/5\(\mu\)g/ml) for 30min, and then placed onto neurons. Sholl analysis was then performed. NA CM had significantly more branches than control at 5, 15, 25 and 35\(\mu\)m from the cell soma. The FGF-2 nAB in combination with NA had significantly less branches than NA alone at 15\(\mu\)m from the cell soma. Data expressed as means ± SEM, n=7-8. *p<0.05, **p<0.01 NA vs. control, #p<0.05 FGF-2 nAB + NA vs. NA alone (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.5.12 Inhibition of IL-6 Signalling blocks NA CM-induced increases in neuronal complexity

As shown previously, IL-6 treatment of primary cortical neurons enhanced neuronal complexity. In addition, NA stimulation of glial cells increases IL-6 mRNA expression. To assess if IL-6 was important for inducing NA CM-induced increases in neuronal complexity, an IL-6 receptor antibody (anti-IL6R, 0.1 μg/ml) or the isotype control IgG2bκ (0.1 μg/ml), was added to the CM for 30 min. Neurons were then treated with the CM plus anti-IL6R or IgG2bκ for 24 h. Sholl analysis was performed as before.

3.5.12.1 Inhibition of the IL-6R blocks NA CM-induced increases in neuronal complexity

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the number of primary neurites \( F(1,27)=7.51, p=0.0108 \) There was also a significant effect of anti-IL6R \( F(1,27)=5.54, p=0.0261 \) but no significant interaction between the two \[ F(1,27)=0.0084, p=0.9278. \] Post-hoc analysis revealed no significant differences between the groups. [Figure 3.59a, Newman-Keuls, \( n=7-8 \)].

**Neuritic Branching**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the number of neuritic branches \( F(1,27)=7.51, p=0.0107 \). There was also a significant effect of anti-IL6R \( F(1,27)=6.08, p=0.0203 \) but no significant interaction between the two \[ F(1,27)=1.17, p=0.287 \]. Post-hoc analysis revealed that NA CM treatment significantly increased the number of neuritic branches compared to control CM treated neurons \( p<0.05 \) and that anti-IL6R in combination with NA CM had significantly less neuritic branches compared to NA CM alone \( p<0.05 \). [Figure 3.59b, Newman-Keuls, \( n=7-8 \)].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM treatment on the neuritic length \( F(1,27)=28.22, p=0.0001 \). There was also a significant effect of the IL-6R blocker \[ F(1,27)=32.9, p=0.0001 \] and a significant interaction between the two \[ F(1,27)=9.278, p=0.0053 \]. Post-hoc analysis revealed that NA CM treatment significantly increased the neuritic length compared to control treated neurons \( p<0.01 \), while anti-IL6R in combination with NA CM had significantly reduced neuritic length compared to NA CM alone \( p<0.01 \). [Figure 3.59c, Newman-Keuls, \( n=7-8 \)].
(a) Primary Neurites

![Bar chart showing the number of primary neurites for Control and Anti-IL6R treatments.](chart-a.png)

(b) Neuritic Branches

![Bar chart showing the number of neuritic branches for Control and Anti-IL6R treatments.](chart-b.png)

(c) Neuritic Length

![Bar chart showing the neuritic length for Control and Anti-IL6R treatments.](chart-c.png)

Figure 3.59: Inhibition of the IL-6R reduces NA CM-induced increases in neuronal complexity

Primary cortical neurons were treated for 24h with NA CM (10μM) which had been incubated for 30min with IgG2bK (0.1μg/ml) or anti-IL6R (0.1μg/ml) for 30min, and then placed onto neurons. Sholl analysis was then performed. Neither NA CM nor anti-IL6R had any significant effect on (a) the number of primary neurites. However, anti-IL6R significantly reduced the NA CM-induced increases in (b) number of neuritic branches and (c) neuritic length. Data expressed as mean + SEM, n=7-8. *p<0.05, **p<0.01 vs. Control CM, #p<0.05, ##p<0.01 vs. NA CM alone. (Two-way ANOVA followed by post-hoc Newman-Keuls).
3.5.12.2 Anti-IL6R attenuates NA CM-induced increases in the Sholl profile of primary cortical neurons

A three-way repeated measures ANOVA demonstrated a significant effect of both NA CM \([F_{(1,224)}=5.10, p=0.04]\) and anti-IL6R \([F_{(1,224)}=13.41, p=0.0026]\) on the number of neuritic branches at points from cell the soma. ANOVA also demonstrated a significant NA CM by distance interaction \([F_{(16,224)}=2.84, p=0.003}\), and distance by anti-IL6R interaction \([F_{(16,224)}=1.97, p=0.0156]\). In addition, post-hoc analysis revealed that NA CM had significantly more branches compared to control CM at 15 \(\mu\)M (\(p<0.01\)) from the cell soma and anti-IL6R + NA treatment had significantly less branches than NA CM alone at 15 \(\mu\)M (\(p<0.05\)). Anti-IL6R also had significantly less branches than control CM at 15, 25 (\(p<0.01\)) and 35 \(\mu\)M (\(p<0.05\)) from the cell soma. [Figure 3.60, Newman-Keuls, \(n=7-8\)].

![Graph showing the effect of NA CM and anti-IL6R on neuritic branches](image)

**Figure 3.60: Anti-IL6R attenuates NA CM-induced increases in the Sholl profile of primary cortical neurons**

Primary cortical neurons were treated for 24h with NA CM (10 \(\mu\)M) which had been incubated for 30min with IgG2b (0.1 \(\mu\)g/ml) or anti-IL6R (0.1 \(\mu\)g/ml) for 30min, and then placed onto neurons. Sholl analysis was then performed. NA CM had significantly more branches than control at 15 \(\mu\)m from the cell soma Anti-IL6R had significantly less branches than control at 15, 25 and 35 \(\mu\)m from the cell soma. In addition, anti-IL6R in combination with NA CM had significantly less branches than NA CM alone at 15 \(\mu\)m from the cell soma. Data expressed as means \(\pm\) SEM, \(n=7-8\). **\(p<0.01\) NA CM vs. Control CM, \#\(p<0.05\), ##\(p<0.01\) anti-IL-6R vs. control, \$p<0.05\), NA CM + anti-IL-6R vs. NA CM alone. (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.6 Signalling pathways mediating the ability of NA CM to increase the complexity of primary cortical neurons

Increases in neuronal morphology have previously been associated with activation of the PI3K pathway (Ditlevsen et al., 2003), the ERK1/2 MAPK pathway (Lee et al., 2009c) and the STAT3 pathway (He et al., 2005). As NA induces the release of several growth factors, all of which can signal via at least one of the above pathways, it was important to assess which pathway was primarily associated with the NA CM-induced increases in neuronal morphology of primary cortical neurons.

The aims of these studies were as follows:

1) To verify, using Western Immunoblotting, that the PI3K, ERK and STAT-3 signalling pathways are activated in primary cortical neurons after NA CM stimulation.
2) To ascertain the ability of inhibitors of the PI3K pathway, wortmannin and LY294002, to attenuate NA CM-induced increases in neuronal complexity.
3) To ascertain the ability of an inhibitor of the ERK1/2 pathway, PD98059, to attenuate NA CM-induced increases in neuronal complexity.
4) To ascertain the ability of an inhibitor of the STAT-3 pathway, S31-201, to attenuate NA CM-induced increases in neuronal complexity.
3.6.7 **NA CM activates signaling pathways associated with neuronal growth in neurons**

To assess the signalling pathways induced by NA CM in neurons, Western Immunoblotting was performed. Neurons were treated for 5min with control or NA CM and then prepared for Western Immunoblotting as described in the methods. Blots were probed for phosphorylated and total ERK1/2, AKT and STAT3.

(a) A Student’s $t$-test demonstrated a significant effect of NA CM on the ratio of the phosphorylated AKT to total AKT ($t=2.74$, d.f.=10, $p=0.0208$) [Figure 3.61a].

(b) A Student’s $t$-test demonstrated a significant effect of NA CM on the ratio of the phosphorylated STAT3 to total STAT3 ($t=2.311$, d.f.=8, $p=0.0496$) [Figure 3.61b].

(c) A Student’s $t$-test demonstrated a significant effect of NA CM on the ratio of the phosphorylated ERK1/2 to total ERK1/2 ($t=3.895$, d.f.=8, $p=0.0046$) [Figure 3.61c].
Figure 3.61: NA CM induces the phosphorylation of AKT, STAT3 and ERK

Primary cortical neurons were treated for 5min with the CM from NA treated glia or control CM. The neurons were harvested and western blotting was performed. NA CM increased phosphorylation of AKT (a), STAT3 (b) and ERK (c). *p<0.05, **p<0.01 vs. control CM. Data expressed as means + SEM (n=5-6). (Student's t-test).
3.6.1 Inhibitors of the PI3K pathway blocks NA CM-induced increases in neuronal morphology

To assess the ability of NA CM to induce neuronal complexity via the PI3K pathway, primary cortical neurons were treated for 30min with wortmannin (Wort, 100nM) or LY294002 (LY, 10μM), highly selective inhibitors of PI3K signalling, followed by stimulation with NA CM. Sholl analysis was performed as before.

3.6.1.1 The PI3K inhibitors wortmannin and LY294002 block NA CM-induced increase in neuronal complexity

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of primary neurites extending from the cell soma \( [F(1,39)=4.308, \ p=0.0446] \). ANOVA also demonstrated a significant effect of inhibitor treatment \( [F(2,39)=4.725, \ p=0.0145] \) and a significant NA CM by inhibitor interaction \( [F(2,39)=3.25, \ p=0.0492] \). Furthermore post-hoc analysis revealed that NA CM had significantly more primary neurites than control CM \((p<0.01)\) and that both wortmannin and LY294002 reduced NA CM-induced increases in number of primary neurites \((p<0.05)\). [Figure 3.62a, Newman-Keuls, \( n=6-8 \)].

**Neuritic Branching**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches of the primary neurons \( [F(1,39)=10.43, \ p=0.0025] \). ANOVA also demonstrated a significant effect of inhibitor treatment \( [F(2,39)=6.604, \ p=0.0034] \) and a significant NA CM by inhibitor interaction \( [F(2,39)=7.374, \ p=0.0019] \). Furthermore post-hoc analysis revealed that NA CM had significantly more neuritic branches than control CM \((p<0.01)\) and that both wortmannin and LY294002 reduced NA CM-induced increases in neuritic branches \((p<0.01)\). [Figure 3.62b, Newman-Keuls, \( n=6-8 \)].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM on the neuritic length of the neurons \( [F(1,39)=35.506, \ p<0.0001] \). ANOVA also demonstrated a significant effect of inhibitor treatment \( [F(2,39)=10.237, \ p=0.0003] \) and a significant NA CM by inhibitor interaction \( [F(2,39)=9.522, \ p=0.0004] \). Furthermore post-hoc analysis revealed that NA CM had significantly longer neurites than control CM \((p<0.01)\) and that both wortmannin and LY294002 reduced NA CM-induced increases in neuritic length \((p<0.01)\). [Figure 3.62c, Newman-Keuls, \( n=6-8 \)].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.62: The PI3K inhibitors wortmannin and LY294002 block NA CM-induced changes in neuronal morphology

Primary cortical neurons were treated for 30min with the PI-3K inhibitors Wort (100nM) and LY (10µM) and then treated for 24h with the CM from glial cells treated with NA (10µM). Sholl analysis was then performed. Both Wort and LY attenuated the NA CM-induced increases in (a) number of primary neurites, (b) number of neuritic branches and (c) neuritic length. Data expressed as means + SEM, n=6-8. **p<0.01 vs. control CM, #p<0.05, ##p<0.01 vs. NA CM alone. (Two-way ANOVA followed by post-hoc Newman-Keuls).
3.6.1.2 The PI3K inhibitors wortmannin and LY block the NA CM-induced increases in the Sholl profile

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM treatment \( [F(1,448)=17.35, \ p=0.001] \), inhibitor treatment \( [F(2,448)=16.08, \ p<0.0001] \) and distance \( [F(6,448)=532.86, \ p<0.0001] \) on the number of neuritic branches at points from cell the soma. ANOVA also demonstrated significant interactions between NA CM and inhibitor treatments \( [F(2,448)=11.48, \ p=0.0002] \), NA CM and distance \( [F(6,448)=4.19, \ p<0.0001] \) and inhibitor treatment and distance \( [F(32,224)=3.78, \ p<0.0001] \). In addition, \textit{post-hoc} analysis revealed that NA CM had significantly more branches compared to control CM at 5, 15, 25\( \mu \text{m} \) (\( p<0.01 \)), 35 and 45\( \mu \text{m} \) (\( p<0.05 \)) from the cell soma. Wortmannin treatment significantly attenuated NA CM-induced increases at 5, 15, 25 (\( p<0.01 \)), 35 and 45\( \mu \text{m} \) (\( p<0.05 \)) while LY treatment also significantly attenuated the NA CM-induced increases in branches at 5, 15, 25, 35\( \mu \text{m} \) (\( p<0.01 \)) and 45\( \mu \text{m} \) (\( p<0.05 \)) from the cell soma. [Figure 3.63, Newman-Keuls, \( n=6-8 \)].

Figure 3.63: The PI3K inhibitors wortmannin and LY reduces the NA CM-induced increases in the Sholl profile

Primary cortical neurons were treated for 30min with the PI3K inhibitors Wort (100nM) or LY (10\mu M) and then treated for 24h with the CM from glial cells treated with NA (10\mu M). Sholl analysis was then performed. NA CM had significantly more branches than control at 5, 15, 25, 35 and 45\( \mu \text{m} \) from the cell soma. In addition; the PI3K inhibitor Wort and LY in combination with NA CM had significantly less branches than NA CM alone at 5, 15, 25, 35 and 45\( \mu \text{m} \) from the cell soma. Data expressed as means ± SEM, \( n=6-8 \). **\( p<0.01 \) NA vs. control, #\( p<0.05 \), ##\( p<0.01 \) Wort + NA vs. NA alone, +\( p<0.05 \), ++\( p<0.01 \) LY + NA vs. NA alone. (Three-way repeated measures ANOVA followed by \textit{post-hoc} Newman-Keuls).
3.6.2 An inhibitor of the MAPK pathway attenuates NA CM-induced increases in neuronal morphology

To assess the ability of NA CM to induce neuronal complexity via the ERK1/2 pathway, primary cortical neurons were treated for 30 min with PD98059 (PD, 10 µM), a highly selective inhibitor of MEK, followed by stimulation with NA CM. Sholl analysis was performed as before.

3.6.2.1 The MAPK kinase inhibitor PD98059 attenuates NA CM-induced changes in neuronal morphology

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of primary neurites extending from the cell soma \( F_{(1,27)} = 5.210, p = 0.0306 \). ANOVA showed no effect of PD treatment or any interaction. Furthermore post-hoc analysis revealed that NA CM had significantly more primary neurites than control CM \( (p<0.05) \) and that PD reduced NA CM-induced increases in number of primary neurites \( (p<0.05) \). [Figure 3.64a, Newman-Keuls, \( n=7-8 \)].

**Neuritic Branches**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches of the primary neurons \( F_{(2,27)} = 25.151, p<0.0001 \). ANOVA also demonstrated a significant effect of inhibitor treatment \( F_{(2,27)} = 8.978, p = 0.0058 \) and a significant NA CM by inhibitor interaction \( F_{(2,27)} = 4.783, p = 0.0376 \). Furthermore post-hoc analysis revealed that NA CM had significantly more neuritic branches than control CM \( (p<0.01) \) and that PD reduced NA CM-induced increases in neuritic branches \( (p<0.01) \). [Figure 3.64b, Newman-Keuls, \( n=7-8 \)].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM on the neuritic length of the neurons \( F_{(1,27)} = 40.368, p<0.0001 \). ANOVA also demonstrated a significant effect of inhibitor treatment \( F_{(2,27)} = 22.839, p<0.0001 \) and a significant NA CM by inhibitor interaction \( F_{(2,27)} = 23.546, p<0.0001 \). Furthermore post-hoc analysis revealed that NA CM had significantly longer neurites than control CM \( (p<0.01) \) and that PD reduced NA CM-induced increases in neuritic length \( (p<0.01) \). [Figure 3.64c Newman-Keuls, \( n=7-8 \)].
Chapter 3: Results

(a) Primary Neurites

\[ \text{No. of Primary Neurites} \]

Control  | PD
---|---
\[ 4 \]  | \[ 6 \]

(b) Neuritic Branches

\[ \text{No. of Neuritic Branches} \]

Control  | NA
---|---
\[ 2.5 \]  | \[ 5 \]

(c) Neuritic Length

\[ \text{Neuritic Length (µm)} \]

Control  | NA CM
---|---
\[ 100 \]  | \[ 150 \]

Figure 3.64: The MAPK inhibitor PD98059 blocks NA CM-induced increases in neuronal morphology. Primary cortical neurons were treated for 30min with the MAPK inhibitor PD (10µM) and then treated for 24h with the CM from glial cells treated with NA (10µM). Sholl analysis was then performed. PD attenuated the NA CM-induced increases in (a) number of primary neurites, (b) number of neuritic branches and (c) neuritic length. Data expressed as means + SEM, \( n=7-8 \). *\( p<0.05 \), **\( p<0.01 \) vs. control CM, #\( p<0.05 \), ##\( p<0.01 \) vs. NA CM alone. (Two-way ANOVA followed by post-hoc Newman-Keuls).
3.6.2.2 The MAPK inhibitor PD98059 blocks the NA CM-induced increases in the Sholl profile

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM treatment \( [F(1,224)=18.30, p=0.0008] \), PD treatment \( [F(1,224)=23.28, p=0.0003] \) and distance \( [F(16,224)=271.27, p<0.0001] \) on the number of neuritic branches at points from cell the soma. ANOVA also demonstrated significant interactions between NA CM and PD \( [F(1,224)=16.66, p=0.0011] \), NA CM and distance \( [F(16,224)=4.67, p=0.0001] \) and PD and distance \( [F(16,224)=3.81, p<0.0001] \). In addition, post-hoc analysis revealed that NA CM had significantly more branches compared to control at 5\( \mu \)M, 15, 25, 35\( \mu \)m (p<0.01) and 45\( \mu \)m (p<0.05) from the cell soma and PD significantly reduced the NA CM-induced increases in branches at 5, 15, 25 and 35\( \mu \)m (p<0.01) from the cell soma. [Figure 3.65, Newman-Keuls, \( n=7-8 \)].

**Figure 3.65: The MAPK inhibitor PD98059 blocks the NA CM-induced increases in the Sholl profile**

Primary cortical neurons were treated for 30min with the MAPK inhibitor PD (10\( \mu \)M) and then treated for 24h with the CM from glial cells treated with NA (10\( \mu \)M). Sholl analysis was then performed. NA CM had significantly more branches than control at 5, 15, 25, 35 and 45\( \mu \)m from the cell soma In addition; PD in combination with NA CM had significantly less branches than NA CM alone at 5, 15, 25 and 35\( \mu \)m from the cell soma. Data expressed as means ± SEM, \( n=7-8 \). *p<0.05, **p<0.01 NA vs. control, ##p<0.01 PD98059 + NA vs. NA alone. (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
3.6.3 **An inhibitor of the STAT3 pathway blocks NA CM-induced increases in neuronal morphology**

To assess the ability of NA CM to induce neuronal complexity via the STAT-3 pathway, primary cortical neurons were treated for 30min with S31-201 (10µM), a highly selective inhibitor of STAT-3 signalling, followed by stimulation with NA CM. Sholl analysis was performed as before.

3.6.3.1 **The STAT3 inhibitor S31-201 blocks NA CM-induced changes in neuronal morphology**

**Primary Neurites**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of primary neurites extending from the cell soma \( F(1,20)=15.83, \ p=0.0007 \). ANOVA also showed a significant effect of S31-201 treatment \( F(1,20)=22.66, \ p<0.0001 \) and a significant interaction between the two \( F(1,20)=13.21, \ p=0.016 \). Furthermore post-hoc analysis revealed that NA CM had significantly more primary neurites than control CM (\( p<0.01 \)) and that S31-201 reduced NA CM-induced increases in number of primary neurites (\( p<0.01 \)). [Figure 3.66a, Newman-Keuls, \( n=6 \)].

**Neuritic Branches**

A two-way ANOVA demonstrated a significant effect of NA CM on the number of neuritic branches of the primary neurons \( F(1,20)=5.908, \ p=0.0246 \). ANOVA also demonstrated a significant effect of S31-201 treatment \( F(1,20)=14.16, \ p=0.0012 \) but no significant interaction between the two \( F(1,20)=3.738, \ p=0.0675 \). Furthermore post-hoc analysis revealed that NA CM had significantly more neuritic branches than control CM (\( p<0.01 \)) and that S31-201 treatment reduced NA CM-induced increases in neuritic branches (\( p<0.01 \)). [Figure 3.66b Newman-Keuls, \( n=6 \)].

**Neuritic Length**

A two-way ANOVA demonstrated a significant effect of NA CM on the neuritic length of the neurons \( F(1,20)=12.17, \ p=0.0023 \). ANOVA also demonstrated a significant effect of inhibitor treatment \( F(1,20)=14.86, \ p=0.001 \) and a significant interaction between the two \( F(1,20)=9.92, \ p=0.005 \). Furthermore post-hoc analysis revealed that NA CM had significantly longer neurites than control CM (\( p<0.01 \)) and that S31-201 reduced NA CM-induced increases in neuritic length (\( p<0.01 \)). [Figure 3.66c Newman-Keuls, \( n=6 \)].
Chapter 3: Results

(a) Primary Neurites

(b) Neuritic Branches

(c) Neuritic Length

Figure 3.66: The STAT3 inhibitor S31-201 blocks NA CM-induced changes in neuronal morphology.

Primary cortical neurons were treated for 30 min with S31-201 (10 μM) and then treated for 24 h with the CM from glial cells treated with NA (10 μM). Sholl analysis was then performed. S31-201 treatment attenuated the NA CM-induced increases in (a) number of primary neurites, (b) number of neuritic branches and (c) neuritic length. Data expressed as means ± SEM, n=6. **p<0.01 vs. control CM, ###p<0.01 vs. NA CM alone. (Two-way ANOVA followed by post-hoc Newman-Keuls).
3.6.3.2 The STAT3 inhibitor S31-201 blocks the NA CM-induced increases in the Sholl profile

A three-way repeated measures ANOVA demonstrated a significant effect of NA CM treatment [$F(1,320)=10.28$, $p=0.0044$], S31-201 treatment [$F(1,320)=21.19$, $p=0.0002$] and distance [$F(16,320)=195.13$, $p<0.0001$] on the number of neuritic branches at points from cell the soma. ANOVA also demonstrated significant interactions between NA CM and S31-201 [$F(1,320)=14.25$, $p=0.0012$], NA CM and distance [$F(16,320)=1.74$, $p=0.0383$] and S31-201 and distance [$F(16,224)=5.66$, $p<0.0001$]. In addition, post-hoc analysis revealed that NA CM had significantly more branches compared than control at 5μM, 15, 25, 35 μm (p<0.01) 45μm and 115μm (p<0.05) from the cell soma and S31-201 significantly reduced the NA CM-induced increases in branches at 5, 15, 25, 35, 45μm (p<0.01) and 115μm (p<0.05) from the cell soma. [Figure 3.67, Newman-Keuls, n=6].

Figure 3.67: The STAT3 inhibitor S31-201 blocks the NA CM-induced increases in the Sholl profile

Primary cortical neurons were treated for 30min with the STAT3 inhibitor S31-201 (10μM) and then treated for 24h with the CM from glial cells treated with NA (10μM). Sholl analysis was then performed. NA CM had significantly more branches than control at 5, 15, 25, 35, 45 and 115μm from the cell soma In addition; the STAT3 inhibitor in combination with NA CM had significantly less branches than NA CM alone at 5, 15, 25, 35, 45 and 115μm from the cell soma. Data expressed as means ± SEM, n=6. *p<0.05, **p<0.01 NA CM vs. control, ##p<0.01 S31-201 + NA CM vs. NA CM alone. (Three-way repeated measures ANOVA followed by post-hoc Newman-Keuls).
Chapter 4

Discussion
Chapter 4: Discussion

The studies presented in this thesis examined the ability of CM from NA-treated primary mixed glial cells to induce neuritic growth in primary cortical neurons. An *in vitro* primary cell culture system was utilised in the present investigation as it allows for separation of CNS cell types, the study of neuronal growth in isolation and the manipulation of signalling pathways and growth factors *in situ*. The results presented in this thesis have revealed many novel and significant findings of the ability of NA to induce neuritic growth via an action on glial adrenoceptors. To start with, it is the first time that NA has been shown to have this growth-inducing ability. Secondly, the β-adrenoceptor, in particular the β2-adrenoceptor, has been shown to mediate the growth inducing ability of NA. The β2-adrenoceptor has previously been linked to the anti-inflammatory and neuroprotective properties of NA stimulation in glial cells (Junker *et al.*, 2002; McNamee *et al.*, 2010b), and so now enhancing neuritic growth can also be included in the functions of this receptor. The results presented here also show that an increase in intracellular cAMP in the glial cells, which is a downstream signalling event following β2-adrenoceptor activation, can mimic the ability of NA to induce neuritic growth. Again, this is in line with the many reports of β2-adrenoceptor mediated neuroprotection and down-regulation of inflammation via an increase in intracellular cAMP (McNamee *et al.*, 2010b).

Furthermore, the results have demonstrated that astrocytes and not microglia are required for the ability of NA to induce neuritic growth. Astrocytes are the primary sources of neurotrophic factors in the CNS and CM from astrocytes has previously been shown to induce neuritic growth and favour neuronal survival (Spohr *et al.*, 2011), thus the results reported within this thesis are in line with the literature. In addition to this, the present work shows that NA stimulation of glial cells results in significantly increased secretion of GDNF, IL-6 and FGF-2, all of which have been shown to be required for NA CM-induced increases in neuritic growth, in combination with the presence of the neurotrophin NGF-β. Furthermore, the NA CM activates the PI3K, the MAPK and the STATS pathway in neurons, and inhibition of any of these three pathways inhibits NA CM-induced neuronal growth.
4.1 CM from NA treated glial cells but not a direct stimulation with NA, induces neuritic growth of primary cortical neurons

The ability of NA to impact upon cell viability of cortical neurons was firstly investigated. NA CM, but not direct treatment with NA, significantly enhanced neuronal viability as measured by the Alamar Blue mitochondrial colorimetric assay after 24h of treatment. This assay relies on the redox potential of the blue dye resazurin to be converted to resorufin by metabolic activity within the cells, and has previously been utilised to study neuronal viability in culture (White et al., 1996). An increase in neuronal viability caused by NA CM without any pre-treatment of a toxic insult is a unique finding. Furthermore, this demonstrates one of several possible functions of the NA CM; firstly, that NA CM is inhibiting a basal level of cell loss within the primary neurons, or two; that NA CM is increasing neurogenesis or neuritic growth of the primary neurons, or three; that NA CM is increasing the metabolic activity of the same number of neurons. Any of these scenarios would increase the metabolic activity of the neurons and thus the Alamar Blue readout.

Following on from this, neuronal morphology was assessed in primary cortical neurons following treatment with the CM from primary mixed glial cells stimulated with NA, or after a direct treatment with NA. Specifically, the number of primary neurites, the number of neuritic branches, the neuritic length and changes in the Sholl profile were investigated. Interestingly, NA CM but not direct NA treatment, significantly enhanced the number of primary neurites extending from the cell soma, the number of neuritic branches and the neuritic length. To the best of my knowledge, this is the first time that NA, via an action on glial cells, has been demonstrated to alter the morphology of neurons. In addition to this, the Sholl profile-(a scatter-plot of the number of neuritic branches plotted against the distance from the cell soma) of each study design was investigated. The Sholl profile is a simple graphical representation of the overall morphology of the neuron. All doses of NA CM-treated neurons demonstrated significantly more branches than neurons treated with control CM at 5, 15 and 25μm from the cell soma while neurons treated with 1μM NA CM also had significantly more branches at 35μm. In the direct NA Sholl profile, both 1μM and 10μM NA had significantly less branches than control from 15-35μm from the cell soma. 5μM NA did not lead to any significant changes in the Sholl profile, the reasons for this are unknown. There is limited evidence in the literature supporting a role for NA to reduce neuritic growth. Inhibition of NA signalling via the β-adrenoceptor blocker,
propranolol, has been shown to increase sympathetic innervation to the rat heart. In the study, basal levels of NA acted to continuously inhibit neuritic outgrowth. The addition of exogenous β-adrenoceptor agonists had no effect on neuritic growth, but inhibition of endogenous NA synthesis increased the growth (Clarke et al., 2010). This study therefore demonstrates that direct NA stimulation acts to reduce neuritic growth, similarly to the results demonstrated within this thesis. Thus it can be hypothesised that direct NA stimulation of the primary cortical neurons in the present work is attenuating basal levels of neuronal branching as reflected in the Sholl profile. A time course analysis of the growth of the neurons following direct NA treatment would need to be undertaken to confirm this.

However, NA CM had the opposite effect. The ability of the CM from NA treated glial cells to increase neuritic growth of neurons, but not direct NA, implies that the NA is stimulating the glial cells to release substances into the CM which act upon the neurons and result in morphological changes. Neurons in vivo co-exist with glial cells, and thus the action of NA on glia is more comparable to ongoing NA stimulation in the brain. Subsequent studies were then undertaken to ascertain potential mediators of these NA CM-induced neuronal changes.

4.2 5-HT does not induce neuritic growth

5-HT, a second monoaminergic neurotransmitter, has previously been shown to induce the expression of a wide range of neurotrophic factors (Pousset et al., 1996; Hisaoka et al., 2004; Juric et al., 2006), has roles in neurogenesis (for review, see Azmitia, 2001) and thus might also alter the morphology of the primary cortical neurons investigated in this thesis. Neither a direct treatment of 5-HT, nor CM from 5-HT treated glial cells had any impact upon the gross parameters of neuronal morphology; primary neurites, neuritic branches or neuritic length. The Sholl profile for 5-HT CM does however show changes in neuronal morphology, specifically, all doses of 5-HT CM had significantly more branches than control between 5-45μm from the cell soma. In addition, 5μM but not 1 or 10μM of direct 5-HT led to significantly more branches than control at 15, 25 and 35μm from the cell soma.

The ability of 5-HT to induce neuritic growth in neurons and neuronal-like cells is controversial. There are some reports which have demonstrated that 5-HT stimulation
leads to an increase in neuritic growth. For example 5-HT increases both the neuritic outgrowth and neuritic length of mouse neuroblastoma cell line Neuro 2A cells (Fricker et al., 2005) and PC12 cells (Homma et al., 2006). Additionally, thalamic neurons show increases in primary neurites, neuritic branching and neuritic length upon 5-HT stimulation. However, this study treated the neurons for 72h, a much longer time-frame than that used in the present study (Persico et al., 2006). Conversely, Haydon et al in 1984 demonstrated that stimulation of primary neurons cultured from the snail with 5-HT showed a reduction in neuronal growth at the growth cone (Haydon et al., 1984), which has since been replicated (McCobb et al., 1988). To add to this confusion, the same culture of neurons can react differently to 5-HT depending on the neuronal phenotype; GABA containing glutamate decarboxylase positive neurons which represent 10% of the total neuronal population of primary rat cortical neurons, show increased axonal length, but glutamate decarboxylase negative neurons showed reductions in both axonal and dendritic lengths, upon 5-HT stimulation (Hayashi et al., 2010). As this distinction was not made in the present study, it is possible that the mixed culture of neurons showed differential growth properties upon 5-HT stimulation which is masking any neuronal-specific effects.

Glial cells, however are known to express serotonergic receptors (for review, see Azmitia, 2001). Serotonin stimulation of astrocytes in culture has been shown to increase BDNF (Juric et al., 2006), GDNF (Hisaoka et al., 2004), IL-6 (Pouset et al., 1996) but not NGF (Krzan et al., 2001) production. However studies show that although 5-HT induces an increase in intracellular concentrations of BDNF in rat cortical astrocytes, the level of BDNF returned to baseline by 8h post stimulation, while NA-induced increases in BDNF required 24-36h for levels to return to baseline (Juric et al., 2006). This might account for the NA vs. 5-HT differences in the present study. The production of trophic factors (either mRNA or protein) upon 5-HT stimulation was beyond the scope of this thesis, but it would be interesting to investigate any differences in noradrenergic and serotonergic stimulation of primary glial cells.
4.3 The NA/5-HT reuptake inhibitor, AMI, induces neuritic growth via both an action on glial cells and a direct action on neurons

AMI, an antidepressant which inhibits the uptake of both 5-HT and NA (Iversen, 2006), was investigated to establish if it would have any effect on the morphology of primary cortical neurons. Antidepressants have previously been shown to enhance neurogenesis in the hippocampus of adult rat brains (for review see Duman et al., 2001). This however requires chronic treatment with antidepressants and so changes in neurogenesis are not seen for 2-4 weeks (Duman et al., 2001). In the present studies, it is shown that a low dose (1μM, 5μM) but not a high dose (25μM) of AMI leads to increases in neuritic morphology. Both the CM and the direct treatment of AMI led to increases in neuronal morphology. For the CM experiment, 5μM AMI increased the number of primary neurites and the neuritic length of the primary cortical neurons, while the direct treatment with AMI showed increases in the number of primary neurites, the number of neuritic branches and the neuritic length for 1μM only. 25μM AMI had no effect in either study design. Since a direct treatment of AMI led to significant changes in neuronal morphology, it remains to be seen whether the CM from AMI results in neuronal changes due to AMI present in the CM, or if AMI is inducing the production of growth factors into the CM which encourages neuritic growth. Astrocytes can take up AMI (Daniel, 2003) and therefore it is possible that much of the AMI is removed from the CM prior to media transfer. If a direct AMI treatment to neurons is resulting in neuronal morphological changes, removal of some of the antidepressant by the astrocytes could explain why a higher dose of AMI is required for CM (5μM) to induce neuronal changes compared to a lower direct dose (1μM). The highest dose utilised in this study, 25μM, however might be neurotoxic; several studies have shown that a high dose of AMI can have toxic effects on neuronal cells. High dose AMI treatment (20μM and 50μM) to the cell lines HT22 and PC12 cells, show reduced cell viability compared to control, which may be attributed to oxidative stress (Post et al., 2000; Bartholoma et al., 2002). Furthermore, primary neurons, specifically primary sympathetic neurons, show reduced cell viability when treated with a wide dose range of AMI (0.1μM to 500μM). Indeed, in the study, a very high dose (500μM) led to neurons with significantly less axonal outgrowth compared to controls (Lirk et al., 2006). In the present study, 25μM AMI had no effect on neuronal morphology (with the exception of 25μM CM AMI showing reduced branching compared to control CM at 25μm from the cell soma). Since lower doses of AMI increased neuritic
branching in the present study, and very high doses of AMI reduces axonal outgrowth (Lirk et al., 2006), it is possible that at 25µM the neuritogenic potential of AMI is being balanced by the neurotoxic and growth-inhibiting potential of high dose AMI.

Interestingly, AMI has been shown to directly bind both TrkA and TrkB, but not TrkC receptors. AMI binding triggers both dimerisation of TrkA and heterodimerisation of TrkA to TrkB (see Figure 4.1). In addition, AMI treatment was able to induce neurite outgrowth of PC12 cells, which was prevented by blocking downstream targets of the Trk receptor such as the PI3K and MAPK pathway (Jang et al., 2009). Thus in the present study it is possible that AMI-induced neuritic growth is somewhat attributable to activation of the Trk receptor. Furthermore, AMI has been shown to increase BDNF concentrations in depressed patients (Hellweg et al., 2008), increase GDNF production from astrocytes (Hisaoka et al., 2007) and frees FGF-2 from its plasma membrane anchor (Hisaoka et al., 2011). Each of these growth factors has been shown in this thesis to increase neuritic growth of primary cortical neurons, and thus may account for the growth permitting properties of AMI.
Figure 4.1: AMI leads to dimerisation of Trk receptors which may lead to neuritic growth via the PI3K and MAPK pathway

AMI has been shown to directly dimerise the Trk receptors, leading to the activation of the PI3K and the MAPK pathways, which are involved in neuritic growth. Trk, tropomyosin-receptor kinase; AMI, amitriptyline; P, phosphorylated residue; PI3K, phosphatidylinositol 3-kinase; GSK, glycogen synthase kinase; MAPK, mitogen-activated protein kinase; MAP, microtubule associated proteins.

4.4 The β2-adrenoceptor is involved in NA CM-induced neuritic outgrowth

NA can bind to either α- or β-adrenoceptors on the cell surface of astrocytes and microglia (for reviews, see Kimelberg, 1995; Pocock & Kettenmann, 2007). Therefore, this study investigated which of the adrenoceptors was primarily responsible for the NA CM-induced neuritic outgrowth. To do this, glial cells were pre-treated with Prop (a β-adrenoceptor antagonist) or Phent (an α-adrenoceptor antagonist) followed by stimulation with NA. Prop blocked NA CM-induced increases in the number of primary neurites, number of neuritic branches and the neuritic length of the cortical neurons. Phent however
showed some attenuation of NA CM-induced increases in neuritic length but had no effect on the number of primary neurites or the number of neuritic branches. Furthermore, Prop fully blocked all NA CM-induced increases in branch number as shown in the Sholl profile while Phent did not. Neither Prop nor Phent treatment of glia alone had any effect on gross neuronal morphology. These results therefore show that the NA CM-induced increases in neuritic growth are primarily attributed to the β-adrenoceptor.

To further study the role of the glial β-adrenoceptor in neuronal growth, the non-selective β-adrenoceptor agonist, Salb, was utilised to see if Salb CM could mimic NA CM-induced neuritic increases. Indeed, Salb CM (5μM and 10μM) led to significant increases in the number of primary neurites, number of neuritic branches and the neuritic length of the cortical neurons. Both doses also significantly increased the numbers of neuritic branches from 5 to 55μm from the cell soma, as represented in the Sholl profile.

The β-adrenoceptor can be further divided into the β1, β2, and β3 subtypes, of which the β1 and β2 are associated with adrenergic mediated neuroprotection (Junker et al., 2002). Therefore, the selective β2-adrenoceptor agonists’ Salm and Clen, and the selective β1-adrenoceptor agonist Xam were examined for their ability to induce neuritic growth via glial activation. Salm CM and Clen CM but not Xam CM induced increases in the number of primary neurites, the number of neuritic branches and the neuritic length of the neurons. Furthermore, Salm CM increased neuritic branches at 5-45μm from the cell soma, while Clen CM increased neuritic branches at 5-35μm from the cell soma. Xam CM showed no changes in the Sholl profile from control CM.

As the β2-adrenoceptor primarily signals via the downstream messenger cAMP, it was then investigated if artificially increasing cAMP levels in the glial cells could also increase neuronal morphology. The cell permeable cAMP analogue dbcAMP, was therefore used. DbcAMP CM significantly increased the number of primary neurites, the number of neuritic branches and the neuritic length of the cortical neurons. DbcAMP CM also significantly increased the number of neuritic branches at 5-55μm from the cell soma as seen in the Sholl profile.

Overall, these results suggest that NA is acting primarily via the β2-adrenoceptor subtype to induce the production of various trophic factors from the glia into the CM to induce neuritic growth.
As previously discussed, this is the first time that NA has been shown to induce neuritic growth of primary neurons via an action on glial cells. However, NA has previously been shown to induce neuronal protection following various toxic insults. For example, primary rat astrocytes treated with NA (10μM) resulted in a CM which attenuated NMDA-dependent glutamate release from primary cortical neurons (Madrigal et al., 2009). Furthermore, co-culture of NA-treated astrocytes with primary neurons protected the neurons from oxygen glucose deprivation, compared to untreated cultures, and this was attributed to an increase in MCP-1 (monocyte chemoattractant protein). It is also appears that the β2-adrenoceptor is vital for NA-induced neuronal protection, as the β2-adrenoceptor antagonists, Prop and ICI 118551, inhibited this release of MCP-1 and thus the neuroprotection was provided via activation of the β2-adrenoceptor (Madrigal et al., 2009). Similar results were also seen by Junker et al (2002), who showed that mixed neuronal and astrocytic hippocampal cultures were protected from glutamate-induced neuronal toxicity by Clen stimulation. In addition, Clen attenuated neuronal damage following a stroke model in mice (Junker et al., 2002), and has also been shown to be beneficial in a rat model of spinal cord injury (Zeman et al., 1999), ischemic damage (Zhu et al., 1998), and is associated with an increase in the expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl following ischemia (Zhu et al., 1999). Thus the ability of NA to induce neuritic growth via the glial β2-adrenoceptor fits with the already neuronal protective functions of this receptor.

4.5 Astrocytes and not microglia are involved in the NA CM-induced neuritic growth

Primary mixed glial cells are composed of predominantly astrocytes (approximately 80%), followed by microglia (10-20%); with minor contributions of neurons, oligodendrocytes and fibroblasts. As NA stimulation of mixed glial cells led to the induction of neuritic growth in primary neurons, it was of interest to investigate whether astrocytes, microglia, or both are involved in this process. Therefore, primary glial cultures were separated as described in the methods into separate cultures of astrocytes and microglia, and then stimulated with NA. The resultant CM was used to treat primary cortical neurons and measures of neuritic growth were taken by Sholl analysis. NA stimulation of primary enriched astrocyte cultures increased the number of primary neurites, the number of neuritic branches and the neuritic length of the primary cortical neurons. However, NA stimulation of primary enriched microglia actually reduced the number of primary
neurites, and had no effect on the number of neuritic branches or the neuritic length. This therefore demonstrates that astrocytes and not microglia are involved in NA CM-induced increases in neuritic growth.

These results are in line with the literature, which implicates the ability of astrocytes to provide protection to neurons and to secrete a variety of growth factors into the surrounding environment. For example CM from untreated primary astrocytes was shown to protect primary neurons from amyloid β-induced neuronal toxicity, although the study did not demonstrate what factors might be present in the CM, the neuroprotection relied on activation of the ERK1/2 pathway, which is induced by many trophic factors (Yamamuro et al., 2003). Similarly, hydrogen peroxide neurotoxicity against primary neurons is attenuated upon the increasing presence of astrocytes in the culture (Desagher et al., 1996). Astrocytes have also been previously demonstrated to be involved in encouraging neuritic growth of neurons. For example, neurons in co-culture with astrocytes show enhanced axonal growth compared to neurons grown with fibroblasts, demonstrating the neurite-promoting properties of astrocytes. However, in the study if the neurons were unable to contact the astrocytes, no stimulation of axonal growth was observed (Dijkstra et al., 1999). In the present study, NA-stimulated astrocytes, but not un-stimulated astrocytes, led to observable differences in neuronal morphology. Both of these results therefore show that astrocytes need to be stimulated to increase production of trophic factors to induce neuritic growth; basal release of trophic factors is insufficient to induce morphological changes in neurons. In agreement with this, treatment of astrocytes with lysophosphatidic acid, a phospholipid derived from cell membranes, leads to a CM which induces neuritic growth of primary cortical neurons via activation of the MAPK pathway, while control CM had no effect (Spohr et al., 2011).

Thus, both the literature and the present set of results demonstrate that astrocytes need to be stimulated to induce neuritic growth in neurons. In this thesis, it was also demonstrated that activation of the β-adrenoceptor via the agonist, Salb, and also an increase in intracellular cAMP via dbcAMP was sufficient to stimulate the astrocytes to result in the release of various mediators into the CM to induce neuritic growth of the neurons.

Although much evidence points to a neuronal growth permitting role of astrocytes, it is important to note that astrocytes are also associated with the inability of neurons to regenerate following neuronal lesion due to the formation of the glial scar. This glial scar
forms both a physical barrier to neuritic growth and also produces proteins which inhibit the growth of neurons (for review, see Fitch & Silver, 2008). Understanding the mechanisms which can switch astrocytes from a growth-inhibiting to a growth-permitting environment for neurons are essential in neuronal regenerative medicine.

4.6 The C6 glioma cell line cannot be used as a model for the ability of primary astrocytes in vitro to induce neuritic growth

In the present thesis, the possibility of utilising the readily available C6 glioma cell line as a model for the ability of NA to induce neuritic growth via an action on astrocytic cells was investigated. Cell lines are advantageous over primary cultures in that they are genetically identical thus reducing inter-experiment variability; they eliminate the need for animals; grow at a consistent rate relative to primary cells thus allowing for easier time management for experimentation; and are easier to manipulate in terms of genetic knock-down or knock-in experimentation.

The studies demonstrated in this thesis show that the C6 cells express the astrocytic markers S100β and GFAP, and also show morphological characteristics similar to primary astrocytes. As the primary goal of this thesis was to investigate the role of the β2-adrenoceptor in inducing neuritic growth, it was essential to show that the cells express this receptor. Further to this, Western Immunoblotting clearly demonstrates that the C6 cells show protein expression of the receptor. Several reports have previously shown that C6 cells express the β-adrenoceptors (Homburger et al., 1981; Neve et al., 1985). However, NA stimulation of the C6 glioma cells did not result in a CM that induced neuritic growth in primary cortical neurons. This may seem surprising given that the cells clearly express the β2-adrenoceptor. As the receptor has previously been shown to be functional in C6 cells, via upregulation of cAMP (Homburger et al., 1981; Neve et al., 1985), it was assumed that it would also be functional in the present set of experiments. However, as C6 cells are continuously growing it is possible that other essential nutrients within the NBM required for neuritic growth are depleted by the glioma cells prior to CM transfer, thus although the NA stimulation may induce the same trophic factors, the availability of other nutrients would be diminished. To address this issue it would be necessary to calibrate a suitable density of C6 cells to utilise combined with an appropriate dilution of the CM to fresh NBM. This however was beyond the scope of this thesis. In addition to this, β2-adrenergic activation of C6 cells may not necessarily result in the
release of the same soluble factors as primary glial cells. For example, NA stimulation of C6 cells did not induce GDNF secretion (data not shown) unlike primary glial cells. The failure of the C6 cells to react similarly to primary astrocytes underlines the essential property of cell lines, in that they are transformed cancerous cells, which do not always react the same way as their parent cells (Lee et al., 2006). It is important to keep this in mind as results derived from cell lines are commonly extrapolated to both primary cells and in vivo models.

4.7 Factors involved in inducing neuronal growth by NA CM

A huge number of growth factors, hormones, cytokines and synthetic molecules have been shown to modulate the morphology of neurons from both in vitro and in vivo models (Greene & Tischler, 1976; Walicke et al., 1986; Patel & McNamara, 1995; Costantini & Isacson, 2000; Chao, 2003; Ditlevsen et al., 2003; Paratcha et al., 2003; Khaibullina et al., 2004; Cui, 2006; Ducray et al., 2006). Thus attempting to investigate the role of each of these in NA CM-induced increases in neuritic morphology was beyond the scope of this thesis. Instead, the mRNA expression, in glial cells, of a range of growth factors associated with neuritic outgrowth and/or induction by NA as determined by a literature search, was investigated following NA stimulation.

The neurotrophins, NGF-β, BDNF, NT3 and NT4/5, were therefore selected as they are considered important target-derived survival factors for neurons and have repetitively, in particular BDNF and NGF-β, been shown to induce neuritic outgrowth (for review, see Cui, 2006). GDNF, a newly-described neurotrophic factor, was also selected based on the ongoing research showing that GDNF is vital for dopaminergic survival (for review see Airaksinen & Saarma, 2002), and its potential for neuritic outgrowth (Hou et al., 1996). As GDNF is a member of the larger TGF-β super-family of ligands (for review see Airaksinen et al., 2006), it was decided to investigate the ability of NA to induce the classical member of this family, TGF-β1. FGF-2 has been shown to be one of the most potent trophic factors for inducing neuritic outgrowth of primary neurons (Patel & McNamara, 1995), and thus was also selected. Similarly, VEGF, CNTF and IGF-1 have also been shown to induce neuritic outgrowth (Niblock et al., 2000; Khaibullina et al., 2004; Leibinger et al., 2009). The cytokines, IL-6 and IL-10 have known roles in attenuating inflammation (for review, see Opal & DePalo, 2000), and as NA is an anti-
inflammatory agent (for review, see Marien et al., 2004), they were therefore selected based on potential novel roles in neuronal protection.

Both NA and the β-adrenoceptor agonist, Salb, were shown to increase the mRNA expression of GDNF, NGF-β, BDNF, IL-6, VEGF and FGF-2. There was no effect on NT4/5, TGF-β1, CNTF or IL-10, and the expression of IGF-1 and NT3 were reduced. Therefore, GDNF, NGF-β, BDNF, IL-6, VEGF and FGF-2 were all further assessed for their ability to induce morphological changes in primary cortical neurons, in addition to neutralisation of signalling by antibodies, and for the ability of NA to stimulate their secretion from glial cells.

4.7.1 GDNF contributes to the NA CM increases in neuronal complexity

GDNF treatment (1, 5, 10ng/ml) of primary cortical neurons for 24h increased the number of primary neurites, the number of neuritic branches, the neuritic length and the Sholl profile of the neurons. Furthermore, neutralisation of GDNF from NA CM by a GDNF neutralising antibody (nAB) attenuated NA CM-induced increases in neuritic length, but not primary neurites or neuritic branches. The GDNF nAB attenuated the NA CM-induced increase in the Sholl profile at 15μm from the cell soma only. Additionally, NA stimulation increased the release of GDNF from primary glial cells. It is of interest to point out that this is the first time that NA has been demonstrated to increase both the mRNA production of GDNF and to stimulate GDNF release from glial cells.

The results presented in this thesis are in line with many other studies in the literature which have demonstrated the ability of GDNF to induce increases in neuritic length. For example, cortical dopaminergic neurons show increased neuritic length which is associated with the interaction of GDNF with the NCAM receptor (Chao et al., 2003; Cao et al., 2008). Furthermore, GDNF is able to increase the neuritic length of hippocampal and cortical neurons which is also dependent on the NCAM and not RET receptor (Paratcha et al., 2003; Nielsen et al., 2009). In addition to this, the ability of GDNF to induce increases in neuritic length is associated with the activation of the PI3K pathway, as knockdown of this pathway via LY294002 inhibits GDNF-induced neuritic growth (Ditlevsen et al., 2003). In line with this, the present study demonstrated that a direct treatment of GDNF induced increases in neuritic length and that the nAB reduced NA CM-induced increases in neuritic length.
However, the ability of GDNF to induce neuritic branching is more complex. Even in the present study, direct GDNF treatment induced neuritic branching, but the nAB failed to attenuate NA CM-induced neuritic branching. There are two important points to note regarding this result. Firstly, the NA CM contains many growth factors which are capable of inducing neuritic branching of primary cortical neurons. The inhibition of GDNF in the CM therefore must not be sufficient to inhibit NA CM-induced neuritic growth, due to redundancy of other factors. Secondly, the GDNF concentration released by NA stimulation of glial cells equalled to 40pg/ml, which is several fold lower than the lowest direct treatment of GDNF (1ng/ml). Interestingly, a study has shown that GDNF demonstrates two bell-shaped curves in its ability to induce neuritic lengthening of dopaminergic neurons. At the lower end, 50pg/ml showed a maximum induction of neuritic growth, while at the higher end, 0.5 to 10ng/ml showed maximum neuritic growth (Costantini & Isacson, 2000). Higher concentrations of GDNF (10ng/ml) which were utilised in the present study have also been shown to induce increases in both neuritic length and neuritic branching of primary serotonergic neurons (Ducray et al., 2006). Thus higher concentrations of GDNF may stimulate neuritic branching, but the lower concentration contained in NA CM may only be sufficient to induce an increase in neuritic length.

4.7.2 The presence of the neurotrophins; NGF-β and BDNF, are required for NA CM-induced increases in neuronal complexity

In the present study, NGF-β administration to primary cortical neurons increased the number of primary neurites extending from the cell soma, the number of neuritic branches and the neuritic length of the neurons. All doses investigated showed increases in the Sholl profile compared to control treated neurons. BDNF administration to primary cortical neurons also increased the number of primary neurites extending from the cell soma, the number of neuritic branches (5ng/ml only) and the neuritic length of the neurons. All doses investigated showed increases in the Sholl profile compared to control treated neurons. Inhibition of neurotrophin signalling via the neurotrophin antagonist, Y1036, attenuated the ability of NA CM to induce increases in neuronal morphology; however, although NA increased mRNA expression of both NGF-β and BDNF in glial cells, it did not stimulate an increase in their release, with BDNF protein completely undetected in the CM.
The ability of direct treatments with both NGF-β and BDNF to increase neuritic morphology of the primary cortical neurons in this thesis is not surprising. The ability of NGF-β to induce neuritic growth is so well known that it is now routinely used to induce a neuritic phenotype in PC12 cells by stimulating neuritic outgrowth and neuritic lengthening (Greene & Tischler, 1976). Similarly there is a huge wealth of literature on the ability of BDNF to induce neuritic growth in neurons (for review, see Cohen-Cory et al., 2010).

There is also much literature on the ability of NGF-β treatment to induce neuritic lengthening from primary neurons. For example, treatment of primary cortical neurons with 50ng/ml NGF-β for one week, produces neurons with increased neuritic length compared to control neurons (Lee et al., 2009c). Furthermore, rat hippocampal neurons showed increased neurite outgrowth upon stimulation with NGF-β (Brann et al., 1999). NGF-β is also associated with increased neuritic branching; localised addition of NGF-β onto primary chick dorsal root ganglion cells by the addition of NGF-β coated beads, induced collateral branching at the site of the bead (Gallo & Letoumeau, 1998). In addition, NGF-β has been utilised to encourage re-growth following neuronal injury. For example, NGF-β treatment increases neuritic sprouting and innervation in the dentate gyrus following injury to the entorhinal cortex of the rat hippocampus. Indeed, use of NGF-β antibodies inhibits neuronal re-growth following injury (Van der Zee et al., 1992).

Similarly, BDNF has been shown to increase neuritic length (Segal et al., 1995) and neuritic branching (Horch & Katz, 2002) of primary neurons. Real-time imaging studies have also demonstrated that BDNF increases axonal length and branching in vivo (Alsina et al., 2001), and axonal branching is significantly reduced in trigeminal neurons in BDNF knockdown in Xenopus (for review, see Cohen-Cory et al., 2010). Furthermore, BDNF is involved in dendritic spine motility, important for creating functional networks during development (Luikart et al., 2008). Furthermore, Eps8 has been shown to negatively regulate axonal branching, and this is inactivated by BDNF-induced MAPK signalling (Ketschek et al., 2011).

Stimulation of neuritic growth by NGF-β and BDNF has been primarily attributed to the PI3K pathway (Jackson et al., 1996; Gallo & Letourneau, 1998; Ketschek & Gallo, 2010), MAPK pathway (Dijkhuizen & Ghosh, 2005) and activation of NFκB (Foehr et al., 2000). Activation of the PI3K pathway by these neurotrophins increases the spontaneous
formation of F-actin patches along an axon. NGF-β increases the concentration of F-actin patches along an axon, while BDNF increases the likelihood that this patch will turn into a functional filopodia (Ketschek & Gallo, 2010; Ketschek et al., 2011). Furthermore, inhibition of PI3K signalling by wortmannin and LY294002 attenuated NGF-β-induced increases in axon collateral formation (Gallo & Letourneau, 1998). Activation of NFκB by NGF-β, although associated with neuritic outgrowth, is however not sufficient to induce growth alone (Foehr et al., 2000). NGF-β-induced increases in axonal growth via TrkA in sympathetic neurons have been attributed to the downstream activation of the phosphatase calcineurin, and subsequent activation by dephosphorylation, of dynamin, resulting in axonal growth (Bodmer et al., 2011).

In the present set of studies, inhibition of Trk signalling via the neurotrophin antagonist inhibited NA CM-induced increases in neuronal morphology, even though NA did not increase the release of BDNF or NGF-β from the glial cells. NGF-β however is present in the CM and therefore would be expected to bind to the TrkB receptor on neurons and thus lead to downstream signalling. Furthermore, this antagonist would prevent any endogenous BDNF from the neurons themselves binding to TrkA. A study by Jin et al (2003) investigated the dendritic growth of cortical neurons in slice culture by BDNF. In their studies, blockade of BDNF in control cultures by a neutralising antibody for 5 days significantly reduced the levels of dendritic branching, demonstrating that endogenous BDNF is important for the ongoing growth of cortical neurons (Jin et al., 2003). Similarly, blockade of TrkA for 36h by a neutralising antibody reduced dendritic complexity of cortical pyramidal neurons compared to control neurons again demonstrating the importance of endogenous BDNF for neuronal growth (McAllister et al., 1997). It can therefore be hypothesised that BDNF is present in the neuronal media and that blockade of BDNF signalling is sufficient to down-regulate any beneficial consequences of NA CM-induced signalling. It is also of interest to note that astrocyte-derived BDNF has been attributed to neuronal degeneration (Colombo et al., 2012). BDNF treatment of astrocytes leads to a CM which reduces neuritic branching and neuritic length of primary neurons via nitric oxide release (Colombo et al., 2012). Furthermore, the importance of NGF-β in stimulating neuritic growth suggests that the NGF-β already present in the CM would in some part contribute to NA CM-induced increases in neuritic complexity. With this in mind, inhibition of Trk signalling via the neurotrophin antagonist demonstrates that the
presence of at least NGF-β, if not also BDNF, are necessary for NA CM to induce neuritic growth.

4.7.3 FGF-2 contributes to NA CM-induced increases in neuronal complexity

In the present study, FGF-2 administration to primary cortical neurons increased the number of primary neurites extending from the cell soma, the number of neuritic branches and the neuritic length of the neurons. All doses investigated showed increases in the Sholl profile compared to control treated neurons. Neutralisation of FGF-2 in the CM by a neutralising antibody to FGF-2 attenuated the ability of NA CM to induce increases in the number of primary neurites and neuritic length but not neuritic branches. Furthermore, NA increased the release of FGF-2 from glial cells.

The literature shows that FGF-2 has previously been shown to be associated with neuronal growth. An early study by Walicke et al demonstrated that FGF-2 bound to a heparin substrate significantly increased both survival and neurite outgrowth of primary hippocampal neurons (Walicke et al., 1986). CM from astrocytes grown on an FGF-2 cross-linked nanofibre matrices for 48h led to a significant increase in neuronal growth compared to CM from astrocytes grown on plastic, which was attributed to be as a result of FGF-2 inducing its own secretion from the astrocytes (Delgado-Rivera et al., 2009). Hippocampal neurons incubated with FGF-2 were shown to increase axonal branching and branch growth, but not to affect primary axon growth compared to control neurons (Aoyagi et al., 1994). The present work did not distinguish between dendrites and axons, however it is demonstrated here that FGF-2 in the same dose range (1-10ng/ml) increases neuritic growth for primary cortical neurons. Similarly, dentate gyrus neurons treated with FGF-2 showed a significant increase in the number of neuritic branches per axon, while dendritic branching was not affected (Patel & McNamara, 1995). Other papers have also shown similar results (Szebenyi et al., 2001). It would be interesting to distinguish in the present work if dendrites versus axons are differentially affected by addition of FGF-2.

A study by Abe et al (2001) demonstrated that the MAPK pathway is required for FGF-2-induced neuritic growth of primary cortical neurons. Primary rat hippocampal neurons demonstrated significant increases in the number of branch points per axon following FGF-2 exposure for 24h. This increase was attenuated by use of the MEK inhibitors U0126 and PD98059. FGF-2-induced ERK phosphorylation was shown to not be inhibited
by wortmannin or a protein kinase C inhibitor, however, unfortunately this study did not investigate if these inhibitors could attenuate the FGF-2-induced increases in neuritic branching (Abe et al., 2001). Similarly, chick ciliary ganglion neurons demonstrate increases in neuritic growth upon FGF-2 exposure which was dependent on the PI3K and MAPK pathway, as well as the phospholipase C pathway (Gilardino et al., 2009). Furthermore the microtubule inhibitors taxol and colchicine, significantly attenuated FGF-2-induced increases in neuronal branching of primary hippocampal neurons, demonstrating that microtubule polymerisation is required for FGF-2-induced neuritic branching (Aoyagi et al., 1995). In the present work therefore, it is likely that FGF-2 present in the NA CM signals via both the PI3K and the MAPK pathways to contribute to the neuritic growth of the primary cortical neurons. Inhibition of FGF-2 signalling via the neutralising antibody failed to attenuate NA CM-induced neuritic branching, and this may be attributed to other factors in the CM.

4.7.4 VEGF does not contribute to the NA CM-induced increases in neuronal complexity

In the present study, VEGF (1-10ng/ml) did not lead to any morphological changes in the primary cortical neurons. A study by Khaibullina et al (2004) also using primary rat cortical neurons however, found that treatment with VEGF did in fact lead to increases in neuritic length. There are many differences between this study and the study reported in this thesis. Firstly the neurons in the study in this thesis were treated for 24h only with VEGF, while Khaibullina et al treated the primary neuronal cells for the duration of their culture life, totalling 3 days. Also, in this thesis, measurements of neuronal morphology were strictly only calculated in isolated neurons to minimise the confounding effects of cell-cell contact in inducing neuritic growth and thus to only examine the effects of soluble mediators present in the cellular medium. However, Khaibullina et al did not make this exclusion (Khaibullina et al., 2004). It is therefore possible that VEGF assists in the induction of neuronal growth but perhaps is not sufficient to do so alone. A similar study by the same research group found that treatment of cortical explants for 3 days with VEGF (25 – 100ng/ml) increased expression of the microtubule protein MAP-2, and increased neuritic growth which was dependent on the VEGF receptor VEGFR2 and the downstream pathways of MAPK and PI3K (Rosenstein et al., 2003). Again, this study used a much higher dose of VEGF for three times the duration of the present studies.
Direct treatment of primary cortical neurons with VEGF (1-10ng/ml) in this thesis did not lead to any gross morphological changes in the neurons as measured by primary neurite number, number of neuritic branches or neuritic length. However, VEGF did lead to increases in the Sholl profile compared to control neurons. This therefore demonstrates that VEGF must be interacting with its respective receptors on the cortical neurons and activating pathways to induce subtle changes in the morphology of the neurons. It is therefore feasible that a higher dose of VEGF as used in the above discussed studies could lead to more gross morphological changes. It is also possible that VEGF, which is present in both control and NA CM, could be contributing to NA CM-induced neuritic growth.

4.7.5 IL-6 is required for the NA CM-induced increases in neuronal complexity

In the present study, IL-6 administration to primary cortical neurons increased the number of neuritic branches and the neuritic length of the neurons, but failed to increase the number of primary neurites extending from the cell soma. All doses (1-10ng/ml) investigated showed increases in the Sholl profile compared to control treated neurons. Inhibition of IL-6 signalling via blockade of the IL-6 receptor by an antibody attenuated the ability of NA CM to induce increases in the neuritic branches and neuritic length. Furthermore, NA increased the release of IL-6 from glial cells.

Cytokines are more commonly associated with neuronal degeneration and thus there is only limited evidence of the ability of IL-6 to induce neuritic growth in neurons. Interestingly however, a sub-clone of PC12 cells, E2 cells, but not the native PC12 cells induce the formation of neurites following IL-6 stimulation in a similar manner to NGF-β stimulation, and this occurred via the JAK-STAT pathway (Wu & Bradshaw, 1996). This difference between clones of PC12 cells might be attributed to the expression of the IL-6 receptor and gp130 (Marz et al., 1997). IL-6 has also been shown to induce neuritic growth from primary cortical neurons; IL-6 treatment for 1-3 days increased the primary neuritic length, the number of primary neurites and neuritic branching from rat hippocampal neurons (Sarder et al., 1996). Further to this, IL-6 has been shown to have neuroregenerative properties. Blockade of IL-6 with a neutralising antibody completely inhibited re-growth of transected hippocampal slices and reduced GAP-43 expression, while exogenous IL-6 enhanced neuronal recovery and promoted axonal sprouting (Hakkoum et al., 2007). IL-6 has also been shown to protect spinal motor neurons from axotomy-induced cell death (Ikeda et al., 1996).
IL-6 has previously been shown to be induced by NA in astrocytes. In the study by Norris et al., primary rat astrocytes maximally produced IL-6 in response to 10 μM NA, the same concentration used here. In addition, microglial cells did not induce IL-6 upon NA exposure, and the effect on astrocytes was attributed primarily to the β2-adrenoceptor via cAMP expression (Norris & Benveniste, 1993).

Research into how IL-6 might be leading to neuritic growth is limited. However, IL-6 via STAT3, can lead to the transcription of RhoU, an atypical Rho GTPase which is associated with the actin cytoskeleton and can trigger filopodia formation (Schiavone et al., 2009), and thus could lead to increased neuritic branching. In addition to this, the IL-6 receptor can also lead to the activation of both the PI3K and the MAPK pathway (Heinrich et al., 2003), both of which are associated with neuritic growth.

4.7.6 Cross-talk between the neuritic growth-inducing factors

The ability of each trophic factor to induce neuronal morphological changes was investigated in isolation in the present study. However, the NA CM contains a combination of NGF-β, IL-6, FGF-2, GDNF and VEGF and potentially many more trophic factors which were not investigated here. Interactions between the above mentioned trophic factors therefore are more than likely contributing to the ability of NA CM to induce neuritic growth.

RET, the GDNF receptor, can also be activated by NGF-β in sympathetic neurons. NGF-β activated phosphorylation of the RET receptor, which was completely abolised by a TrkA antagonist, showing it to be TrkA dependent (Tsui-Pierchala et al., 2002). Furthermore NGF-β is also capable of activating STAT3, which is more commonly associated with IL-6. However, NGF-β activation of STAT3 does not result in the regular tyrosine-phosphorylated STAT3, instead, NGF-β stimulation of both the sympathetic neuronal-like PC12 cells and primary cortical neurons led to the phosphorylation of a serine residue (serine\textsuperscript{727}) on STAT3 but not the phosphorylation of tyrosine\textsuperscript{705}. Additionally, this phosphoSTAT3 was located in the mitochondria, and was essential for NGF-β-induced neurite outgrowth of the PC12 cells. It is believed that NGF-β-induced STAT3 phosphorylation occurs via the MAPK and the tyrosine kinase Src pathways (Zhou & Too, 2011). Thus although NA does not increase the concentration of NGF-β released from the glial cells, the very presence of NGF-β in the CM can enhance

194
signalling for both GDNF and IL-6, both of which are increased by NA. Indeed, administration of both NGF-β and GDNF to peripheral dorsal root ganglion neurons resulted in increased axonal outgrowth as compared to either treatment alone (Madduri et al., 2009). Similarly, NGF-β and IL-6 show synergistic neuronal survival abilities when co-treated to primary cholinergic neurons (Hama et al., 1989). NGF-β might also enhance FGF-2-induced signalling. For example, primary olfactory neuroepithelium show an increase in neuritic growth when stimulated with a combination of IL-1β, IL-6, NGF-β and FGF-2. The authors used many other combinations, and trophic factors alone, none of which significantly increased neuritic growth (Vawter et al., 1996). Although IL-1β was not investigated in the present study, it is interesting that a combination of IL-6, NGF-β and FGF-2 were required for this enhancement of neuritic growth.

Many trophic factors can induce their own and other trophic factor expression and release from cells. For example, BDNF can stimulate its own release from hippocampal neurons in culture, an action which is Trk-dependent (Canossa et al., 1997). FGF-2 on the other hand can increase GDNF mRNA in C6 cells (Suter-Cazzolara & Unsicker, 1996) and can increase both the mRNA (Vige et al., 1991) and the secretion of NGF-β from primary astrocytes in culture (Fukumoto et al., 1991). The ability of FGF-2 to protect primary hippocampal neurons from glutamate toxicity has also been attributed to GDNF release by the neurons upon FGF-2 stimulation, and neutralisation of GDNF in the culture abolished FGF-2 mediated protection (Lenhard et al., 2002). Additionally, GDNF has also been shown to induce the expression of FGF-2 from glial cells which was dependent on the MAPK pathway (Hauck et al., 2006). A study by Drago et al discovered that blockage of IGF-1 by a neutralising antibody inhibited the ability of FGF-2 to induce neurogenesis of neuroepithelial cells (Drago et al., 1991).

From these studies it is obvious that trophic factors often synergise and combine to create downstream effects. Often the abilities of one trophic factor rely on the presence of another. Thus in the present study, it is interesting that inhibition of any of the factors by antibody neutralisation, or via Y1036 attenuated to some degree the NA CM-induced increases in neuritic growth. It is clear that the neurons require the synergism of the combination of factors to grow in response to the CM. Interestingly, a combined therapy of artificially increasing cAMP along with the introduction of the neurotrophin, NT-3, led to a significant recovery of spinal cord neurons into lesion sites compared to control or either treatment alone (Lu et al., 2004). As NA, and specifically activation of the β2-
adrenoceptor, leads to the production of growth factors involved in neuritic growth and an increase in intracellular cAMP, this could be an exciting candidate for neuronal regeneration.

4.8 Signalling Pathways involved in NA CM-induced increases in neuronal morphology

As the previous results have demonstrated, NA stimulates the release of GDNF, IL-6 and FGF-2 from the glial cells. Furthermore, these factors, in addition with neurotrophin signalling, contribute to NA CM-induced neuritic growth. These growth factors primarily signal via the PI3K, the MAPK and the STAT3 pathways, therefore the contribution of these pathways to NA CM-induced neuritic growth was investigated.

4.8.1 The PI3K pathway is involved in NA CM-induced increases in neuronal morphology

In the present set of studies, the ability of NA to induce neuritic growth via the PI3K, the MAPK/ERK and the STAT3 pathways were investigated. NA CM induced AKT phosphorylation in the primary cortical neurons. Furthermore, use of the PI3K inhibitors, wortmannin and LY294002 attenuated NA CM-induced increases in the number of primary neurites, number of neuritic branches and the neuritic length. Both wortmannin and LY294002 also attenuated all NA CM-induced increases in the Sholl profile at 5-45μm from the cell soma.

In general, the PI3K pathway is activated when the PI3K enzyme is recruited to phosphorylated residues, usually on activated receptor tyrosine kinases. PIP3 is then formed which recruits and leads to the phosphorylation of AKT, protein kinase C and the GTPase Rac. Activation of this pathway can occur in response to many stimuli, including NGF-β, GDNF, IL-6 and FGF-2 exposure (Takahashi, 2001; Chao, 2003; Heinrich et al., 2003; Bottcher & Niehrs, 2005).

The substrate for wortmannin, a fungal metabolite, was first identified as the PI3K enzyme in 1993 (Arcaro & Wymann, 1993). LY294002, derived from a bioflavinoid, was soon after also identified as a specific inhibitor of PI3K (Vlahos et al., 1994). Both wortmannin and LY294002 are commonly used tools for inhibiting the PI3K pathway; however, they are not as specific as first identified. LY294002 has been shown to not only inhibit PI3K,
but other kinases as well such as DNA-dependent protein kinase, casein kinase 2 and Pim-1. It might also inhibit Ca\textsuperscript{2+} signalling, the NF\kappa B pathway, the activation of casein kinase 2 (CK2), GSK3\beta (Gharbi et al., 2007), and also the mammalian target of rapamycin (mTOR) (Brunn et al., 1996; Davies et al., 2000). Wortmannin can also inhibit the myosin light chain kinase but does not inhibit CK2. (Davies et al., 2000). Regardless of these facts, both remain useful molecular tools for inhibiting the PI3K pathway.

The induction of a neuronal phenotype by NGF-β in PC12 cells has proved instrumental in unravelling the role of the PI3K pathway in the formation and elongation of neurites. For example, soon after the specific inhibition on PI3K was discovered, wortmannin was identified as completely attenuating NGF-β-induced neuritic growth in PC12 cells, cementing the key role of this pathway in neuritic growth (Kimura et al., 1994). Since then, PI3K has been associated with both the initiation (Jackson et al., 1996) and the elongation (Kobayashi et al., 1997) of NGF-β-induced neuritic growth in PC12 cells.

The importance of the PI3K pathway in neuritic growth has also been demonstrated in primary neurons. For example, PI3K induces increases in neuritic length of primary sympathetic neurons (Atwal et al., 2000) and PI3K signalling via NGF-β coated beads induced collateral branching in primary dorsal root ganglion cells (Gallo & Letourneau, 1998). In addition, the formation of F-actin patches, precursors to neuritic branches, require PI3K signalling (Ketschek & Gallo, 2010; Ketschek et al., 2011). Indeed, the pharmacological increase of PI-3K activity increased the concentration of F-actin patches in primary sensory neurons (Ketschek & Gallo, 2010). PI3K is also involved in spine motility which is important for creating functional networks during development (Luikart et al., 2008). Furthermore, primary hippocampal neurons show increased dendritic branching and primary dendrites upon over-expression of PI3K and AKT. This also increased the dendritic length and the number of filopodia-like protrusions. Furthermore, inhibition of PI3K or AKT significantly reduced the dendritic length and the number of filopodia-like protrusions (Kumar et al., 2005).

A major downstream function of phosphorylated AKT is in the inactivation of GSK3β. GSK3β is a serine/threonine kinase with a high basal activity in resting cells which is involved in many neuronal processes including neurogenesis, neuronal migration, neuronal polarisation, axonal growth and axon guidance. GSK3β has a huge amount of substrates including CREB, the nuclear factor of activated T cells (NFAT) family,
SMAD1, c-Jun, β-catenin and regulates the activity of microtubules (for review, see Hur & Zhou, 2010). There is a vast amount of evidence linking the inactivation of GSK3β to neuronal growth; global inhibition of GSK3β induces the formation of multiple axons while over-expression prevents axonal development in neurons (Yoshimura et al., 2005; Hur & Zhou, 2010). Furthermore local inactivation of GSK3β can convert dendrites into axons (Jiang et al., 2005). GSK3β also activates many substrates involved in microtubule dynamics, such as collapsing response mediator protein 2, adenomatous polyposis coli, Tau and MAP1B. Overall, the inactivation of GSK results in the stabilisation of growing microtubules and promotion of microtubule assembly (for review, see Hur & Zhou, 2010). In addition to inactivation of GSK3β, phosphorylated AKT can also activate a number of proteins which interact directly with the growing neurite (for excellent review see Read & Gorman, 2009). Another major target of the PI3K pathway is the Rho GTPases. These are family of guanine nucleotide binding proteins which switch between the active GTP-bound and the inactive GDP-bound state, facilitated by guanine nucleotide exchange factors. In particular the RhoA, Rac1 and Cdc42 members of the family have been associated with neuritic growth as they have functions in modulating the actin cytoskeleton, membrane trafficking, microtubule dynamics and transcriptional activity (for excellent review see Govek et al., 2005).

Thus there is overwhelming evidence that the PI3K pathway, in particular the downstream phosphorylation of AKT, is involved in neuritic growth. Also, as the factors secreted by NA have been shown to induce PI3K signalling (Takahashi, 2001; Chao, 2003; Heinrich et al., 2003; Bottcher & Niehrs, 2005), it comes as no surprise that NA CM both induced phosphorylation of AKT and that knock-down of PI3K signalling via both LY294002 and wortmannin was capable of blocking NA CM-induced neuritic growth.

4.8.2 The MAPK pathway is involved in NA CM-induced increases in neuronal morphology

NA CM induced ERK1/2 phosphorylation in the primary cortical neurons. Furthermore, use of the MEK inhibitor PD98059 attenuated NA CM-induced increases in the number of primary neurites, number of neuritic branches and the neuritic length. PD98059 also attenuated all NA CM-induced increases in the Sholl profile.
The MAPK/ERK pathway is commonly activated upon phosphorylation of an activated tyrosine kinase receptor, the subsequent activation of Ras and the ultimate activation of ERK1/2. The ERK1/2 pathway has been shown to be activated upon stimulation with NGF-β, GDNF, IL-6 and FGF-2 (Airaksinen et al., 1999; Heinrich et al., 2003; Reuss & von Bohlen und Halbach, 2003; Obara & Nakahata, 2010).

PD98059 was originally identified as a highly specific inhibitor of MEK activation by Raf or MEK kinase (Alessi et al., 1995), however since then it has been found to also interfere directly with arachidonic acid metabolism via the inhibition of cyclooxygenases (Borsch-Haubold et al., 1998). PD98059 has also been shown to inhibit both the activation of ERK1/2 and of ERK5 (which is activated by MKK5). (Davies et al., 2000). However, Davies et al (2000) did show that PD98059 was quite specific in inhibiting the MAPK pathway and did not inhibit the activation of any other protein kinase within its recommended concentration range (Davies et al., 2000). PD98059 therefore remains a widely used tool for inhibiting the ERK1/2 pathway.

Again the NGF-β-induced neuritic growth of PC12 cells has proved instrumental in discovering the role of the MAPK pathway in encouraging neuritic growth. Early studies demonstrated that although both NGF-β and EGF resulted in activation of the ERK1/2 pathway, only NGF-β resulted in sustained activation of the pathway. As NGF-β and not EGR results in neuritic growth of PC12 cells, sustained activity of ERK1/2 appears to be essential (Traverse et al., 1992). Later studies consolidated the role of ERK1/2 activation in PC12 neuritic growth, as increases in constitutive activity of the MAPK pathway induced neuritic growth and inhibition of the pathway blocked NGF-β-induced growth (Cowley et al., 1994). Utilisation of the MEK inhibitor, PD98059, exploited in the present study, was also shown to significantly reduce neurite outgrowth in PC12 cells stimulated with NGF-β (Ihara et al., 1997; Sole et al., 2004).

Leading on from studies in PC12 cells, primary neurons were also shown to be dependent on the MAPK pathway for neuritic growth. The MAPK, ERK1/2 branch is involved in increasing neuritic length of primary sympathetic neurons (Atwal et al., 2000). Furthermore, the ability of FGF-2, laminin and N-cadherin to induce neuritic outgrowth of primary embryonic chick retinal neurons all require the ERK1/2 branch of MAPK signalling (Perron & Bixby, 1999). In addition, primary rat hippocampal neurons, showed a low basal level or ERK phosphorylation. Inhibition of this basal activity by U0126 did
not show any changes in neuronal morphology. However, inhibition of FGF-2-induced MAPK activity significantly attenuated FGF-2 mediated neuritic branching, thus suggesting that a threshold level of MAPK activity is required for inducing changes in neuronal morphology (Abe et al., 2001). Furthermore, activation stimulated neuritic growth of primary cortical neurons can be inhibited by the MEK inhibitor U0126 (Redmond et al., 2002). Similarly, induction of neuritic outgrowth of again primary cortical neurons by a plant extract could also be prevented upon ERK inhibition by U0126 but not via a JNK or p38 inhibitor (Lee et al., 2009c).

From the results reported within this thesis and the evidence above, it is clear that the MAPK pathway is essential for mediating neuritic growth of both neuronal cell lines and primary cortical neurons. However, how is activation of the MAPK pathway leading to these changes? Both CaM kinase IV and CREB-mediated gene expression are associated with the induction of dendritic complexity, and there are reports which suggest that ERK1/2 might take advantage of this pathway to induce neuritic growth (Redmond et al., 2002). MAPK signalling is also known to directly phosphorylate microtubules associated with neuronal growth (Veeranna et al., 1998). Activation of the MAPK pathway has also been shown to up-regulate the emergence of active filopodia from actin patches (for review, see Gallo, 2011).

4.8.3 The STAT3 pathway is involved in NA CM-induced increases in neuronal morphology

NA CM induced STAT3 phosphorylation in the primary cortical neurons. Use of the STAT3 inhibitor, S31-201, attenuated the NA CM-induced increases in the number of primary neurites, the number of neuritic branches and the neuritic length of the primary cortical neurons. S31-201 also attenuated all NA CM-induced increases in the Sholl profile.

The STAT-3 pathway is commonly associated with IL-6 signalling whereby phosphorylation of the gp130 molecules leads to the recruitment of Jaks and thus the phosphorylation, dimerisation and activation of STAT3 proteins which translocate to the nucleus and activate gene transcription (for review, see Spooren et al., 2011). However, NGF-β can also lead to the activation of STAT3 (Zhou & Too, 2011). Furthermore, there is limited evidence that FGF-2 stimulation can lead to the activation of the STAT3
pathway (Yoshimatsu et al., 2006) there is however little/no evidence that GDNF can activate this pathway. In the present thesis, STAT3 signalling is likely to be induced primarily via the induction of IL-6 by the glial cells.

The STAT3 inhibitor, S31-201, utilised in this study has been shown to selectively inhibit the DNA binding activity of STAT3 and thus to prevent any transcriptional activity (Siddiquee et al., 2007).

Evidence in the literature that the STAT3 pathway is important for neuritic growth is limited compared to for PI3K and for the MAPK pathways. For example, inhibition of STAT3 activity by use of a dominant negative mutant completely abolished neurite outgrowth of Neuro-2A cells by stimulation with a cannabinoid agonist (He et al., 2005). This parallels the results seen in the present thesis, whereby NA CM-induced increases in neuritic morphology were completely abolished by S31-201. S31-201 alone did not significantly reduce neuritic branching or length of control CM-treated neurons, thus demonstrating that the induction of STAT3 phosphorylation by NA CM is essential for NA CM-induced increases in neuronal morphology, but prevention of STAT3 signalling does not actively prune away existing branches, or interfere with basal levels of neuritic growth. Similar results were found by knocking down STATS for serotonin-induced neuritic outgrowth of Neuro-2A cells (Fricker et al., 2005).

The ability of the STAT3 pathway to modify neuronal morphology may be related to the ability of STAT3 to bind to stathmin, a microtubule binding protein; and the promotion of microtubule formation by STAT3 (Verma et al., 2009). In addition to this, activation of Jak-STAT signalling can often lead to the activation of the PI3K and the MAPK pathway (Heinrich et al., 2003).

4.8.4 Cross-talk between the PI3K, MAPK and STAT3 Pathways

There is evidence in the literature concerning cross-talk between the three pathways investigated here. For example, over-expression of Ras, upstream of ERK1/2, leads to increases in dendritic length and filopodia, and inhibition of MEK via U0126, or PI3K via LY294002 blocked the ability of Ras to induce the dendritic changes, thus suggesting that Ras is essential in dendritic complexity formation and utilised both pathways for this ability (Kumar et al., 2005). Furthermore, a study by Jang et al (2009) demonstrated that blockade of the PI3K pathway via LY294002 and wortmannin as well as blockade of the
MEK pathway via PD98059 inhibited the NGF-β-induced increases in neurite outgrowth of PC12 cells. (Jang et al., 2009). Moreover, activation of the MAPK pathway has been shown to result in the serine phosphorylation of STAT3 via ERK1/2, JNK and the p38 branch (for review, see Bowman et al., 2000). Fricker et al show that 5-HT-induced neuritogenesis is dependent on all three of these pathways; PI-3K, MAPK and STAT3 (Fricker et al., 2005). Lastly, a very insightful study by Liu et al (2001) showed that inhibition of the PI3K and the ERK1/2 pathway inhibited axonal outgrowth from control and NGF-β stimulated primary sensory embryonic neurons, while inhibition of the STAT pathway via JAK inhibition had no effect on axonal growth. However, using lesion-conditioned adult sensory neurons, (neurons which had been lesioned prior to culture preparation), inhibition of the PI3K and the ERK1/2 pathway was shown to have no effect on the regenerative potential of the neurons, but inhibition of the JAK pathway completely abolished the regenerative ability of the neurons. This was in concert with a large induction of STAT3 phosphorylation upon regeneration (Liu & Snider, 2001). This therefore demonstrates that each pathway has important but different roles in neuritic growth. In the present thesis, inhibition of any of the three pathways led to an attenuation of NA CM-induced neuritic growth. The growth factors which mediate the NA CM-induced neuritic growth can activate some if not all of the three pathways demonstrated in this thesis to be involved in NA CM-induced neuritic growth. As there is cross-talk between the growth factors and between the signalling pathways, it can be theorised that a threshold of signalling activation is required prior to neuritic growth.

4.9 The induction of neuritic growth; the answer to neuronal degeneration?

The inability of neurons to regenerate following brain trauma, infection, neuronal degenerative disorders or stroke underlies one of the most crucial medical challenges of our time. Perhaps then, understanding the mechanisms involved in encouraging neuritic growth can lead us closer to a cure for the above mentioned conditions.

Neuritic growth is associated with learning and memory, and thus perhaps encouragement of neuritic growth could ameliorate the symptoms associated with Alzheimer’s disease (for review, see Holtmaat & Svoboda, 2009). Further to this, neuritic growth could prove beneficial for other conditions. Schizophrenia, for example, is associated with a down-regulation of AKT and many other molecules associated with neuritic growth e.g. GSK3β, Wnt and Gap-43 to name but a few. This has led to a neurite patho-physiological model of
schizophrenia, in which abnormal neuritic pruning leads to the symptoms associated with the pathology. This abnormal pruning may also account for the most consistent findings in schizophrenia, that of reduced brain volume and ventricular enlargement (for review, see Emamian et al., 2004; Bellon et al., 2011). The study of the association of neurotrophins with schizophrenia and their possibility as a viable therapeutic is ongoing. It is also interesting to note that lesion sites in the CNS show signs of growth cone advancement but are inhibited by the non-permissive environment, primarily created by astrocytes (for review, see Fitch & Silver, 2008). Stimulation of astrocytes to encourage a growth-permitting environment is therefore essential for neuronal regeneration.

However, although neuritic growth might prove beneficial in some circumstances, neuritic growth can also be harmful. In the injured spinal cord, spontaneous formation of neuritic collaterals due to increased concentrations of neurotrophic factors is associated with pain, autonomic dysreflexia (overactivation of the sympathetic nervous system which can be life-threatening) and bladder dyssynergia. Indeed, blocking the function of NGF-β in spinal cord injury models can reduce these symptoms (for review, see Hagg, 2006). Furthermore, dysregulation of the FGF system is associated with juvenile spinal muscular atrophy (SMA), a monogenetic disease characterised by motoneuron loss in the spinal cord. A mouse model of SMA showed increased FGFRs in the mouse spinal cord which was associated with hyper-phosphorylation of both AKT and ERK1/2 (Hensel et al., 2012). Thus the induction of neuritic growth, although might prove beneficial, needs to be highly regulated. Regardless of this, understanding the underlying mechanisms is important for the advancement of neuronal regeneration research.
4.10 Research Limitations and Future Directions

The results presented in this thesis are based on the ability of NA CM to induce neuritic growth via soluble mediators released by glial cells. To that end, neurons growing in isolation and not in contact with any other neuron were studied. It is important to note that all neurons in vivo are retained in a network, and thus have many additional signals through electrical activity and cell-contact to the soluble mediators investigated here. To address this issue, one could investigate the ability of NA CM to induce neuronal changes in a network, by analysing neuritic density in vitro. Additionally, live-cell imaging could be utilised to examine ongoing neuritic growth.

All structural changes in this thesis were examined via βIII-tubulin staining, thus the preliminary changes that occur upon the initiation of growth cone advancement or neuritic branching via actin was not visualised. All positive staining with βIII-tubulin represent filopodium that have already been invaded by neuronal microtubules, therefore it could be interesting to investigate early structural changes induced by NA CM by staining for F-actin. Furthermore, as βIII tubulin is a global neuritic marker, it would be interesting to dissociate differences in growth patterns for axons and dendrites by staining for Tau and MAP-2 respectively.

In addition to the growth factors studied in this thesis, many others could potentially be involved in NA CM-induced neuritic growth. For example, MCP-1 has been shown to be induced by NA and to be involved in neuronal protection (Madrigal et al., 2009), perhaps it too might be involved in NA CM-induced neuronal growth. Also perhaps the relatively newly discovered ERK5 branch of the MAPK pathway, which is induced by NGF-β and BDNF, and required for neuronal protection (Obara & Nakahata, 2010), could be involved in neuritic growth.
Chapter 4: Discussion

4.11 Conclusion

Understanding the mechanisms involved in the normal growth of a healthy neuron is imperative for further understanding the regenerative potential of CNS tissue. In this thesis, the ability of NA to encourage glial cells to promote neuronal growth has been investigated. This work raises the possibility that exploiting brain-permeable noradrenergic agonists could in the future be utilised to encourage repair after a brain trauma or infection.

The NA CM led to a robust induction of both mRNA and protein for IL-6, with only small increases for GDNF and FGF-2. Furthermore, inhibition of STAT3 signalling via S31-201 completely attenuated NA CM-induced neuritic growth. In addition to this, neutralisation of the IL-6 receptor led to a complete inhibition of neuritic growth in terms of both neuritic length and neuritic branching. Therefore, it is proposed that IL-6 is the prime candidate for NA CM-induced neuritic growth. In line with this proposal it is noteworthy that in addition to activating STAT3 signalling via the gp130 co-receptor, IL-6 can also activate the MAPK and PI3K pathways (Heinrich et al., 2003; Spooren et al., 2011). Thus IL-6 can induce activation of all three pathways which have been implicated in this thesis to be involved in NA CM-induced neuritic growth. In figure 4.2, a mechanism for NA CM-induced neuritic growth is displayed. NA binds to the β2-adrenoceptor on the astrocyte which upon activation of PKA leads to a massive release of IL-6, accompanied by a smaller release of GDNF and FGF-2 from the cell. These growth factors then bind to their respective receptors on the neuronal membrane. IL-6 signalling leads to the activation of the JAK-STAT pathway in addition to the MAPK and PI3K pathways. The PI3K and MAPK pathways are further activated by the presence of NGF-β, GDNF and FGF-2 in the environment, leading to a huge activation of these pathways. The three pathways then converge to together induce neuritic growth of the neuron.

As neuritic growth is important for functional recovery following neuronal degeneration, this novel ability of NA to induce neuritic growth predominantly via astrocyte-derived IL-6 should be thoroughly explored as a new strategy for neuronal repair.
Figure 4.2: A unified theory for NA CM-induced neuritic growth

NA stimulation of astrocytes leads to the increased release of IL-6 and GDNF, the freeing of FGF-2 from the extracellular matrix (ECM) and the continued release of NGF-β from the astrocytes. These growth factors activate their respective receptors on the neurons to induce the activation of the STAT3, MAPK and PI3K pathway, which ultimately lead to neuritic growth of the neurons.
Chapter 5

References


growth factor-mediated acceleration of axonal branching in cultured rat hippocampal

axonal branching and elongation of cultured rat hippocampal neurons. *Jpn J Pharmacol*
**68**, 223-226.

GDNF expression in cultured astrocytes by inflammatory stimuli. *Neuroreport* **8**, 3309-
3312.

Arcaro A & Wymann MP. (1993). Wortmannin is a potent phosphatidylinositol 3-kinase
inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses.
*Biochem J* **296 (Pt 2)**, 297-301.

Arenas E, Trupp M, Akerud P & Ibanez CF. (1995). GDNF prevents degeneration and

of vascular endothelial growth factor mRNA expression in rat brown adipose tissue:
implication in cold-induced angiogenesis. *Biochem J* **328 (Pt 1)**, 179-183.

Atwal JK, Massie B, Miller FD & Kaplan DR. (2000). The TrkB-Shc site signals neuronal


Chapter 5: References


Chapter 5: References


Chapter 5: References


Chapter 5: References


Chapter 5: References


Chapter 5: References


Chapter 5: References


glutamate neurotoxicity in cultured hippocampal neurons by induction of NGF. *Brain Res* **717**, 44-54.


Chapter 5: References


Chapter 5: References


Chapter 5: References


Chapter 5: References


